Multifunctionalization of Proteins: Strategies for Combining Semi-Synthetic and Bioorthogonal Techniques by Warner, John Blaine
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2014
Multifunctionalization of Proteins: Strategies for
Combining Semi-Synthetic and Bioorthogonal
Techniques
John Blaine Warner
University of Pennsylvania, jbw312b@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Chemistry Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1494
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Warner, John Blaine, "Multifunctionalization of Proteins: Strategies for Combining Semi-Synthetic and Bioorthogonal Techniques"
(2014). Publicly Accessible Penn Dissertations. 1494.
http://repository.upenn.edu/edissertations/1494
Multifunctionalization of Proteins: Strategies for Combining Semi-
Synthetic and Bioorthogonal Techniques
Abstract
Proteins play important roles in biological processes including muscle movement, initiating immune
responses, and memory formation. Full understanding of protein function requires determining its structure,
assignment of function, and elucidation of interactions with other proteins or metabolites. Protein
modification is useful for installing chemical entities that allow researchers to specifically probe function,
attach fluorophores for localization, covalently trap protein interactions, or perform affinity enrichment from a
complex milieu. Installation of functional groups otherwise not accessible from canonical protein expression
requires a toolbox of protein modification strategies. We have developed strategies for using a combination of
techniques to functionalize proteins, including E. coli aminoacyl transferase (AaT) mediated N-terminal
protein modification, Amber codon suppression for incorporation of unnatural amino acids (Uaas),
auxotrophic strain incorporation of Uaas, and click chemistry reactions. A chemoenzymatic approach is used
with AaT mediated N-terminal transfer of an azide functionality and subsequent click- chemistry to
fluorescently label protein N-termini. We also use AaT to install a unique N-terminal protein semi-synthesis
ligation site. Additionally, Amber codon suppression is used to site-specifically incorporate Uaa side chains
with click-chemistry handles, intrinsic fluorophores, and photocrosslinkers into proteins. Click-chemistry is
used with Amber codon suppression to control protein function in a highly selective manner. We also use
auxotrophic strain incorporation to globally replace a natural amino acid with an isostere Uaa to introduce
azide and alkyne functional groups. Protein multifunctionalization is achieved by combining these
modification methods in a single expressed protein. Effectively achieving this combination has required
careful consideration of both molecular biology and chemical reactivity. We demonstrate the combination of
these techniques to label alpha-synuclein, a protein which is involved in neurodegenerative diseases.
Moreover, the protocols for multiple labeling that we have developed should be generally practicable for a
variety of proteins.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Chemistry
First Advisor
E. James Petersson
Keywords
alpha synuclein, amber codon suppression, aminoacyl transferase, click chemistry, multifunctionalization,
unnatural amino acids
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/1494
Subject Categories
Chemistry
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/1494
MULTIFUNCTIONALIZATION OF PROTEINS: STRATEGIES FOR COMBINING 
SEMI-SYNTHETIC AND BIOORTHOGONAL TECHNIQUES 
 
John B. Warner 
 
A DISSERTATION 
in 
Chemistry 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
 
2014 
 
Supervisor of Dissertation 
 
_____________________ 
E. James Petersson 
Assistant Professor of Chemistry & Assistant Professor of Biochemistry and Molecular 
Biophysics, Perelman School of Medicine 
 
Graduate Group Chairperson 
 
______________________ 
Gary A. Molander 
Hirschmann-Makineni Professor of Chemistry 
 
 
Dissertation Committee: 
Christopher B. Murray, Richard Perry University Professor 
Ivan J. Dmochowski, Associate Professor of Chemistry 
Tobias  Baumgart, Associate Professor in Physical & Biological Chemistry 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
MULTIFUNCTIONALIZATION OF PROTEINS: STRATEGIES FOR COMBINING 
SEMI-SYNTHETIC AND BIOORTHOGONAL TECHNIQUES 
 
COPYRIGHT 
 
2014 
 
John B. Warner 
 
  
  iii 
 
 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
To Jiná, for being there for me. 
  
  iv 
 
 
ACKNOWLEDGEMENTS 
 
 Firstly, it goes without saying that I would not have come this far if it had not 
been for the guidance and mentorship of my advisor Professor E. James Petersson. I had 
the fortune to work on many projects in the lab and acquire a plethora of skills I didn’t 
think I ever would. Though we are no longer ‘essential personnel’, I would still trek in 
through a blizzard to give group meeting. My undergraduate advisor, Professor Silvana 
Andreescu, was also very influential to shaping my views and practices as a young 
scientist and without that training I certainly would not be where I am today. I would also 
like to acknowledge the support and guidance of my committee members: Professor 
Christopher Murray, Professor Ivan Dmochowski, and Professor Tobias Baumgart.  
 Throughout my years in the Petersson Lab I have had the privilege to work with 
many talented undergraduate, graduate, and post-doctoral students: Nick Marotta, Anne 
Wagner, Eileen Moison, Mark Fegley, Lee Vandivier, Chrissie Grindley, Alyssa Klein, 
Rebecca Wissner, Lee Speight, Solongo Batjargal Ziraldo, Jerri Wang, Colin Fadzen, 
Anand Muthusamy, Dr. Tomohiro Tanaka, Haviva Garrett, Dr. Moumita Samanta, Keith 
Keenan, Stella Chen, Chris Walters, Benson Chen, and Dr. Yun Huang. As well as new 
members joining the lab and extending our legacy: Jack Ferrie and Itthipol 
Sungwienwong. My lab mates have made coming to work every morning enjoyable and 
exciting.  
 I have also had the fortune to collaborate with an amazing group of scientists at 
the Perelman School of Medicine at the University of Pennsylvanian’s Center for 
Neurodegenerative Disease Research. Professor Virginia M.Y. Lee, Dr. Kelvin Luk, and 
  v 
 
 
Dr. Dustin Covell have been invaluable in my research endeavors. UPenn Chemistry is 
fortunate to have an amazing support staff that keeps the building running and the 
research going. My sincerest gratitude goes out to: Judith Currano, George Furst, Jun Gu, 
Rakesh Kohli, Chris Lanci, Tom Troxler, Mandy Swope, Kristen Muscat, Candice 
Adams, Yvonne Kline, Leslie Shinn, Dan Burke, Bruce Dolliver, Rico Vargas, Josh 
Henry, Andrei Korchynsky, Cuong Nguyen, Claire Din, and Tony Baruffi.  
 I came to UPenn with a great cohort of fellow graduae students, many of which 
have since moved into new phases of their careers. The Chemistry program is a close and 
tight knit community that freely doles advice and reagents (often when desperately 
needed). Matthew ‘Will’ Eibling, Brittany Riggle, Julie Griepenburg, Julia Richards, 
Garry Seward, Chris Butts, Joe Swift, Ian Farrell, Chih-Jung Hsu, Ben Capraro, Danielle 
Reifsnyder Hickey, Rob Hickey, Julia Lehman, and many others who helped make 
UPenn so great. Finally, I would like to thank my families for their love and support 
through the long hours, missed holidays, and fancy jargon.     
 
  
  vi 
 
 
ABSTRACT 
 
 
MULTIFUNCTIONALIZATION OF PROTEINS: STRATEGIES FOR COMBINING 
SEMI-SYNTHETIC AND BIOORTHOGONAL TECHNIQUES 
. 
John B. Warner 
E. James Petersson 
 
 Proteins play important roles in biological processes including muscle movement, 
initiating immune responses, and memory formation. Full understanding of protein 
function requires determining its structure, assignment of function, and elucidation of 
interactions with other proteins or metabolites. Protein modification is useful for 
installing chemical entities that allow researchers to specifically probe function, attach 
fluorophores for localization, covalently trap protein interactions, or perform affinity 
enrichment from a complex milieu. Installation of functional groups otherwise not 
accessible from canonical protein expression requires a toolbox of protein modification 
strategies. We have developed strategies for using a combination of techniques to 
functionalize proteins, including E. coli aminoacyl transferase (AaT) mediated N-
terminal protein modification, Amber codon suppression for incorporation of unnatural 
amino acids (Uaas), auxotrophic strain incorporation of Uaas, and click chemistry 
reactions. A chemoenzymatic approach is used with AaT mediated N-terminal transfer of 
an azide functionality and subsequent click- chemistry to fluorescently label protein N-
termini. We also use AaT to install a unique N-terminal protein semi-synthesis ligation 
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site. Additionally, Amber codon suppression is used to site-specifically incorporate Uaa 
side chains with click-chemistry handles, intrinsic fluorophores, and photocrosslinkers 
into proteins. Click-chemistry is used with Amber codon suppression to control protein 
function in a highly selective manner. We also use auxotrophic strain incorporation to 
globally replace a natural amino acid with an isostere Uaa to introduce azide and alkyne 
functional groups. Protein multifunctionalization is achieved by combining these 
modification methods in a single expressed protein. Effectively achieving this 
combination has required careful consideration of both molecular biology and chemical 
reactivity.  We demonstrate the combination of these techniques to label α-synuclein, a 
protein which is involved in neurodegenerative diseases.  Moreover, the protocols for 
multiple labeling that we have developed should be generally practicable for a variety of 
proteins. 
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CHAPTER 1 : INTRODUCTION TO UNNATURAL AMINO ACIDS AND 
CURRENT PROTEIN MODIFICATION STRATEGIES AND TECHNIQUES 
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1.1 The Central Dogma of Molecular Biology 
Francis Crick first postulated the transfer of information between 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein as the foundation for 
the central dogma of molecular biology1,2. The central dogma, shown in Figure 1.1, 
outlines the transfer of information between nucleic acids and from nucleic acids to 
proteins. The central dogma establishes the cytosine, guanine, adenine, and thymine 
(DNA) or uracil (RNA) nucleobases as the principal components of genetic material. 
Similarly, there exists a standard set of the 20 natural amino acids (Naas) as the building 
blocks for proteins. 
 
Figure 1.1-Central Dogma of Molecular Biology.  
The transcription of genetic information from DNA to RNA which is translated into Protein is shown by the solid 
arrows. Represented by the dashed arrow is the less frequent event of RNA reverse transcription to DNA. Not shown 
are the protein mediated replication of DNA and the self-replication of RNA. 
 
Modification of the Naas occurs at the protein level either co-translationally or 
post-translationally to alter the functions of proteins. Protein structure and folding, 
enzymatic catalysis, and biomolecular signaling are governed by protein sequence and 
amino acid modifications. Cellular protein post-translational modifications (PTMs) 
include phosphorylation, acylation, alkylation, glycosylation, and oxidation3. Protein 
phosphorylation and de-phosphorylation by kinases and phosphatases regulate signaling 
cascade pathways4. Acetylation and methylation of histones are responsible for regulation 
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of transcriptional events5.  Protein ubiquitylation signals protein re-localization within the 
cell and often results in degradation6. Glycosylation provides signaling cues for protein 
folding, can confer an increased half-life, and mediates recognition events7,8. Proteins can 
also be modified with functional groups that do not occur naturally to endow novel 
functionality. 
Modification of proteins with functional groups such as fluorophores, 
crosslinkers, affinity tags, and reactive handles allows researchers to learn more about the 
function or role of a protein. A single fluorophore allows one to monitor cellular 
localization and protein trafficking, and in appropriate combinations, fluorophores can 
allow one to monitor protein dynamics and protein-protein interactions. Fluorescence 
resonance energy transfer (FRET) is a distance dependent phenomenon of a fluorophore 
pair. A donor fluorophore is directly excited and then transfers energy through a non-
radiative process to an acceptor fluorophore whose fluorescence emission is recorded. 
Fluorophore FRET pairs must have a degree of spectral overlap between the donor 
fluorescence and the acceptor excitation profiles (Figure 1.2A). Because it is distance-
dependent, FRET can be used to study conformational dynamics and protein interactions. 
Protein dynamics can alternatively be probed by fluorophore quenchers9. In our lab 
thioamides have been shown to efficiently quench a wide range of fluorophores with 
minimum perturbation10-13. Protein crosslinkers create a covalent bond between 
molecules that traps transient interactions. Photocrosslinkers are crosslinkers that are 
chemically inert until irradiated with light, typically at UV wavelengths. 
Photocrosslinking provides spatial and temporal control when probing protein 
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The reaction of Lys with activated esters, such as N-hydroxysuccimidyl esters, forms an 
irreversible amide bond (optimal pH of 8-9, (Figure 1.3A) and similarly isothiocyanates 
react (optimal pH 9-9.5) to form a thiourea linkage (Figure 1.3B). Probes containing N-
hydroxysuccimide or isothiocyanates provide a simple method to labeling proteins with 
free amine groups. The free amine of Lys can also undergo reductive amination with an 
aldehyde to form an imine. Reduction of the imine by reagents such as lithium aluminum 
hydride or sodium borohydride forms a stable secondary amine (Figure 1.3C). Amine 
reactive probes are useful, but often a protein will contain several free amine sites for 
conjugation, so there is rarely selectivity for protein modification. 
1.3 Modification of Cysteine Residues 
Cysteine (Cys) is a less commonly occurring Naa than Lys that can be easily 
modified. Cys also contains a nucleophile, in the form of a thiol group, capable of 
selective reactivity. Maleimide probes are commonly used to modify Cys residues at 
biological pHs (Figure 1.3D). The maleimide undergoes a Michael addition with the free 
thiolate of Cys to form a stable linkage. Modification of Cys residues by alkylation is 
commonly performed using reagents such as acrylamide, iodoacetamide, or 4-
vinylpyridine (Figure 1.3E)14. Alternatively, under slightly basic conditions, the thiol can 
undergo oxidative elimination to yield dehydroalanine when it is appropriately activated 
as a leaving group15. Dehydroalanine can then undergo conjugate addition with a thiol to 
obtain a modified Cys residue (Figure 1.3F). S-Allylcysteine was generated from Cys 
through dehydroalanine and then used in olefin cross-metathesis with the second 
generation Hoveyda–Grubbs catalyst16. Cys residues are also capable of forming 
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reversible vinyl sulfide linkages with electron-deficient alkynoic amides, esters and 
alkynone probes17. Lys and Cys represent the best and most common endogenous protein 
nucleophiles for selective chemical modification. Chemical techniques have also been 
applied to modify functional groups other than amine or thiol side chains on protein. 
 
Figure 1.3-Labeling of Endogenous Amino Acids.  
Modification of lysyl amines using A) an activated ester probe, B) an isothiocyanate probe, or C) an aldehyde 
containing probe with subsequent reduction. Modification of Cys thiolates using D) a maleimide probe, E) alkylation 
using an iodoacetamide probe, or F) elimination to dehydroalanine and subsequent modification with a thiol probe. G) 
Modification of activated Asp or Glu carboxylic acids with amine probes.  
1.4 Modification of Additional Amino Acid Functionalities 
Aspartic acid (Asp) and glutamic acid (Glu) contain reactive carboxylic acid side 
chains. However, the carboxylic acid must first be activated with reagents such as water 
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soluble carbodiimides prior to amine conjugation (Figure 1.3G)18. Imidazole, the side 
chain of histidine (His), is a weak nucleophile, but will react readily with epoxide 
reagents19. Tyrosine (Tyr) is selectively modified using a hetero-Diels-Alder reaction 
with functionalized olefin substrates20. Tyr can also been modified in a Mannich-type 
reaction using an aldehyde and electron-rich analine derivatives21. An aldehyde 
containing electron withdrawing diazonium was coupled to Tyr and then further 
functionalized at the introduced aldehyde via oxime formation22. Arginine (Arg) residues 
have been identified as susceptible to reaction with modified aldehydes and ketones23 
through mechanisms found in the Maillard reaction24. Reductive amination using 
transition-metal catalysts have been demonstrated on Lys25, Tyr26, and Tryptophan 
(Trp)27 side chains. 
Though not a specific amino acid, the α-amino of the protein N-terminus can be 
selectively modified. The α-amino group can be selectively modified by controlling 
reaction pH owing to a significant difference between the pKa of the N-terminal α-amine 
and the lysyl ε-amine28. N-terminal serine (Ser) or threonine (Thr) residues present 
unique configurations that facilitate selective modification. The 2-amino alcohol structure 
of Ser and Thr is readily oxidized by periodate to an aldehyde29,30. Globally, protein N-
termini  can be treated with pyridoxal-5-phosphate (PLP) to generate an N-terminal 
aldehyde31. The reaction proceeds via condensation of the PLP aldehyde with the protein 
N-terminal α-amino forming an imine, which is subsequently hydrolyzed to form a 
reactive aldehyde or ketone at the N-terminus. N-terminal aldehydes can then be further 
modified with hydroxylamines or aminooxy probes to form stable hydrazone or oxime 
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linkages. The techniques for modification of proteins using either Naa side chains or the 
N-terminus are useful but limited by a lack of specificity. 
1.5 Bioorthogonal Chemical Reactions: ‘Click Chemistry’ 
 The protein labeling methods discussed thus far are chemically selective but lack 
specificity. For example, amine reactive probes will react only with amines, but will 
however react with all accessible amines. To exert more control over protein labeling, the 
concept of ‘click’ chemistry, introduced by Sharpless and co-workers, has been adopted 
to biomolecule labeling with great success. The following stipulations were imposed for 
click chemistry: 
“The reaction must be modular, wide in scope, give very high 
yields, generate only inoffensive byproducts that can be removed by 
nonchromatographic methods, and be stereospecific (but not necessarily 
enantioselective). The required process characteristics include simple 
reaction conditions (ideally, the process should be insensitive to oxygen 
and water), readily available starting materials and reagents, the use of no 
solvent or a solvent that is benign (such as water) or easily removed, and 
simple product isolation. Purification, if required, must be by 
nonchromatographic methods, such as crystallization or distillation, and 
the product must be stable under physiological conditions.” (Kolb, Finn, 
and Sharpless 2001)32. 
Additionally, when developing new reactions to modify proteins they should also 
be bioorthogonal: chemoselective against endogenous protein functionalities. 
Several bioorthogonal click chemistry reactions have been developed to modify or label 
proteins. Imine bond formation is a widely used in conjugating either amine, aminooxy, 
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or hydrazide compounds with aldehydes or ketones33. Amines react significantly faster 
with aldehydes than ketones to form an imine, also referred to as a Schiff base. In the 
presence of water the Schiff base is reversibly formed, but if reduced, forms a stable 
linkage (Figure 1.4A). Reaction of a hydrazide with an aldehyde yields a stable 
hydrazone bond (Figure 1.4B). The oxime linkage formed between an aminooxy moiety 
and an aldehyde is more hydrolytically stable than that of the hydrazone (Figure 1.4C). 
The formation of both the hydrazone and oxime proceed fastest at an acidic pH but have 
been shown to be catalyzed at physiological pH by addition of para substituted aniline 
derivatives which form a protonated Schiff base with the aldehyde34,35. 
 Although noted in the literature as far back as the 1900’s36-38, the reaction 
between a 1,3-dipole and a dipolarophile to form a five membered ring was pioneered by 
Huisgen and co-workers and is commonly referred to as a Huisgen cycloaddition39. An 
azide, either aryl or alkyl, and an alkene or alkyne are most frequently used as substrates 
in the cycloaddition and provide a high degree of bioorthogonality. The Huisgen 
cycloaddition proceeds in high yield but often requires high temperatures to drive the 
reaction. A CuI-catalyzed Azide-Alkyne Cycloaddition (CuAAC) was found to proceed 
with regioselectivity at ambient temperatures in only hours by Sharpless and co-workers 
(Figure 1.4D)40. During investigations of CuAAC reactions, it was found that 
polytriazoles served as rate-accelerating ligands for CuI41,42. The ability of polytriazoles 
to stabilize CuI and facilitate formation of the CuI-acetylide in aerobic and aqueous 
conditions was further probed by Finn and co-workers43,44. Ligand-accelerated CuAAC 
has become the most widely used bioorthogonal click reaction. 
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The CuAAC reaction, though robust, requires the presence of CuI which is toxic 
to both bacteria and mammals45. Thus, several alternative metal-free cycloaddition 
reactions have been developed to work in vivo.  Cyclooctynes possess a large amount of 
ring strain about the carbon-carbon triple bond that is relieved upon triazole formation 
with an azide in 1,3-dipolar cycloaddition. The Strain-Promoted Azide-Alkyne 
Cycloaddition (SPAAC) proceeds at ambient temperatures without addition of metals or 
ligands46. SPAAC reaction rates are accelerated by the addition of electron-withdrawing 
groups proximal to the carbon-carbon triple bond (Figure 1.4E)47,48. As an alternative to 
strained cyclooctynes it was shown that electron deficient oxanorbornadienes undergo a 
metal-free [3+2] cycloaddition-retro-Diels-Alder reaction with azides49. A [4+2] Diels-
Alder cycloaddition was also developed using a modified norborene as the dienophile and 
tetrazine as the diene, which evolves N2 upon cycloaddition and forms an irreversible 
linkage (Figure 1.4F)50. Tetrazine was also found to form a stable linkage with trans-
cyclooctenes following an inverse-electron demand Diels-Alder mechanism, again with 
the expulsion of N2 (Figure 1.4G)51. Additionally a photoinducible 1,3-dipolar 
cycloaddition between a 2,5-diaryl tetrazole and a substituted alkene was reported 
utilizing mild UV irradiation (Figure 1.4H)52-54. 
Hermann Staudinger developed the Staudinger reaction, or reduction, between an 
azide and a phosphine. The azide and phosphine react to form an aza-ylide that is rapidly 
hydrolyzed in water to produce a phosphine oxide and an amine. Bertozzi and co-workers 
introduced an electrophilic trap into the phosphine to capture the aza-ylide and produce a 
stable amide bond upon intramolecular cyclization55. The Staudinger ligation was then 
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further modified to include a cleavable inker to liberate phosphine oxide and leave a 
native amide bond (Figure 1.4I)56. The Staudinger ligation has found a primary use in 
protein semi-synthesis but is also applicable for site-specific modifications on full 
proteins. 
Oxime or hydrazone formation from aldehydes, CuAAC, SPAAC, Diels-Alder 
based cycloadditions, and the Staudinger ligation are widely used bioorthogonal click 
chemistry reactions. Fulfilling the requirements for click chemistry requires introduction 
of functional groups into proteins outside of the 20 Naas. Thus, the development of 
methods for introducing unnatural amino acids (Uaas) with ‘clickable’ functional groups 
has been essential to implementing these reactions on proteins. 
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Figure 1.4-Bioorthogonal Click Chemistry Reactions.  
Reaction of aldehydes with A) amines, B) hydrazides, and C) hydroxyamines to form stable secondary amines, 
hydrazones, and oximes respectively. Azide reactivity and bioconjugations to D) alkynes using CuI and E) strained 
cyclooctynes. Metal free conjugation of tetrazines with F) norborene and G) trans-cyclooctenes. H) Light induced 
conjugation using tetrazoles and alkenes. I) Staudinger ligation using an azide and a phosphine containing probe.  
 
1.6 Cellular Metabolite Analogs as Unnatural Amino Acids 
Site-specific modification of proteins requires incorporation of novel functional 
groups into proteins. Progress to incorporate novel functionality was aided by the 
observation that analogs of cellular metabolites are often biomolecular inhibitors. A sub-
set of cellular metabolites are structural analogs of the 20 Naas57. Several Naa metabolite 
analogs can be functionally incorporated into proteins through the endogenous protein 
translational machinery58-64. Uaas are structural analogs of the Naas that are 
translationally competent. Uaas can be used to incorporate novel functional groups into 
proteins, allowing researchers to gain mechanistic insight into protein assembly, folding, 
and function. In some early work in this area, it was found that incorporation of p-
fluorophenylalanine inhibited polypeptide cleavage in the maturation of poliovirus 
protein65. Functions such as collagen formation and oligosaccharide processing are also 
perturbed by Uaa incorporation66,67. It has also been shown that proteins containing Uaas 
have altered susceptibility to degradation, aggregation, or precipitation68. Uaas can have a 
perturbing cytotoxic effect on organisms acting as metabolite competitors. Of the large 
number of Uaa structural analogs that have been tested, few are incorporated without 
cytotoxicity to the organism (Table 1.1).  
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Table 1.1-Metabolite Unnatural Amino Acids Incorporated into Proteins.  
Shown in bold are the Uaas that exhibit minimal cytotoxicity. This table is compiled from the following references: 
Richmond 1962, Hortin & Boime 1983, and Wilson & Hatfield 198457,66,67.  
Natural Amino Acid Metabolite Analog Unnatural Amino Acid 
Arginine Canavanine 
 Indospicine 
Asparagine 3-Fluoroasparagine 
Aspartic acid 3-Fluoroaspartic acid 
Histidine 2-Thiazolealanine 
 1-2-4-Triazole-3-alanine 
 2-Fluorohistidine 
 2-Methylhistidine 
 3-Amino-1,2,4-triazoylalanine 
Isoleucine O-Methylthreonine 
 4-Thiaisoleucine 
 O-Ethylthreonine 
 4-Fluoroisoleusine 
 Alloisoleucine 
Leucine β-Hydroxyleucine 
 5,5,5-trifluoroleucine 
Lysine S-(β-Aminoethyl)cysteine 
 4,5 -trans-Dehydrolysine 
 6-C-methyllysine 
 5-Hydroxylysine 
 2,6-Diamino-4-hexynoic acid 
 4-Oxalysine 
 4-Selenalysine 
Methionine Ethionine 
 Norleucine 
 Selenomethionine 
 cis-Crotylglycine 
Phenylalanine 2-, 3- or 4-Fluorophenyalanine 
 Thienylalanine 
 2,5-Dihydrophenylalanine 
 3-Phenylserine 
 3-Furyl-3-alanine 
 m-Tyrosine 
Proline Azetidine-2-carboxylic acid 
 cis-4-Bromoproline 
 3,4-Dehydroproline 
 cis-4-Fluoroproline 
 trans-4-fluoroproline 
 cis-4-Hydroxyproline 
 Thiazolidine-4-carboxylic acid 
 4-Thioproline 
 4-Selenoproline 
Threonine α-Arnino-β-hydroxyvaleric acid 
Tryptophan 7-Azatryptophan 
 4-, 5- or 6-Fluorotryptophan 
Tyrosine Fluorotyrosine 
Valine α-Amino-β-chlorobutyric acid 
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1.7 Increasing the Efficacy of Auxotrophic Incorporation 
DNA sequencing69,70, site-directed mutagenesis71, and cloning via the polymerase 
chain reaction (PCR)72 were among several advances in molecular biology that provided 
the means to overcome the limitations posed by Uaa toxicity. A genetically encoded and 
small molecule inducible platform for protein expression in cellular auxotrophs was first 
demonstrated by Tirrell and co-workers73,74 and later by Budisa and co-workers75. An 
auxotrophic organism is genetically engineered such that its survival is dependent upon 
exogenous addition of a metabolite, a Naa in these examples. Auxotrophic Escherichia 
coli (E. coli) strains were created to allow for growth to a saturated level, after which the 
appropriate Naa could be depleted and fresh media supplied with the Uaa while protein 
expression was induced. Global replacement of methionine (Met) with selenomethionine 
(1) was performed for a β-strand polypeptide with the purpose of inducing chain reversals 
for controllable material formation73. The advantage of an inducible promoter was then 
demonstrated with the incorporation of p-fluorophenylalanine (15), which is not 
inherently suitable to sustaining cellular growth, into a peptide forming anti-parallel β-
sheets74. Incorporation of novel functional groups like fluorocarbons alter the 
hydrophobicity of proteins. This approach was then applied to the full length protein 
annexin V expressed in E. coli with the replacement of Met with norleucine (4), ethionine 
(2) and telluromethionine (3)75. Budisa and co-workers were able to incorporate 3-
chlorotyrosine (16) and 3-fluorotyrosine (17) into annexin V76. Optimization of 
auxotrophic incorporation was achieved through careful control of the Naa and Uaa 
concentrations, improved auxotrophic strains, and tightly regulated protein induction 
vehicles. 
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1.8 Expanding the Repertoire of Unnatural Amino Acids in Auxotrophic 
Incorporation  
5-Hydroxytryptophan (5HW, 24) is an intrinsically fluorescent amino acid with 
an excitation range that is red shifted compared to that of tyrosine and tryptophan. 
Incorporation of 5HW was first demonstrated in the Ca2+ binding protein oncomodulin 
using a tryptophan (Trp) auxotrophic E. coli with an oxygen sensitive promoter to 
minimize toxicity of 5HW77. Efforts to minimize 5HW toxicity employed a temperature 
sensitive promoter to express staphylococcal nuclease A protein containing 5HW78. An 
alkene functional group was incorporated into a β-strand polypeptide in the form of 3,4-
deyhdroproline (13) using E. coli that are auxotrophic for proline79. 3,4-Dehydroproline 
is capable of undergoing selective chemical modification with reagents such as hydrogen 
peroxide and molecular bromine to yield either 3,4-dihydroxyproline or 3,4-
dibromoproline respectively. Alternatively an alkene containing Uaa homoallyglycine 
(5), a methionine analog, was incorporated into mouse dihydrofolate reductase (mDHFR) 
in E. coli to yield similar functionality80. Auxotrophic strain methodology primarily relies 
on the use of endogenous cellular machinery for Uaa incorporation. However, exogenous 
translational components can be used to increase yields and expand the Uaa substrate 
scope. 
Incorporation of Uaas via auxotrophic incorporation is limited by the ability of the 
aminoacyl tRNA synthetase (RS) to aminoacylate the cognate transfer RNA (tRNA) with 
the Uaa. The substrate scope for the tolerance of methionyl RS (MetRS) to acylate 
several Met Uaa analogs was explored in vitro and in vivio. It was found that under 
normal cellular conditions only Met, homoallyglycine (5), or homopropargylglycine (6) 
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are efficiently acylated and incorporated into proteins81. In vitro acylation experiments 
demonstrated the capacity for MetRS to acylate a broad range of substrates82. By 
overexpressing MetRS during cellular growth norleucine (4) and trans-crotylglycine (8) 
were incorporated into mDHFR83. The substrate scope of MetRS was further expanded to 
include azidonorleucine (9) by mutating the amino acid binding pocket to accommodate 
bulkier functional groups84. Norvaline (10), norleucine (4), allylglycine (11), 
homoallylglycine (5), homopropargylglycine (6), and 2-butynylglycine (12) were 
incorporated into proteins in E. coli when the editing domain of leucyl RS (LeuRS) was 
mutated to disrupt proofreading activity85. The scope of Uaas that can be incorporated is 
generally enhanced by increasing RS levels, and thereby increasing the acylation 
efficiency of Uaas to the corresponding tRNA86. Mutation of RSs either at the amino acid 
binding pocket or the editing domain, if applicable, also leads to greater tolerance for Uaa 
incorporation. Mutations to phenylalanyl RS (PheRS) allowed for the incorporation of p-
bromophenylalanine (18), p-iodophenylalanine (19), p-ethnylphenylalanine (20), p-
cyanophenylalanine (21), p-azidophenylalanine (22), and p-acetylphenylalanine (23) into 
mDHFR87,88,89. While Uaas containing new functionalities have been incorporated using 
auxotrophic methods, the inherent limitations of a need for high similarity to a Naa and 
requisite global incorporation make the method limited (Figure 1.5). Protein modification 
at a single site within the protein using a broader suite of amino acids is more desirable. 
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Figure 1.5-Unnatural Amino Acids Incorporated using Auxotrophic Incorporation.  
Uaas 1-7 are incorporated using MetRS and Uaas 8 and 9 using a mutant of MetRS. Uaas 10-12 are incorporated using 
a mutant LeuRS. Uaas 13 and 14 are incorporated through ProRS. Uaas 15-17 are incorporated using PheRS and Uaas 
18-23 using a mutant PheRS. Uaa 24 is incorporated using TrpRS. Selenomethionine (1)73, Ethionine (2)75, 
Telluromethionine (3)75, Norleucine (4)75, Homoallylglycine (5)80, Homopropargylglycine (6)81, Azidohomoalanine 
(7)90, trans-Crotylglycine (8)91, Azidonorleucine (9)84, Norvaline (10)85, Allylglycine (11)85, 2-Butynylglycine (12)85, 
3,4-Dehydroproline (13)79, 4-Fluoroproline (14)92, p-Fluorophenylalanine (15)74, 3-Chlorotyrosine (16)76, 3-
Fluorotyrosine (17)76, p-Bromophenylalaine (18)88, p-Iodophenylalanine (19)89, p-Ethnylphenylalanine (20)89, p-
Cyanophenylalanine (21)89, p-Azidophenylalanine (22)89, p-Acetylphenylalaine (23)87, and 5-Hydroxytryptophan 
(24)77. 
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1.9 Unnatural Amino Acid Incorporation via Nonsense Suppression 
Site-specific incorporation of Uaas allows for the introduction of a single Uaa 
functional group into a protein. The engineered methods for Uaa incorporation have their 
roots in some natural biosynthetic pathways.  Protein selenols are incorporated 
ribosomally as selenocysteine, often referred to as the 21st amino acid, and are found in 
enzymes such as dehydrogenases, reductases, and peroxidases in both prokaryotes and 
eukaryotes93. Selenium, though toxic in high concentration, was found to be an essential 
trace element for biological functioning94. Interestingly, selenium deficiency can lead to a 
condition called white muscle disease in which damaged tissues are replaced by collagen. 
Selenocysteine is incorporated into proteins co-translationally using an Opal nonsense 
codon in protein messenger RNA (mRNA). The nonsense codons, Opal (UGA), Amber 
(UAG), and Ochre (UAA), are codons that serve to signal termination of protein 
translation. A so-called suppressor seryltRNA with an Opal anticodon (tRNAUGASer) is 
acylated with serine (Ser) and the hydroxyl of Ser is then enzymatically exchanged for 
selenium95. Selenocysteine is then ribosomally misincorporated at the Opal codon into 
the protein of interest. The incorporation of selenocysteine provides the foundation for 
misacylation of tRNA with Uaas using nonsense codon suppression.  
Nonsense codon suppression relies on the ability of a cognate suppressor tRNA to 
successfully decode one of the three nonsense codons (Figure 1.6). Early work on 
increasing suppressor efficiency determined that regions outside the 3 bases of the 
anticodon loop of tRNA are essential to incorporation96,97. These advances led directly to 
the seminal work by Schultz and co-workers on incorporating p-nitrophenylalanine (28), 
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2-amino-4-phenylbutanoic acid, p-fluorophenylalanine (15), (S)-3-amino-2-
benzylpropionic acid, and (S)-2-hydroxy-3-phenylpropionic acid into β-lactamase98. The 
authors utilized the following: 1) the replacement of an encoding amino acid with an 
Amber nonsense codon using PCR mutagenesis and 2) in vitro chemical acylation of a 
cognate suppressor tRNACUA using methods developed by Hecht. An in vitro, or cell free, 
translation system was then used to direct Amber codon containing DNA transcription 
and protein translation. Amber codon suppression was also investigated 
contemporaneously to Schultz’s work wherein isotopically-labeled Tyr was incorporated 
into a 16 residue polypeptide99. Using chemically acylated tRNA Uaas were introduced 
into proteins that contained backbone modifications such as replacement of the amide 
bond with an ester or N-alkyl amide100. Protein stability, solvation, and packing density 
were probed by varying the number and arrangement of methyl groups on Leu derived 
Uaas101. The mechanisms of Ras, a guanosine triphosphatase, and staphylococcal 
nuclease, which cleaves phosphodiester bonds, were also probed by incorporation of 
various Uaas102,103. Nitroxyl 1-oxyl-2,2,5,5-tetramethylpyrroline and 1-oxyl-2,2,6,6-
tetramethylpiperdine were incorporated as spin labels for electron paramagnetic 
resonance (EPR) spectroscopy. Intrinsic fluorophore probes 7-azatryptophan and dansyl-
L-lysine were incorporated for fluorescence spectroscopy. p-Benzoylphenylalanine (43), a 
photocrosslinking Uaa, was incorporated into T4 lysozyme to probe protein 
interactions104. The key step in nonsense suppression requires acylation of a suppressor 
tRNA with an Uaa, which can be accomplished using chemical, chemoenzymatic, or 
enzymatic methods. 
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by the cognate RS and not by endogenous RSs. Schultz and co-workers began with a well 
characterized E. coli glutaminyl RS (GlnRS)/tRNA2Gln pair and performed mutagenesis 
to disrupt tRNA2Gln affinity for other E. coli RSs and mutate the anticodon loop to ‘CUA’ 
for Amber suppression. The GlnRS was then mutated to increase affinity for the 
tRNACUAGln while disrupting affinity towards other E. coli tRNAs. Using E. coli, 
acceptable levels of in vivo synthesis of protein with an Uaa were not observed due to 
incomplete aaRS/tRNA orthogonality and low acylation efficiency114. The orthogonality 
of RS/tRNA pairs between prokaryotes and eukaryotes is well established115. A yeast 
PheRS/tRNACUAPhe pair was installed in E. coli, which harbors mutations that prohibit p-
fluorophenylalanine (15) incorporation. mDHFR with an Amber codon was expressed in 
E. coli using the yeast PheRS/tRNACUAPhe pair and was found to contain 65% p-
fluorophenylalanine (15) and a mix of Lys and Phe that resulted from incomplete 
orthogonality of the RS/tRNA pair116. A yeast GlnRS/tRNACUAGln pair was also shown to 
be orthogonal to E. coli translation components. A selection system was developed to 
optimize yeast GlnRS for Uaa incorporation based on positive and negative screening 
(Figure 1.8). In the positive screen, an Amber codon was inserted into a gene coding for 
anti-bacterial resistance so that production of protein required RSs that could incorporate 
either a Naa or an Uaa. In the negative selection protocol, an Amber codon was 
incorporated into a toxic protein, barnase, and the Uaa is withheld. Acylation of Naas by 
the mutant RSs results in cellular death and only cells containing RSs that do not 
incorporate Naas survive. Mutant RSs are put through several iterations of this cycle until 
a clone is produced that only charges an Uaa117. Despite the success of the yeast PheRS 
and GlnRS pairs, their total orthogonality with E. coli translation machinery could not be 
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existed on which to base rational design for expanding or tailoring the amino acid binding 
pocket to accept Uaas. However, a homology model was utilized based upon a crystal 
structure of TyrRS from Bacillus stearothermophilus (Bst). Using homology models to 
guide the Uaa RS evolution strategy, the intrinsic fluorophore 3-(2-naphthyl)alanine (44) 
was incorporated in E. coli125. Uaas that possess reactive handles to modify proteins such 
as O-allyltyrosine (41)126, p-acetylphenylalanine (23)127, m-acetylphenylalanine (39)128, 
and p-propargyloxyphenylalanine (42)129 have been incorporated using evolved RSs. 
Additional Uaas such as p-aminophenylalanine (26)130, p-iodophenylalanine (19)131, p-
fluorophenylalanine (15)132, O-o-nitrobenzyl-tyrosine (53)133, (7-hydroxycoumarin-4-yl)-
ethylglycine (50)134, 4-(2-bromoisobutyramido)-phenylalanine (47)135, 4-(6-methyl-s-
tetrazine-3-yl)-aminophenylalanine (48)136, 3-(6-hydroxy-2-naphthyl)alanine (54)137, and 
acridon-2-ylalanine (46)138 have all been incorporated in E. coli using evolved Mj 
TyrRSs. Incorporation of Uaas using Tyr based RSs is a powerful technology, but seems 
to ultimately limit the scope of Uaas to Tyr or Phe derivatives. 
To expand the diversity of Uaas that can be incorporated, RS/tRNA pairs from 
different species were screened for orthogonality. If selenocysteine is the 21st amino acid 
then pyrrolysine (Pyl) would be considered the 22nd. Pyl incorporation was discovered in 
the archaea species Methanosarcina barkeri (Mb). Methanosarcinaceae possess a 
dedicated Amber suppressor tRNA/PylRS pair for incorporation of Pyl. It was shown that 
tRNAPyl and PylRS are orthogonal when used in E. coli139. Using strategies similar to the 
Mj TyrRS selection protocol, a Mb PylRS was evolved to incorporate Nε-acetyllysine 
(67) into myoglobin produced in E. coli140. Using the Mb PylRS/tRNAPyl pair Nε-[(2-
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propynyloxy)carbonyl]lysine (78) , Nε-[(2-azidooxy)carbonyl]lysine (79)141, Nε-tert-
butyloxycarbonyllysine (70), Nε-L-cysteinyllysine (74), Nε-D-cysteinyllysine (75), Nε-L-
thiaprolyllysine (76)142, and Nε-5-norborene-2-yloxycarbonyllysine (80)143 were also 
incorporated. Liu and co-workers altered the specificity of PylRS to acylate Phe-like 
Uaas by mutating and expanding the PylRS substrate binding pocket144,145,146. An 
additional orthogonal RS/tRNA pair for E. coli was established by re-visiting the yeast 
PheRS/tRNACUAPhe pair with mutations to eliminate Lys and Phe  misincorporation147. 
The Mj, Mb, and yeast RS/tRNACUA pairs represent the most frequently used systems for 
incorporation of Uaas into proteins in E. coli. The selection process identifies an RS for a 
particular Uaa with selectivity against the 20 Naas. However, there is no additional 
negative selection against other Uaas, which allows an Uaa RS to be potentially 
permissive toward several Uaas. Several Trp analogs: 6-chlorotryptophan (63), 6-
bromotryptophan (64), 5-bromotryptophan (65), 3-benzothienylalanine (60)148, 1-
methyltryptophan (61), and 6-methyltryptophan (62)149 were incorporated by a pair of 
yeast PheRS mutants. Additionally, two Mj TyrRS mutants were identified that are 
permissive for broad classes of Phe analogs150,151. Overall, as one can see in Figure 1.9, a 
large number of Uaas have been incorporated into proteins in E. coli containing reactive 
functional handles, chromophores, or PTM mimetics.   
1.12 In Vivo Incorporation of Unnatural Amino Acids in Eukaryotes 
Expression of Uaas in E. coli is useful for isolating and purifying recombinant 
proteins. Expression of modified proteins in eukaryotes allows for in vivo assays but is 
complicated by a higher complexity of transcriptional machinery. Early work to 
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incorporate Uaas in eukaryotes was first performed in Xenopus oocytes using 
microinjected chemically acylated suppressor tRNA and transcribed mRNA bearing an 
Amber codon. Uaas were incorporated into nicotinic acetylcholine receptors near putative 
ligand binding sites in order to determine the effect the amino acid side chain had on 
signaling152,153. Alternatively it was also shown that microelectroporation was a viable 
method for delivering mRNACUA and chemically acylated suppressor tRNACUA to 
Chinese Hamster Ovary (CHO) cells for Uaa incorporation154. Wheat germ cell-free 
translation systems were used to identify possible orthogonal RS and suppressor tRNA 
pairs. It was found that an E. coli mutant TyrRS and tRNACUATyr were orthogonal to the 
wheat germ translational machinery and could incorporate 3-iodotyrosine in response to 
an Amber codon155. tRNA expression in eukaryotes is dependent upon two internal 
promoters: the A box and B box. E. coli tRNA contains only the box B promoter and 
efforts to incorporate an A box yielded non-functional E. coli RS/tRNA pairs. Bst 
tRNATyr, which contains both the A box and B box promoters, is functional with E. coli 
TyrRS while maintaining orthogonality in CHO cells156. An additional orthogonal mutant 
TrpRS/tRNAUCATrp pair was isolated from Bacillus subtilis (Bsu) and used into 
incorporate 5HW (24) into human embryonic kidney (HEK) cells in response to an Opal 
codon157. The library of Uaas incorporated in mammalian cells was expanded by 
evolving E. coli TyrRS mutants in yeast, using a strategy similar to the positive and 
negative selection rounds used for Mj RS evolution. Evolved E. coli mutant TyrRSs were 
then used with Bst suppressor tRNACUATyr to incorporate several Uaas into CHO and 
HEK cells158,159.  
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Mj Uaa RSs evolved in E. coli are not functional in mammalian cells due to a lack 
of orthogonality. Evolution of an UaaRS in eukaryotic cells is not easily achieved outside 
of yeast. Therefore, a PylRS/tRNA pair was isolated from Methanosarcina maize (Mm) 
that is orthogonal in both E. coli and mammalian cells. Evolution of Mm RSs can be 
optimized rapidly in E. coli and then used directly in mammalian cells. Evolution of a 
Mm PylRS/tRNACUAPyl for Nε-cyclopentyloxycarbonyllysine (68) and O-nitrobenzyl-
oxycarbonyl-Nε-lysine (73) was achieved in E. coli and used to express Uaa protein in 
HEK cells160. E. coli screening was also utilized for evolution of a Mb PylRS/tRNACUAPyl 
pair for incorporation of Nε-bicyclo[6.1.0]non-4-ene-9-ylmethanol-oxycarbonyllysine 
(81) and Nε-trans-cyclooctene-4-ol-oxycarbonyllysine (82) in HEK cells161. The library 
of Uaas that can be incorporated in mammalian cells should be greatly expanded by 
evolving mutually orthogonal RS/tRNA pairs in E. coli.  This, in combination with the 
ability to select PylRS variants for Uaas that do not resemble Pyl, should greatly expand 
the utility of Uaa mutagenesis. 
Incorporation of Uaas in yeast, though still a eukaryote, is facilitated by the fact 
that E. coli RS/tRNACUA pairs have high orthogonality and Amber suppression 
efficiency. Yeast are also amenable to rapid evolution of UaaRSs using the positive and 
negative pressures developed for E. coli. Using Ec TyrRS/tRNACUATyr p-
acetylphenylalanine (23), p-benzoylphenylalanine (43), p-azidophenylalanine (22), O-
methyltyrosine (27), and p-iodophenylalanine (19) were incorporated into protein in 
yeast162. Using the same strategy, several different E. coli LeuRSs were evolved to 
incorporate α-aminocaprylic acid (66) and S-nitrobenzyl-cysteine (58)163, dansylalanine 
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(51)164, and 3-(6-acetylnaphthalene-2-ylamino)-2-aminopropanoic acid (49)165. 
Development of an orthogonal Mb PylRS/tRNACUAPyl required insertion of Mb 
tRNACUAPyl into a dicistronic yeast tRNA cassette and mutation of an identity element. 
With these features accomplished, a previously evolved Mb mutant PylRS for E. coli was 
used to incorporate several Pyl analogs into yeast166. To date, a large and ever-growing 
number of Uaas have been incorporated into proteins in vivo in either prokaryotes or 
eukaryotes (Figure 1.9). However, site-specific incorporation of Uaas, as described thus 
far, is limited to using one of the three unused nonsense codons.  
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Figure 1.9-Amino Acid Identities: p-fluorophenyalanine (15)116,132, p-bromophenylalanine (18)151, p-
iodophenylalanine (19)131, p-cyanophenylalanine (21)151,167, p-azidophenylalanine (22)124,151, p-acetylphenylalanine 
(23)127, p-chlorophenylalanine (25)151, p-aminophenylalanine (26)151, O-methyltyrosine (27)123, p-nitrophenylalanine 
(28)151, 4-methyl-phenylalanine (29)150, p-trifluroacetylphenylalanine (30)150, 4-trifluoromethyl-phenylalanine (31)150, 
3-fluoro-4-methylphenylalanine (32)150, 3-fluoro-4-trifluoromethylphenylalanine (33)150, 2,3-difluoro-4-
methylphenylalanine (34)150, 2,3,5,6-tetrafluoro-4-methylphenylalanine (35)150, p-boronophenylalanine (36)168, p-
isopropylphenylalanine(37)151, o-nitrophenylalanine (38)151, m-acetylphenylalanine (39)128,  p-
oxobutanoylphenylalanine (40)169, O-allyltyrosine (41)126, p-propargyltyrosine (42)129. p-benzoylphenylalanine (43)122, 
3-(2-naphthyl)alanine (44)125, p-phenylphenylalaine (45)151, acridon-2-ylalanine (46)138, 4-(2-
bromoisobutyramido)phenylalanine (47)135, 4-(6-methyl-s-tetrazin-3-yl)aminophenylalanine (48)136, 3-(6-
acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (49)165, (7-hydroxycoumarin-4-yl) ethylglycine (50)134, 
dansylalanine (51)164, O-tert-butyltyrosine (52)151, O-o-Nitrobenzyl-tyrosine (53)133, 3-(6-hydroxy-2-naphthyl)alanine 
(54)137, 2-amino-3-[4-hydroxy-3-(1H-pyrazol-1-yl)phenyl]propanoic acid (55)170, 3-(8-hydroxyquinoline)alanine 
(56)171, benzylserine (57)151, S-nitrobenzyl-cysteine (58)163, O-nitrobenzyl-serine (59)172, 5-hydroxytryptophan (24)157, 
benzothienylalanine (60)148, 1-methyl-tryptophan (61)149, 6-methyl-tyrptophan (62)149, 6-chloro-tryptophan (63)148, 6-
bromo-tyrptophan (64)148, and 5-bromo-tryptophan (65)148. α-aminocaprylic acid (66)163, Nε-acetyllysine (67)140, Nε-
cyclopentyloxycarbonyllysine (68)160, Nε-trifluoroacetyllysine (69)166, Nε- tert-butyloxycarbonyllysine (70)141, Nε- 
benzyloxycarbonyllysine (71)173, Nε-[(1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)-carbonyl]lysine (72)166, O-
nitrobenzyl-oxycarbonyl-Nε-lysine (73)160, Nε- L-cysteinyllysine (74)142, Nε- D-cysteinyllysine (75)142, Nε- L-
thiaprolyllysine (76)142, Nε-[(2-(3-methyl-3H-diazirin-3-yl)ethoxy)carbonyl]lysine (77)166, Nε-[(2-
propynyloxy)carbonyl]lysine (78)141, Nε-[(2-azidooxy)carbonyl]lysine (79)141, Nε-5-norbornene-2-yloxycarbonyllysine 
(80)143, Nε- bicyclo[6.1.0]non-4-ene-9-ylmethanol-oxycarbonyllysine (81)161, and Nε- trans-cyclooctene-4-ol-
oxycarbonyllysine (82)161. 
 
1.13 Frame-shift Suppression and Multiple Unnatural Amino Acid Incorporation 
Site-specific Uaa incorporation through nonsense suppression is restricted to the 
use of Amber, Opal, or Ochre codons. Mutations that insert bases into the anticodon loop 
of suppressor tRNAs have been shown to suppress four base codons, +1 frame-shifts, 
during translation174. Sisido and co-workers first demonstrated that a suppressor tRNA 
with a four base anticodon, derived from an extension of a rarely used Arg codon in E. 
coli could efficiently translate protein via frame-shift suppression175. This strategy was 
then extended to decoding of a five base codon through mechanisms of tRNA hopping176. 
A library of four base anticodons was screened and a set of four base codon tRNAs were 
identified for efficient translation in E. coli177. Incorporation of two Uaas into a single 
protein was demonstrated for in vitro and in vivo translation using two four base codon 
frame-shifts with chemically acylated tRNA178,179. The archaebacterium Pyrococcus 
horikoshii (Ph) LysRS/tRNALys was used to develop an orthogonal pair for decoding of a 
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four base codon in vivo in E. coli due to tolerance in the anticodon loop of the tRNA180. 
Similarly, the Ph ProRS/tRNAPro pair was also developed to decode four base frame-
shifts in E. coli181. Taking advantage of its dual orthogonality, a Mm PylRS/tRNAPyl pair 
was designed to decode a four base codon in both E. coli and HEK cells182. Utilizing a Mj 
mutant TyrRS/tRNACUATyr and a Mm mutant PylRS/tRNAUAAPyl two Uaas were 
incorporated into GFP in E. coli in response to an Amber and Ochre codon 
respectively183. With a single stop codon translation efficiencies typically range from 20-
30%, and with addition of multiple stop codons, efficiencies are reduced even further184. 
Nonsense codon suppression is limited by competition with peptide chain 
termination by release factor-1 (RF-1). In E. coli, ribosomal protein synthesis is regulated 
by recognition of a Shine-Dalgarno (SD) sequence in mRNA and an anti-SD sequence in 
the 16S component of the ribosome. It was found that mutation of the SD and anti-SD 
sequences yielded an orthogonal mRNA-ribosome pair for selective translation184. Chin 
and co-workers have shown that by using orthogonal ribosomes, evolved to have 
preferential binding of suppressor tRNA over RF-1, suppression efficiency of Uaas can 
be increased to greater than 60% for a single Uaa and greater than 20% with multiple 
Uaas185. An orthogonal ribosome was further developed to efficiently decode four base 
codons, ribo-Q1, and incorporate multiple Uaas. Using a Mj mutant TyrRS/tRNAUCCUTyr 
and a Mb mutant PylRS/tRNACUAPyl pair two Uaas were efficiently incorporated using 
frame-shift and Amber suppression respectively186. Site-specific incorporation of single 
or multiple Uaas into a protein provides chemical handles for multifunctional protein 
labeling.  
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1.14 Genetically Encoded Unnatural Amino Acids for Click Chemistry 
 While some Uaas directly provide new functionality as intrinsic fluorophores or 
photocrosslinkers, others provide a chemical handle for further modification. Site-
specific incorporation of Uaas with handles for click chemistry provides unprecedented 
control for protein modification. Aldehydes have been genetically incorporated in the 
forms of p-acetylphenylalanine (23) , m-acetylphenylalanine (39), and a β-diketone-
phenlalanine derivative (40). As noted above, aldehydes react with aminooxy or 
hydrazide containing probes to form either stable oxime or hydrazone linkages. p-
Acetylphenylalanine (23) was expressed in mDHFR and subsequently modified with 
biotin-hydrazide87 and both Z domain protein and Rhodopsin were fluorescently labeled 
using fluorescein-hydrazide127,159.  m-Acetylphenylalanine (39) was incorporated in Z 
domain protein and labeled in vitro and in vivo with fluorescein- or biotin-hydrazide128. 
The β-diketone-phenylalanine derivative (40) was expressed in Z domain protein and 
labeled with Alxe Fluor 488-hydroxylamine169.  The Uaas homoallylglycine (5) and O-
allyltyrosine (41) contain alkene functionalities which have been incorporated into 
proteins genetically. Alkenes can be utilized in olefin metathesis and other transition 
metal catalyzed reactions187-189. An aqueous palladium catalyzed Mizoroki-Heck reaction 
was used with incorporated p-iodophenylalanine (19) to biotinylate Ras protein190. 
Bioconjugation via terminal alkynes utilizes CuAAC with an azide based probe. 
Alyknes have been genetically incorporated using Uaas such as homopropargylglycine 
(6), p-ethynylphenylalanine (20), p-propargyltyrosine (42), and an alknyl-pyrrolysine 
derivative (78). Homopropargylglycine (6) and p-ethynylphenylalanine (20) were 
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incorporated into both E. coli and mouse embryonic fibroblast cells and labeled with the 
fluorogenic dye 3-azido-7-hydroxycoumarin via CuAAC191,192. Cytochrome c3 was 
modified with a viologen-azide, an electron donor used to probe the photodriven 
reduction of the cytochrome c3 heme , through incorporated p-propargyltyrosine (42)193. 
SPAAC was performed in vivo using a strained cyclooctyne-pyrrolysine (81) with a 
fluorogenic coumarin-azide probe in E. coli194. It was also shown that strained 
cyclooctyne-pyrrolysine (81) reacts with tetrazine probes (see below)195. Incorporation of 
azides into proteins allows for bioconjugation using CuAAC, SPAAC, or Staudinger 
ligation chemistries. Recall that CuAAC labeling of an azide moiety requires the addition 
of toxic CuI, while Cu-free SPAAC requires only a strained octyne-probe. Similarly, the 
Staudinger ligation requires only the addition of a phosphine-probe. Thus, both SPAAC- 
and Staudinger-based labeling can be performed in cells. Genetically encodable Uaas 
bearing azides include azidohomoalanine (7), azidonorleucine (9), p-azidophenylalanine 
(22), and an azido-pyrrolysine derivative (79). A method for attachment of a polyethylene 
glycol chain (PEGylation) was developed for protein containing p-azidophenylalanine 
(22) using alknyl-PEG and CuAAC196. Protein glycosylation was mimicked by 
expressing protein with azidohomoalanine (7) and glycosylating with glycol-azide 
probes197,198. Genetically incorporated azides, alkyl or aryl, react readily with 
dibenzylcyclooctynes (DBCO) for protein labeling199,200. Strained cyclooctyne-
fluorophore probes have also been used for in vivo imaging of metabolite-azides47,201. 
The Staudinger ligation was used to label phage expressing p-azidophenylalanine (22) 
containing peptides with fluorescein containing phosphine202. mDHFR with 
azidohomoalanine was labeled with a FLAG-tag phosphine90. 
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 Tetrazines can be used in either [4+2] cycloadditions or inverse-electron demand 
Diels-Alder bioconjugations with norborene or trans-cyclooctene probes respectively. 
Introduction of tetrazine functionality in Uaas was demonstrated with a tetrazine-
phenylalanine derivative (48)136. trans-Cyclooctene conjugation to the encoded tetrazine 
was used to relieve quenching of GFP by the tetrazine Uaa. Though not demonstrated, a 
range of probes could be attached to trans-cyclooctenes or norborenes for protein 
labeling. Conversely, Uaas including norborene-pyrrolysine derivatives (80), a trans-
cyclooctene-pyrrolysine derivative (82), and a bicyclononyne-pyrrolysine derivative (81) 
have been genetically incorporated and subsequently modified with tetrazine-probes. 
‘Turn-on’ fluorogenic tetrazine probes were designed with fluorescein, 
tetramethylrhodamine, or boron dipyrromethene chromophores and quenching by 
tetrazine was relieved by conjugation to a norborene-pyrrolysine Uaa containing protein. 
This particularly useful technique was used to image HEK cell surface proteins143. 
Bicyclononyne-pyrrolysine (81) and trans-cyclooctene-pyrrolysine (82) were 
subsequently shown to also induce a turn-on of fluorescence upon reaction with quenched 
tetrazine probes161. Norborene-pyrrolysine (80) is also capable of reacting with tetrazines, 
nitrile imines, and photochemically activated tetrazoles to form stable protein 
conjugates203.  A comparison of the reaction kinetics of genetically encodable Uaas 
highlights the utility of tetrazine-trans-cyclooctene ligations in bioconjugation 
chemistry204. 
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1.15 Macromolecular Labeling Strategies for Proteins  
Modification or labeling of proteins with Uaas allows for site-specific control 
with minimal perturbation of the target protein, but involves manipulation of the 
translation system. In lieu of Uaa incorporation proteins can also be modified site-
specifically using a variety of macromolecular approaches. Protein modification can be 
accomplished using proteins, peptide tags, or amino acid recognition elements that direct 
subsequent labeling with high affinity. One common method utilizes antibodies that have 
been biologically engineered with a high affinity for a specific antigen or target molecule. 
Antibodies can be modified with fluorophores, often at Lys or Cys residues as previously 
discussed, while still retaining high antigen specificity205,206. Labeling of proteins using 
antibodies can be accomplished using one of two methods: 1) direct labeling of the 
antibody with affinity for the protein of interest or 2) labeling a protein of interest with a 
primary antibody followed by addition of a secondary, fluorescently labeled, antibody 
that has affinity for an epitope on the primary antibody. Peptides that serve as antigens 
for antibody recognition, FLAG-tag and Myc-tag, can be appended to protein sequences 
for labeling207,208. Due to the inherent size limitations imposed by antibody labeling, this 
technique is primarily reserved for histological staining and immunoblotting. Green 
fluorescent protein (GFP) is one of several fluorescent proteins (FP) which are found in 
aquatic species and emit light, ranging from blue to red, from a peptide based 
chromophore209. Modern Molecular Biology methods have made it trivial to generate 
fusion proteins consisting of a protein of interest, a short linker, and a FP or other reporter 
protein. Tsien and co-workers have pioneered the field of in vitro and in vivo protein 
labeling using fusion proteins with GFP and other FP variants210. A SNAP-tag was 
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developed that fuses a protein of interest to O6-alkylguanine-DNA alkyltransferase 
(hAGT) which is capable of transferring an O6-alkylguanine-probe to a Cys residue of 
hAGT211. Fusion constructs have also been made utilizing a protein Halo-Tag which 
incompletely catalyzes the removal of a halogen from a synthetic aliphatic hydrocarbon 
ligand212. SNAP- and Halo-tagging methods expanded the scope of labels that could be 
appended to proteins beyond just fluorophores. However, all of these fusion constructs 
require the attachment of large probes that may disrupt the innate function of the protein 
of interest. 
As an alternative, smaller peptide based fusion constructs have been developed 
that utilize strong metal-ligand affinities. Evidence of toxic trivalent arsenic binding to 
paired thiols in proteins led Tsien and co-workers to develop a tetracysteine motif 
(CCXXCC) peptide designed to bind to two trivalent arsenic atoms attached to a 
fluorescein scaffold (FlAsH)213. Analogous to FlAsH, a red emitting probe based on a 
biarsenical resorufin (ReAsH) was also developed214. FlAsH and ReAsH have be used in 
vivo for live cell imaging and also have the benefit of an increase in fluorescence of 
roughly 50,000 fold upon binding to the tetracysteine motif215. Incorporation of poly-His 
tags into proteins has long been used as a purification strategy with Ni2+ chelating resins. 
Ni2+-Nitrilotriacetic acid (Ni2+-NTA) is the most common complex for binding poly-His 
tags. When Ni2+-NTA is conjugated with a fluorophore, it forms a high affinity complex 
that can label poly-His containing proteins216,217. Peptides that selectively bind 
lanthanides, which in the presence of a fluorophore can display long-lived luminescence 
emissions, have been successfully incorporated into proteins218. Oligo-Asp peptide tags 
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were designed with high affinity for a fluorophore modified Zn(II)-2,2’-dipicolylamine-
Tyr (Zn(II)DpaTyr) based ligand219. The oligo-Asp:Zn(II)DpaTyr interaction was 
developed to be covalent upon binding to the oligo-Asp peptide on the protein of interest 
by reaction of an attached α-haloketone with a Cys thiol group220. The macromolecular 
strategies for protein labeling discussed above are outlined in Table 1.2. Protein 
Modification using Uaas or macromolecular tags requires genetic encoding and 
ribosomal translation. Semi-synthetic and enzymatic modification strategies are useful for 
incorporation of functionalities that are not ribosomally permissible. 
Table 1.2-Macromolecular Protein Labeling Strategies. 
Tag Affinity Epitope Recognition Element Labeling Strategy 
GFP GFP (protein) Fusion protein Intrinsically fluorescent 
Antibodies 
 
Antigen-antibody 
Covalent modification of 
primary or use of labeled 
secondary antibodies 
FLAG-tag AspTyrLysAspAsp-
AspAspLys 
Antigen-antibody Labeled anti-FLAG 
antibodies 
Myc-tag GluGlnLysLeuIslSer 
-GluGluAspLeu 
Antigen-antibody Labeled anti-Myc 
antibodies 
SNAP-tag hAGT (protein) Enzymatic catalysis O6-alkylgunaine modified 
probes 
Halo-tag Dha (protein) Enzymatic catalysis Aliphatic alkyl halide 
modified probes 
Tetra-Cys CysCysProGlyCysCys Metal-ligand affinity FlAsH or ReAsH 
Poly-His (His)n n=6-10 Metal-ligand affinity Ni2+-NTA modified 
probes 
Oligo-Asp (Asp4)n n=1-3 Metal-ligand affinity Zn2+-Dpa-Tyr modified 
probes 
 
1.16 Protein Modification Using Semi-Synthesis 
 One of the oldest methods for synthesizing peptides or proteins containing Uaas is 
solid phase peptide synthesis (SPPS). SPPS relies on the step-wise addition of N-
terminally protected amino acids to the free N-terminus of the growing poly-peptide 
chain, which is attached to a polymer support at the C-terminus221. Use of SPPS allows 
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for the incorporation of amino acids and functionality that would typically be excluded 
from ribosomal synthesis. Polypeptides of ~50 amino acids can be reliably synthesized 
using SPPS. Synthesizing polypeptides and proteins greater than 50 amino acid residues 
requires ligation strategies for connecting peptide fragments in solution. Ideally, these 
should be unprotected and the connections should be native amide bonds. Native 
chemical ligation (NCL) was developed to ligate a peptide containing a chemically 
generated C-terminal thioester with a peptide containing an N-terminal Cys. After initial 
engagement of the two fragments through transthioesterification, an S-to-N acyl shift 
produces a native amide bond at Cys222 (Figure 1.10). NCL extends the size range of 
proteins synthesized to ~15 kDa (from a single ligation), but is still limited by synthetic 
fragment size. To reduce the burden of SPPS for segments containing only Naas, protein 
fragments with an N-terminal Cys can be recombinantly expressed in E. coli223. In a 
complementary development, generation of a C-terminal thioester was realized by 
intercepting intein excision during protein splicing in a method known as expressed 
protein ligation (EPL)224. Using EPL, fluorophores, Uaas, heavy isotopes, and backbone 
modifications have been incorporated into proteins225,226. NCL and EPL result in a native 
amide bond but require the presence of a Cys residue. Several methods for Cys de-
sulfurization to alanine (Ala) have been well explored. Application of β- or γ-mercapto 
amino acids such as β-mercaptophenylalanine, β-mercaptoleucine, γ-mercaptovaline, γ-
mercaptolysine, γ-mercaptothreonine, and γ-mercaptoglutamine allows one to effectively 
carry out ligations at their corresponding amino acids (after de-sulfurization)227,228. 
Applying recombinantly expressed and synthetic fragments to NCL and EPL allows for a 
large diversity of functionality to be introduced into proteins. 
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aureus (Sa), SrtAsa, specifically cleaves a Thr/Gly linkage in a Leu-Pro-Xaa-Thr-Gly 
(LPXTG) motif and forms a new linkage at the Thr carboxy terminus with the amino 
terminus of a pentaglycine peptidoglycan234. Protein labeling using SrtAsa requires 
insertion of the LPXTG motif into the C-terminus of the protein of interest. Fluorophores, 
biotin, and Uaas for click chemistry can be incorporated into a tri- or penta-glycine 
containing peptide that is then ligated to the C-terminus of the LPXTG containing 
peptide235,236 . SrtAsa is also capable of ligating longer peptide chains and proteins such 
as GFP237. Proteins engineered to contain an N-terminal Gly are capable of acting as 
substrates for ligation to probe-LPXT depsipeptides, where the instability of the ester 
bond drives N-terminal protein modification238. Proteins were labeled at both the N- and 
C-terminus using SrtAsa and a sortase from Streptococcus pyogenes (Sp), SrtAsp, which 
is capable of using Ala-based N-terminal substrates rather than Gly-based substrates 239. 
 E. coli Biotin ligase (BirA) catalyzes the ligation of biotin to the ε-amine of a Lys 
residue located within a 15 amino acid acceptor peptide (AP). Ting and co-workers 
transposed the AP into a protein of interest which allowed for BirA dependent 
biotinylation with either biotin or a ketone containing analog of biotin240. Phage display 
was used to identify a novel yeast acceptor peptide (yAP) for yeast biotin ligase (yBL), 
which does not recognize the AP from E. coli and is therefore orthogonal to BirA241. 
BirA and yBL, along with their cognate AP and yAP respectively, were used to label 
proteins on the surface of HeLa cells with quantum dot (QD) labeled monovalent 
streptavidin derivatives of different wavelengths. The functionality incorporated in biotin 
derivatives was expanded to include azides and alkynes by screening several species of 
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biotin ligases242. In a similar manner to BirA, lipoic acid ligase from E. coli (LplA) was 
harnessed for protein bioconjugations. LplA catalyzes the ligation of lipoic acid to the ε-
amino of a Lys within an acceptor peptide (LAP) on one of three proteins involved in 
oxidative metabolism. Lipoic acid analogs containing reactive handles were screened for 
efficacy with LplA and a consensus sequence was determined for LplA recognition.  The 
22 amino LAP was inserted into a protein of interest, labeled using an azido-lipoic acid 
derivative, and subsequently fluorescently modified243. The 22 amino acid LAP was later 
reduced to 13 amino acids244. The utility of LplA was expanded by generating a mutant 
capable of ligating a fluorescent 7-hydroxycoumarin substrate, eliminating the need for a 
separate fluorophore conjugation step245. 
Subtiligase was one of the first enzymatic methods for N-terminal protein 
modification. Active site mutations of the serine protease subtilisin BPN’ produced 
subtiligase, which ligated tetrapeptide esters to a dipeptide with minimal undesired 
hydrolysis246. Preferential N-terminal sequences for subtiligase modification were 
determined using peptide phage display247. The N-terminal sequences that subtiligase 
targets are wide-ranging. Thus, subtiligase has generality which is sometimes desirable, 
but modification can only usefully be carried out in vitro. An alternate method for N-
terminal protein modification is the use of N-myristoyl transferase (NMT). NMT uses 
myristoyl-CoA as a substrate to transfer myristoyl to proteins containing an N-terminal 
Gly. This function is conserved throughout all eukaryotes but absent in prokaryotes like 
E. coli. Tolerance for an azide derived myristoyl-CoA was achieved using NMT from 
Candida albicans (Ca)248. Using CaNMT and the azide substrate proteins containing an 
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N-terminal Gly can be modified in intact E. coli and functionalized using click 
chemistry249. While subtiligase modification is general, it must be driven by high 
concentrations of the amine nucleophile because subtiligase derives from a protease.  
NMT modification is driven toward amide formation by the instability of the CoA 
thioester donor, but has limited substrate scope.  An alternative strategy comes from an E. 
coli enzyme that is inherently an N-terminal modifier with broad specificity. 
In E. coli, protein degradation is governed by the N-end rule pathway250. E. coli 
aminoacyl transferase (AaT) is an enzyme in the N-end rule pathway that transfers Leu, 
Phe, or Met to protein containing an N-terminal Lys or Arg251,252. The resulting N-
terminal dipeptides signal the protein for degradation through the ClpS/ClpAP pathway. 
Aminoacylated tRNA serves as an activated donor for N-terminal transfer. The selectivity 
of AaT has been explored using misacylated tRNAs, and a wide range of Uaas have been 
transferred to the N-termini of peptides and proteins253-256. Based upon detailed 
crystallographic data,257-259 minimal donor molecules for AaT transfer have been 
explored based on truncations of the tRNA acceptor stem260. In our own laboratory, the 3´ 
adenosine of tRNA was found to be the minimal segment required to maintain AaT 
recognition and transfer. Using synthetic aminoacylated adenosine donors, a 
chemoenzymatic method for protein labeling was developed261. Further expansion of 
AaT mediated N-terminal modification has been applied to facilitate traceless NCL at 
Met residues262. N-terminal protein modification using AaT is highly selective in 
complex environments and tolerates a broad range of donor substrates.  Enzymatic 
modification of proteins (see Table 1.3 for a summary), combined with Uaa 
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incorporation, macromolecular labeling, and semi-synthetic techniques, creates a toolbox 
for protein multifunctionalization. 
Table 1.3-Enzymatic Methods for Protein Modification. 
Enzyme Recognition Epitope Labeling Cofactor 
TGase ProLysProGlnGlnPheMet Amine-containing probes 
Sortase C-terminal LeuProThrGly N-terminal poly-Gly probes 
BirA AP Modified biotin probes 
LplA LAP Modified lipoic acid probes 
Subtiligase N-terminal MetPhePro Modified peptides/protein/probes containing 
AlaAlaProPhe-Lys/Phe-glycolate esters 
NMT N-terminal Gly Modified myristol-CoA probes 
AaT N- terminal Arg/Lys Met, Phe, Leu analogs 
 
1.18 Multifunctionalization of Proteins 
Introduction of multiple functionalities or labels into a protein requires use of one 
or more bioorthogonal labeling techniques. The bioorthogonal labeling techniques need 
to be mutually orthogonal or capable of being carried out sequentially. Several 
approaches for introduction of multiple functionalities into proteins have been explored, 
varying in their complexity and degree of selectivity. Cys, as detailed above, is easily 
labeled and inserted into proteins using site-directed mutagenesis. One technique for the 
double labeling of a protein using Cys exploits the accessibility of residues at different 
sites in the protein. Two Cys residues are introduced into a protein where one site is 
easily accessible under native conditions, while the other site is occluded. Labeling of the 
accessible Cys is performed, followed by denaturation of the protein and labeling of the 
now exposed second Cys263,264. This method was expanded to include protein-protein 
interactions as a mode for burying a Cys residue265. It was also shown that the 
microenvironment of a Cys residue can be used to direct chemical reactions for labeling. 
Generation of a Cys-sulfonium can be controlled to be substitute with an azide or 
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undergo β-elimination to form dehydroalanine depending on the shielding of the α-proton 
in the protein microenvironment266. The dehydroalanine and azide functionalities can 
then be orthogonally modified using electrophilic addition or click reactions, 
respectively. A more generalizable approach was achieved by labeling a tetracysteine 
motif with FlAsH followed by maleimide labeling of a Cys residue267. Cys insertion has 
also been combined with TGase enzymatic post-translational labeling to incorporate a 
FRET fluorophore pair. The Cys was labeled with an Alexa 488-maleimide and TGase 
was used to append an Alexa647-cadaverine268. Though introduction these methods 
achieve double labeling in reasonably high yields, the TGase and tetracysteine motifs 
may be somewhat perturbing to the protein. 
 Uaas provide a versatile set of bioorthogonal chemical handles for protein 
multifunctionalization. Auxotrophic incorporation allows for codon reassignment of a 
natural amino acid for an Uaa. By utilizing organisms with one or more auxotrophic 
phenotypes, different Uaas can be incorporated into a single protein. In vivo expression of 
a ‘teflon’ protein was demonstrated by replacing Pro, Phe, and Trp, for a total of 24/267 
residues, with fluorinated analogs269. Global replacement of Pro, Phe, and Trp resulted in 
a highly substituted fluorinated protein, but with a large decrease in protein yield. Also, 
using auxotrophic incorporation of Uaas, a trifunctionalized protein was generated by 
replacement of Met, Pro, and Trp with homopropargylglycine (6), cis-4-fluoroproline 
(14), and 4-azatryptophan. The protein exhibited intrinsic fluorescence from 4-
azatryptophan and could be modified with glycans using CuAAC at 
homopropargylglycine (6). Incorporation of cis-4-fluoroproline (14) provided protein 
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stability to offset the destabilizing effect of incorporation of multiple Uaas270. 
Auxotrophic incorporation of a single azidohomoalanine (7), through protein 
engineering, and subsequent SPAAC PEGylation was combined with Cys fluorophore 
labeling to generate a protein with dual functionality271. In another example, a 
chemoenzymatic method for protein double labeling was designed using incorporation of 
a single azidohomoalanine (7) through auxotrophic incorporation, and SrtA labeling of a 
C-terminal LPXTG motif. The azidohomoalanine (7) was fluorescently modified with a 
DBCO-probe, and the C-terminus was modified with a polyglycine-probe272. Labeling a 
protein via auxotrophic incorporation will not be appropriate in cases where global 
replacement of an amino acid is not acceptable. 
 Incorporation of Uaas through nonsense or frameshift suppression allows for site-
specific introduction of a probe or chemical handle for protein modification. Amber 
codon suppression was combined with Cys-maleimide labeling to generate double-
labeled protein. p-Acetylphenylalanine (23) was incorporated using a Mj mutant 
TyrRS/tRNACUA pair and modified with an Alexa488-hydroxylamine. The single Cys site 
was labeled with Alexa594-maleimide273. While it is theoretically a highly optimal 
method for multiple labeling, site-specific incorporation of multiple Uaas is hampered by 
a number of technical difficulties.  In cells, it is limited by the ability to generate multiple 
orthogonal RS/tRNA pairs. Using chemically acylated tRNA limits the requirements to 
only identifying orthogonal tRNA pairs. Several groups have used chemically acylated 
tRNA to incorporate two Uaas using an Amber codon and a four base codon pair. Using 
this technique, p-aminophenylalanine modified with a fluorophore and a differently 
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modified Lys residue were incorporated into a single protein274. Similarly 
biphenylphenylalaine and 7-hydroxycoumarin Uaas were incorporated as a FRET pair for 
monitoring protein conformational dynamics275. Using chemically acylated tRNA and 
frameshift suppression, calmodulin was synthesized with a BODIPY Fl-lysine and 
BODIPY558-lysine FRET pair for elucidating conformational dynamics276.  
Unfortunately, chemical acylation of tRNA is ultimately limited by low protein yields 
owing to a lack of enzymatic turnover and the complexity of aminoacyl tRNA synthesis. 
 Use of multiple orthogonal RS/tRNA pairs allows for incorporation of different 
Uaas in vivo. p-Acetylphenylalanine (23) and alknyl-pyrrolysine (78) were incorporated 
into calmodulin protein using simultaneous Amber and Opal nonsense codon 
suppression. This was accomplished using a Mj p-acetylphenylalanine (23) RS/tRNACUA 
and a Mm alknyl-pyrrolysine (78) RS/tRNAUCA orthogonal pair. After protein expression, 
p-acetylphenylalaine (23) was fluorescently labeled using a hydrazine probe and alknyl-
pyrrolysine (78) was fluorescently labeled using CuAAC277. Conformational dynamics 
upon peptide binding in the presence of Ca2+ were monitored using single molecule 
FRET. A similar strategy was applied using Amber and Ochre nonsense codon 
suppression for incorporation of two Uaas. Mj mutant TyrRS/tRNACUA and Mm mutant 
PylRS/tRNAUUA were used to incorporate p-azidophenylalanine (22) and α-
aminocaprylic acid (66), respectively. Two mutually orthogonal labeling reactions were 
used to install two fluorophores. A rhodamine110-DBCO was used to label p-
azidophenylalanine (22) through a SPAAC reaction and a coumarin-hydroxylamine was 
used to label the carbonyl-lysine derivative (67)278. Intramolecular protein crosslinking 
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through triazole bond formation was facilitated using ribo-Q1 to incorporate alknyl-
pyrrolysine (78) using a Mb PylRS/tRNACUA pair and p-azidophenylalanine (22) using a 
Mj mutant PheRS/tRNAUCCU pair186. An alternative to using multiple nonsense or 
frameshift codons in tandem is the combination of nonsense suppression with 
auxotrophic incorporation. Amber codon suppression has been combined with 
auxotrophic incorporation, either single or double auxotrophic phenotypes, to generate 
protein with azide or alkyne functionality, photocrosslinkers, and modified amino acid 
analogs279,280 . 
 Several researchers have used intein and split-intein techniques to generate 
double-labeled proteins. C-terminal thioesters were generated from inteins and 
subsequently reacted with (bis)oxyamine to form a keto reactive hydroxylamine. 
Following hydroxylamine formation an N-terminal Cys was revealed by site-specific 
proteolysis. In a one-pot reaction the Cys was modified with a coumarin-thioester and the 
hydroxylamine was reacted with a keto-fluorescein281. NCL has also been used as an 
approach to obtain double-labeled protein through controlled Cys labeling as follows. An 
intein is used to generate an N-terminal protein or peptide containing an internal Cys. The 
Cys is labeled using a fluorophore-maleimide probe and then is used in NCL with a 
peptide with an N-terminal Cys. The Cys thiol remaining after NCL is then labeled with a 
second fluorophore-maleimide probe282. In our laboratory, it was shown that NCL could 
be combined with Amber codon suppression. Protein was expressed containing p-
cyanophenyalanine and an enzymatically generated N-terminal Cys. This fragment was 
then subjected to NCL with a synthetic peptide containing a thioamide quencher and a C-
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terminal thioester. The p-cyanophenylalanine (21)/thioamide provide a minimally 
perturbing FRET pair for conformational dynamics283. Ligation at a Met precursor was 
applied to generate protein labeled with a p-cyanophenylalanine (21)/thioamide FRET 
pair in a traceless fashion. Protein was expressed containing p-cyanophenylalanine (21) 
and enzymatically cleaved to have an N-terminal Lys. The N-terminal Lys was then 
modified at the α-amine with a protected homocysteine using AaT. This fragment was 
then used in NCL with a thioamide N-terminal fragment. Post-ligation the homocysteine 
was methylated to Met resulting in a traceless ligation at Xaa-Met-Lys-Xaa sequences284. 
Protein multifunctionalization is achieved by combining Uaa incorporation, 
macromolecular tagging, protein semi-synthesis, and enzymatic modification. 
Functionalization of a protein allows for structure-function studies, cellular localization, 
and probing of protein interactions.  
1.19 Introduction to α-Synuclein (αS) 
α-Synuclein (αS) is an intrinsically disordered 140 amino acid protein that is a 
key contributor to the pathology of Parkinson’s disease (PD)285. Patients with PD suffer 
from resting tremor, rigidity, and bradykinesia. Post-mortem analysis reveals that fibrillar 
aggregates of αS are the main component of Lewy bodies in patients with PD286-288. αS is 
comprised of three domains: the N-terminus, which contains semi-conserved KTKEGV 
repeats, a central region known as the non-amyloid-β component (NAC) domain, and a 
negatively charged C-terminal domain (Figure 1.11A)289,290. Residues 61-95, comprising 
the NAC domain, drive the formation of β-sheet rich amyloidogenic aggregates291. In 
vitro aggregation studies suggest a nucleation-propagation mechanism for αS fibril 
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which has been suggested to lead to an increased aggregation propensity300. Genetic 
mutations alter the physiological properties of αS and lead to PD. It is not known whether 
PD results from a loss of function or gain of toxicity.  
Genetic knockouts of αS in primary tissue cultures and model organisms show no 
lethality or impaired neuronal development. Although no known function of αS has been 
definitely assigned, it has been postulated to be involved in synaptic plasticity and vesicle 
trafficking301. Soluble NSF Attachment Receptor (SNARE) proteins mediate 
neurotransmitter release and vesicle recycling. αS has been shown to drive the formation 
of SNARE protein complexes in a chaperone like mechanism302. Overexpression of αS, 
mimicking levels similar to a genetic duplication or triplication, inhibited synaptic vesicle 
recycling303. Antisense oligonucleotide suppression of αS in cultured neurons led to a 
decreased pool of synaptic vesicles implying an inhibitory regulatory function304. αS is 
capable of adopting an α-helical structure upon binding to membranes, a process 
mediated by initial insertion of the N-terminal domain305. Depending on the size and 
curvature of membranes used, αS forms either a folded, broken helix conformation306,307 
or an extended single helix conformation308-310. However, upon aggregation of αS fibrils 
have been shown to disrupt membranes and form pore-like oligomers or protofibrils311-
313. αS is also subject to several post-translational modifications that have various effects 
on disease state pathology.  
αS isolated from Lewy bodies contain PTMs including ubiquitination314,315, 
phosphorylation316-319, nitration320, oxidation321, and proteolytic truncation322. αS is 
susceptible to ubiquitination at Lys21, 23, 32, and 34 in non-fibril form and Lys6, 10, and 
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12 in fibrils in vitro. In vivo ubiquitination results were similar to those observed for in 
vitro fibril αS323. Interpreting these findings suggests that pathological αS is primarily 
ubiquinated after aggregation. Ubiquitination of proteins leads to protein degradation 
through either the ubiquitin proteasomal system or the autophagy lysosomal pathway. 
Overexpression of ubiquitin with αS was shown to rescue a Drosophila model of PD324. 
Phosphorylation of αS at Ser129 decreases the rate of fibrillization in vitro compared to 
wild type (WT) αS325. Similarly, phosphorylation at Ser87 also decreases fibrillization 
rates in vitro and reduces binding to membranes326. In lieu of homogenously 
phosphorylated proteins, several studies have used phospho-mimetics to study αS327-329. 
Results of these studies should be analyzed with caution as they utilize substitution of 
endogenous amino acids to mimic the charge and size of a phosphate group325. 
Monomeric or dimeric nitrated αS variants exhibit accelerated fibrillization in vitro at 
low concentrations. Nitration of αS also inhibited the binding to lipid vesicles through 
disruption of helix formation330. C-terminal truncations of αS are found to accelerate 
aggregation rates in vitro when used at substoichiometric concentrations to WT αS331. 
The 20S proteasome produces αS fragments, C-terminal truncations from incomplete 
degradation, similar to those observed in vivo.  A greater degree of cellular toxicity was 
also observed when incubated with substoichiometric amounts of C-terminal truncated 
αS332. Oxidation of Met residues in αS is achieved rapidly by reaction with dopamine, an 
abundant neurotransmitter333. In vitro experiments showed that oxidized αS inhibited 
fibrillization. Methionine oxidation also decreases membrane binding affinity334. It is 
postulated that αS mediates oxidative cellular stress through Met oxidation and 
membrane dissociation. Following membrane dissociation, oxidized Met residues could 
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be substrates for cytosolic methionine sulfoxide reductase, reducing them back to Met. 
PTMs of αS modulate membrane binding, fibrillization kinetics, and cellular toxicity. 
Understanding of the role of αS in normal neuronal function and under disease state 
conditions can be greatly aided by the generation of site-specifically modified and labeled 
proteins. 
1.21 Labeling Strategies for αS 
 Currently, there exist several strategies for site-specifically modifying and 
labeling αS. Despite its large size, it was shown that attachment of YFP to the C-terminus 
of αS was a viable method for fluorescent labeling335. In vivo amyloid formation was 
monitored using changes in YFP lifetime fluorescence resulting from FRET with the 
intrinsic fluorescence of αS that develops during aggregation336. Lifetime imaging of 
intracellular oligomeric αS was observed by appending either hemagglutinin or V5 
immuno-tags and labeling with the corresponding primary antibodies and fluorescent 
secondary antibodies337. Membrane affinity of the N- and C-termini was determined 
using fixed neuronal cells labeled at the N- and C-terminus using antibodies of different 
species followed by fluorescently labeled secondary antibodies338. Introduction of the 
tetracysteine motif into αS demonstrated highly specific and maleimide free labeling 
using either FlAsH or ReAsH339,340. While use of FPs, antibodies, or peptide tags are 
highly site-specific, their large sizes may perturb cellular pathology. Trp, Tyr, and Phe 
are minimally perturbing, intrinsically fluorescent amino acids that can be used to 
monitor conformational dynamics. Introduction of a Trp residue was used to characterize 
αS oligomers during aggregation341,342. The size and spatial orientation of oligomers were 
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observed using the FRET pairs Trp/Tyr and Trp/p-nitrotyrosine (chemically generated), 
but require an all Phe background343,344. Intrinsically fluorescent Naas are useful but 
require intensive mutagenesis to produce Trp- and Tyr-free protein constructs so that 
fluorescence data can be easily interpreted.  
Alternatively, synthetic probes can be incorporation into αS through conjugation 
to Naas such as Lys and Cys. Lys is an abundant amino acid in αS and labeling is non-
selective. However, by controlling protein:dye ratios homogenous populations of labeled 
αS were obtained345.  Introduction of single Cys mutants into αS (which lacks 
endogenous Cys) provided a selective reactive handle for conjugation of maleimide 
containing fluorophores in order to probe early aggregation events and binding to lipid 
vesicles346-348. EPR spin probes have also been attached using Cys-maleimide 
conjugation349,350. Several groups have double labeled αS using introduction of two Cys 
residues and stochastically controlled fluorophore-maleimide labeling308,351-358. An ideal 
strategy would be one that permits multiple site-specific protein modifications, 
reproducibly yielding homogenously labeled protein.  
As described previously, site-specific multifunctionalization of a protein requires 
two orthogonal labeling strategies. Protein multifunctional can also utilize endogenous 
amino acids for labeling. A fluorophore FRET pair was incorporated using Cys-
maleimide labeling in conjunction with intrinsic Trp fluorescence. The conformational 
dynamics of αS were probed using an introduced Trp and coumarin via Cys-maleimide 
labeling359. Orthogonal Cys-maleimide and pH controlled N-terminal α-amine specific 
labeling were used to introduce a longer wavelength FRET pair360. NCL is a useful tool 
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for incorporating functional moieties that are not accessible through traditional 
conjugation techniques. Using NCL, αS was synthesized containing mono-ubiquitin at 
Lys6, N-terminal acylation, and phosphorylation at Tyr125361-363. Protein modification 
was traditionally limited to accessible N- and C-terminal fragments. Advances in NCL 
have allowed for the total chemical synthesis of αS that could contain modifications 
throughout the entire protein364. Our lab has demonstrated the incorporation of a Trp-
thioamide fluorophore-quencher pair into αS using a semi-synthetic strategy365. 
Additionally, we have demonstrated a chemo-enzymatic approach to αS semi-synthesis 
using traceless NCL at Met for incorporating modifications such as a coumarin amino 
acid262. Amber codon suppression was used with either NCL or NCL at Met to 
incorporate a p-cyanophenylalanine (21)/thioamide FRET pair into αS semi-
synthetically283,284. αS is a suitable model protein for the development of novel protein 
modification strategies. It is subject to PTMs including phosphorylation, ubiquitination, 
and methylation among several others. The native function of αS has been suggested, but 
not definitely assigned. Similarly, the mechanism of the toxicity observed in 
dopaminergic neurons caused by αS is also still unknown. Generation of modified and 
labeled αS constructs should aide researchers in determining function and mode of 
toxicity. 
The aim of this thesis will be to apply the aforementioned protein modification 
strategies to model protein systems. The following methods will be used to modify 
proteins with Uaas: 1) AaT mediated N-terminal protein modification, 2) Amber codon 
suppression, and 3) auxotrophic strain incorporation. By combining orthogonal labeling 
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strategies we sought to obtain multifunctionalized protein. Our protein modification 
strategies are capable of introducing intrinsic fluorophores, chemical handles for click-
chemistry, and ligation sites for protein semi-synthesis. Click- chemistry and protein 
semi-synthesis will be used to introduce fluorophores, FRET pairs, photocrosslinkers, 
and affinity enrichment probes. As an alternative to protein labeling, we will also use 
click-chemistry handles to control protein function in a highly selective fashion.  
  
  
  59 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 : N-TERMINAL PROTEIN MODIFICATION USING SIMPLE 
AMINOACYL TRANSFERASE SUBSTRATES 
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Reprinted (adapted) with permission from (Anne M. Wagner, Mark W. Fegley, John B. 
Warner, Christina L. J. Grindley, Nicholas P. Marotta, and E. James Petersson. J. Am. 
Chem. Soc. 2011, 133, 15139–15147.). Copyright (2011) American Chemical Society. 
 
2.1 Introduction 
The conjugation of synthetic molecules to proteins contributes to biomedical 
research by enabling the immobilization of proteins on surfaces, modifications with 
chromophores to make in vitro sensors, or tagging with in vivo imaging agents366-370.  In 
most cases, the formation of well-defined conjugates is valuable, if not essential.  The 
protein termini are attractive targets for conjugation, because in many cases appending 
synthetic molecules at the termini will have minimal undesired effects on protein folding 
and function371-391.  This is particularly applicable in cases where the terminus is 
relatively unstructured.  As part of our research on minimalist labeling strategies for 
biophysical studies, we sought a method for N-terminal modification that could be 
carried out easily under conditions that maintain folding without substantial prior protein 
manipulation11. 
Selective N-terminal modification has been achieved by a variety of chemical and 
enzymatic methods, each with benefits and drawbacks.  Small molecule strategies permit 
the attachment of a variety of molecules, but they are subject to side reactions, 
incomplete specificity for the N-terminus, and may need to be carried out in organic 
solvent mixtures28,31,381,392-399.  Reverse proteolysis methods can be used to modify the N-
terminus under conditions that do not require protein unfolding, but the reaction can be 
difficult to drive to completion without high protein concentrations223,226,247,400-410.  
Several other chemoenzymatic methods are valuable in functioning under benign 
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conditions, but have moderate-sized target sequences which must be appended to the 
protein234,235,237,411-413,414,415. Here, we describe a minimal system for N-terminal protein 
labeling that utilizes only adenonsine esters of natural or unnatural aminoacids and a 
single, readily available enzyme.  This process gives high yields of modified proteins 
under non-denaturing conditions and requires only a single basic amino acid for specific 
recognition. 
Aminoacyl tRNA transferases (AaTs) are members of a growing class of enzymes 
that use aminoacyl tRNAs in secondary metabolism416.  The E. coli AaT catalyzes the 
transfer of leucine (Leu), phenylalanine (Phe), or methionine (Met) from an aminoacyl 
tRNA to a protein bearing an N-terminal arginine (Arg) or lysine (Lys)258,417,418.  The 
addition of Leu or Phe targets that protein for degradation by ClpA as part of the N-end 
rule pathway250,419-421.  Kaji et al. first observed AaT aminoacylation activity in crude E. 
coli preparations417,422,423.  Soffer and Leibowitz subsequently reconstituted the purified 
enzyme and characterized its specificity for both the RNA and amino acid components of 
the donor molecule, demonstrating its first use in transferring an unnatural amino acid, p-
fluorophenylalanine424,425. 
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Figure 2.1-Transferase-mediated N-terminal protein modification.  
Top: Fully enzymatic methods use aminoacyl-tRNA synthetase (aaRS), tRNA, aminoacyl transferase (AaT), amino 
acid, and ATP.  Bottom: Chemoenzymatic methods use only a synthetic nucleic acid donor and transferase.  In this 
work, an aminoacyl mononucleoside (Rn = H) was used. Reprinted from Wagner 2011261. 
 
Recently, purified AaT has been used to modify proteins in vitro with a variety of 
unnatural amino acids charged onto tRNAs, either by chemical semi-synthesis or the use 
of a mutant aminoacyl tRNA synthetase (aaRS)253,255,260,383.  Abramochkin and Shrader 
discovered that AaT was tolerant of variation in the acceptor stem (aminoacylation site) 
of the tRNA, and Sisido and coworkers have shown that much shorter oligonucleotides 
(Figure 2.1 Bottom, Rn = 2 – 22 nucleotides) can act as donors251,260,426.  As part of their 
structural characterization of AaT, Tomita and coworkers found that AaT could bind 
phenylalanyl adenosine and transfer Phe to peptides in trace amounts259.  However, the 
use of adenosine mononucleoside as a donor substrate for AaT has not, to our knowledge, 
been further explored. 
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2.2 Results and Discussion 
We have found that a variety of hydrophobic amino acids can be transferred from 
adenosine donors with high yields at relatively low protein concentrations(Figure 2.2)261. 
These donors were synthesized from commercially-available active esters of the amino 
acids. The aminoacyl adenosine substrate scope of the wild type AaT enzyme was 
determined using model peptides and found to be quite broad. We then sought to modify 
larger protein substrates with this approach. However, it is possible that proteins are 
modified with different efficiencies than peptide substrates260,425,426.  To address this 
question and to demonstrate the utility of our method in tagging full-sized proteins with 
useful fluorophores or affinity purification tags, we modified the milk protein α-casein 
(bearing a native N-terminal Arg after proteolysis of a leader sequence)427.  First, 
modification using Phe donor 4a was assessed by Edman degradation; where successful, 
quantitative addition of Phe was observed.  
 
Figure 2.2-Aminoacyl Donors Tested with AaT. 
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 In a more complex set of experiments, we first modified α-casein (23 kDa) with 
Azf using an adenosine donor 4c. The degree of 4c transfer was monitored using a Cu-
catalyzed azide-alkyne cycloaddition (“click” reaction) to append a fluorescein label428-
431. (See Figure 2.3A) Prior to fluorescent-labeling, the initial transfer of Azf was 
analyzed by trypsin digest and MALDI MS of α-casein. (Figure 2.3C)  The N-terminal 
peptide ArgProLys disappeared from the mass spectrum following modification and a 
peptide corresponding to AzfArgProLys was observed (also a mass corresponding to 
AzfArgProLys after loss of N2 during ionization, N2 loss was also observed for the 
authentic small peptide AzfLysAlkaAcm).  Complete conversion of α-casein was 
observed in MALDI MS due to double addition of 4c to drive reaction. 
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bearing protein was reacted with fluorescein alkyne (FlAlk) in the presence of CuI.  The 
results of this labeling experiment, as well as appropriate control reactions are shown in 
Figure 2.3B.  One can see that fluorescent α-casein is only observed under the proper 
conditions (Lane 8), where both the chemoenzymatic labeling by AaT with 4c and the 
subsequent click reaction is successful.   
Finally, we demonstrated the utility of AaT to transfer a simple adenosine donor 
in a complex cellular milieu.  A similar labeling experiment was performed in crude E. 
coli lysate with unpurified AaT.  Azf transfer was successful, as shown by the 
observation of fluorescence after labeling with FlAlk.  Control reactions (see Figure 2.4) 
show no observable labeling of any protein, implying that endogenous levels of proteins 
terminating in Arg or Lys are too low to be observed here. 
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Figure 2.4-PAGE Analysis of α-Casein Modification in Cleared E. coli Lysate.   
Left: Coomassie-stained gel.  Right: Fluorescence image from 302 nm excitation.  Lanes (left to right): 1) Molecular 
weight markers (Masses in kDa: 17, 25, 30, 46, 58, 80, 175); 2) Cleared lysate reacted with FlAlk; 3) Cleared lysate 
modified with 4c then reacted with FlAlk; 4) Cleared lysate with α-casein (0.012 mg) modified with 4c then reacted 
with FlAlk; 5) Cleared lysate with α-casein (0.12 mg) modified with 4c then reacted with FlAlk; 6) Molecular weight 
markers. Reprinted from Wagner 2011261. 
 
2.3 Conclusions 
 Substantial recent effort has been devoted to developing methods for labeling 
proteins under conditions that maintain protein folding and activity432-434.  E. coli 
aminoacyl tRNA transferase can work under these conditions, and specifically modifies 
the N-terminus, a useful point for conjugation. Our reaction conditions and yields 
compare favorably to two well-established methods in the field.  Subtiligase (reverse 
proteolysis) reactions can be carried out in a few hours, but rarely go to 
completion405,406,410.  The pryidoxyl-5-phosphate (PLP) transamination reactions of 
Francis and coworkers can require elevated temperatures to achieve high yields and are 
subject to a number of side reactions398,399.  AaT transfer reactions are highly specific (no 
Lys sidechain modifications were observed in our work or the work of others) and can be 
driven to completion by subsequent repeated additions of donor. Fully enzymatic 
methods require no prior synthesis and aminoacyl tRNAs are more efficient substrates for 
AaT.  On the other hand, our methods can be scaled up to modify larger quantities of 
protein since they do not require the use of purified tRNA. 
 We have shown that our method can be used to transfer reactive handles to the N-
terminus under “protein friendly” (pH ~ 7, high salt, 37 °C) conditions and that the 
labeled protein product can be easily purified afterward.  Given the previous success of 
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Sisido and co-workers, we expect that further mutation of AaT will allow us to transfer 
larger sidechains that may permit direct transfer of fluorescent probes or affinity tags.  We 
also hope to use the available crystal structures to redesign AaT to act on other N-
terminal sequences through a combination of rational design and selection.  Finally, our 
demonstration that AaT can modify α-casein in crude lysates, coupled with the cell-
permeability of our moderately polar donors raises the exciting possibility of using AaT 
as part of an in vivo labeling strategy. 
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2.5 Materials and Methods 
2.5.1 General Information.   
Trifluoroacetic acid (TFA) was purchased from Sigma-Aldrich (St. Louis, MO). 
All solvents were purchased from Fisher Scientific (Pittsburgh, PA). All solvents were 
purchased from Fisher Scientific (Pittsburgh, PA).  E. coli BL21(DE3) cells and 
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QuikChange® site-directed mutagenesis kits were purchased from Stratagene (La Jolla, 
CA).  The pEG6 plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander 
Varshavsky (California Institute of Technology).  Ni-NTA resin was from Qiagen 
(Valencia, CA, USA). Sequencing-grade trypsin was purchased from Promega (Madison, 
WI).  Restriction Grade Factor Xa protease was purchased from Novagen (San Diego, 
CA, USA). Bradford reagent assay kits were purchased from BioRAD (Hercules, CA).  
Protease inhibitor cocktail was purchased from Sigma-Aldrich (St. Louis, MO). All other 
reagents were purchased from Fisher Scientific (Pittsburgh, PA). 
MilliQ filtered (18 MΩ) water was used for all aqueous solutions (Millipore; 
Billerica, MA).  Matrix-assisted laser desorption ionization (MALDI) mass spectra were 
collected using a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, 
MA).  “Low resolution” electrospray ionization (ESI) mass spectra (LRMS) were 
obtained on a Waters Acquity Ultra Performance LC connected to a single quadrupole 
detector (SQD) mass spectrometer.   
2.5.2 Synthesis, Characterization, and Kinetics of Aminoacyl Donor Molecules. 
 This section was performed by Anne M. Wagner and can be found in Wagner et 
al. 2011261. 
2.5.3 Aminoacyl Transferase Expression and Purification.   
 E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3) 
cells using a procedure adapted from Graciet et al252.  E. coli were grown in a primary 
culture of 5 mL LB at 37 °C to OD600 of 0.5 and then were rediluted into a secondary 
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culture of 500 mL LB and grown to OD600 of 0.6.  AaT expression was induced using 0.1 
mM isopropyl β-D-thiogalactoside and cells were grown at 25 °C for ~16 h.  Cells were 
pelleted at 5, 000 rpm using a GS3 rotor and Sorvall RC-5 centrifuge.  Cell pellets were 
resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 mM imidazole, 300 mM 
KCl, and 5 mM β-mercaptoethanol, pH 8.0) and included protease inhibitor cocktail, 1 
mM PMSF, and 10 units/mL DNAse1–Grade II.  Following resuspension, the cells were 
lysed using sonication.  Soluble proteins were collected via centrifugation at 13, 200 rpm 
for 15 min.  Collected soluble protein was gently shaken for 1 h at ambient temperature 
with Ni-NTA resin.  The resin was prepared by rinsing with Ni-NTA binding buffer and 
then washed with four volumes of Ni-NTA wash buffer (50 mM Tris, 50 mM imidazole, 
300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0).  The proteins were eluted with 
elution buffer (50 mM Tris, 250 mM imidazole, 300 mM KCl, and 5 mM β-
mercaptoethanol/pH 8.0).  Pure elution fractions of E. coli AaT were dialyzed overnight 
in transferase buffer (50 mM Tris, 30% glycerol, 120 mM (NH4)2SO4, 5 mM β-
mercaptoethanol, pH 8.0).  The dialyzed enzymes were stored at - 80°C.  Protein 
concentrations were determined using the Bradford assay and a bovine serum albumin 
standard curve according to the manufacturer’s instructions435. 
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Figure 2.5-PAGE Analysis of AaT Expression and Purification.   
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2) Preinduction; 3) 
Postinduction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) Ni-NTA column flow-through; 7) Column 
wash 1; 8) Column wash 3; 9) Elution fraction 1; 10) Combined elution fractions 3-5 after overnight dialysis. Reprinted 
from Wagner 2011261. 
 
2.5.4 α-Casein N-Terminal Modification.   
α-Casein (4.8 mg) was modified with Azf-A (4c) in a reaction volume of 1 mL in 
modified AaT buffer (50 mM HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2) and AaT 
(0.05 mg).  The reaction mixture was incubated at 37 °C for 12 h, AaT was removed 
using Ni2+ resin (Ni-NTA Superflow, Qiagen), and then buffer exchanged four times into 
phosphate buffered saline (PBS, 12 mM NaH2PO4, 50 mM NaCl, 4.7 mM KCl, pH 8.0) 
by Spectra/Por 1 dialysis tubing (Spectrum Labs; Rancho Dominguez, CA).  Azf-
modified α-casein was used directly after buffer exchange into PBS.  Aliquots (1 nmol) 
of α-casein were diluted into PBS (22 µL) containing either fluorescein-alkyne (FlAlk, 91 
µm) or propargylamine (Alk, 227 µM) for copper-catalyzed azide-alkyne cycloaddition 
(CuAAC).  The CuAAC reaction was initiated by addition of CuSO4 (100 µM), tris-(3-
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hydroxypropyltriazolylmethyl) amine (THPTA, 500 µM), and sodium ascorbate (5 mM).  
For control reactions, equivalent volumes were replaced with either PBS or water.  The 
reaction mixtures were incubated at 4 °C for 2h.  Reactions were boiled with gel loading 
dye LDS (Pierce; Rockford, IL) for 10 min at 95 °C and analyzed by SDS-PAGE.  
Fluorescence images were obtained with a Geldoc (Bio-RAD; Hercules, CA) using an 
excitation wavelength of 302 nm for detection of fluorescein. α-Casein was also directly 
visualized by Coomassie Brilliant Blue staining (see Figure 2.3). 
2.5.5 Edman Degradation Analysis of α-Casein Modification.   
 Phe was ligated to α-casein using 4a as described previously with the following 
modifications.  The substrate (1 mM) was 10 times more concentrated, and the total 
volume was 4 times greater.  This reaction was run overnight; at the 4 h time point, an 
additional 50 µL dose of 25 mM 4a donor was added to the reaction.  The His10-tagged 
AaT was separated from the reaction via nickel bead purification: 100 L Ni-NTA resin 
was added at a ratio of 25 µL per 12.5 µM AaT, the beads were shaken with the reaction 
for 2 hours, then separated via centrifugation at 13, 200 rpm for 2 min.  The supernatant 
was removed, diluted to 1 mL with Milli-Q water, and dialyzed against PBS overnight at 
4 °C to remove any residual 4a.  The protein was electroblotted onto PVDF membrane 
and sent to Johns Hopkins University Synthesis and Sequencing Facility (Baltimore, MD) 
for Edman Degradation analysis. Section 2.5.5 was performed by Anne M. Wagner. 
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Figure 2.6-Edman Degradation Analysis of α-Casein Modification.   
Top: Unmodified α-casein.  R peak area is 196 counts of total, F peak area is  44 counts.  Bottom: Phe-modified α-
casein.  F peak area is 97 counts, R peak area is 53 counts. Reprinted from Wagner 2011261. 
 
2.5.6 Tryptic Digest Analysis of α-Casein Modification.   
α-Casein-Azf (33 µg), or α-Casein (33 µg), was digested with sequencing grade 
modified Trypsin (0.6 µg) in 27 µL of 25 mM ammonium bicarbonate pH 7.5 (freshly 
prepared).  Digestions were carried out at 37 °C for 14 hours.  Trypsin digest aliquots (1 
µL) were combined with α-cyano-4-hydroxycinnamic acid (1 µL of a saturated solution 
in 1:1 H2O/CH3CN with 1% TFA) and analyzed by MALDI MS (see Figure 2.3C). 
2.5.7 α-Casein Labeling in Cleared Cell Lysate.  
AaT was expressed in E. coli BL21-Gold (DE3) cells as previously described.  A 
cleared cell lysate was obtained by centrifugation following cell lysis using sonication.  
Protein were modified in a final reaction volume of 110 µL with Azf-A (4c, 3 mM) using 
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AaT (25 µL) from cleared lysate in AaT buffer (50 mM HEPES pH 8.0, 150 mM KCl, 10 
mM MgCl2). α-Casein (0.012 mg or 0.12 mg) was added to the reaction and incubated at 
37 °C for 2 h, after 1 h, an additional 0.3 µmole of 4c was added.  For control reactions, 
equivalent volumes were replaced with water.  Excess 4c was removed by buffer 
exchange four times against phosphate buffered saline (PBS, 12 mM NaH2PO4, 50 mM 
NaCl, 4.7 mM KCl, pH 8.0) by Spectra/Por 1 dialysis tubing.  Aliquots (18 µL) of 4c 
modified lysates were diluted to a final volume of 22 µL using PBS containing FlAlk 
(182 µM) for copper-catalyzed “click” reactions.  The “click” reaction was initiated by 
addition of CuSO4 (100 µM), THPTA (500 µM), and sodium ascorbate (5 mM).  The 
reaction mixtures analyzed by PAGE gel using Coomassie staining and fluorescence as 
above.   
2.5.8 “Click” Reagent Synthesis.  
 Fluorescein 5,6-proparglyamide (Fluorescein-alkyne, FlAlk) was synthesized as 
previously described429.  Briefly, propargylamine (8.7 µL, 136 µmol) was added to a 
solution of 5,6-Carboxyfluorescein N-hydroxysuccinimide ester (32 mg, 68 µmol) in 
tetrahydrofuran (5 mL).  The reaction was stirred continuously and monitored by TLC.  
Solvent was removed by under reduced pressure.  Purification by silica chromatography 
(Rf = 0.3, 20% methanol in dichloromethane) afforded fluorescein-alkyne as a red-orange 
solid. 
 Tris-(3-hydroxypropyltriazolylmethyl)amine (THPTA) was also synthesized as 
previously described436.  Briefly, to a solution of 3-bromo-propanol (2 g, 14.4 mmol) in 
dichloromethane (10 mL) was added Ac2O (2.94 g, 28.8 mmol) and NEt3 (2.91 g, 28.8 
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mmol).  The reaction was stirred continuously and monitored by TLC.  An aqueous 
solution of sodium bicarbonate was added and the phases were separated.  The organic 
layer was washed once more with sodium bicarbonate and twice with brine.  Solvent was 
removed under reduced pressure and 3-bromopropyl acetate was afforded as a colorless 
oil. 
 To a solution of 3-bromopropyl acetate (1.086 g, 6.0 mmol) in water (10 mL) was 
added sodium azide (780 mg, 12 mmol).  The solution was stirred at 90 °C overnight.  
The solution was extracted three times with 15 mL dichloromethane and dried with 
magnesium sulfate.  Solvent was removed under reduced pressure to afford 3-azidopropyl 
acetate as a pale yellow oil.  To a solution of tripropargylamine (12.3 mg, 0.94 mmol) in 
tetrahydrofuran (6.5 mL) was added 3-azidopropyl acetate (0.672 g, 4.7 mmol) and Cu(I) 
acetate (5.8 mg, 5 mol%).  The solution was refluxed overnight under inert atmosphere.  
Solvent was removed under reduced pressure.  Silica chromatography purification (Rf = 
0.5, 5-10% methanol in dichloromethane) afforded acetyl-protected THPTA as a yellow 
oil. 
 A solution of acetyl-protected THPTA (397 mg, 0.71 mmol) in 2.0 M ammonia in 
methanol (10 mL) was continuously stirred overnight at 40 °C.  Solvent was removed 
under reduced pressure.  The solid was washed and filtered four times with acetonitrile 
and dried under reduced pressure to afford THPTA as a white solid. 
 For both FlAlk (25 % overall yield) and THPTA (98 % overall yield), 
intermediate and product identities were confirmed by comparison of 1H NMR and 
LRMS (ESI) MS data to previous reports429,436. 
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Figure 2.7-Click Chemistry Reagents. 
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CHAPTER 3 : AMINOACYL TRANSFERASE MEDIATED EXPRESSED 
PROTEIN LIGATION AT METHIONINE 
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Reprinted (adapted) with permission from (Tomohiro Tanaka, Anne M. Wagner, John B. 
Warner, Yanxin J. Wang, E. James Petersson. Angew. Chem. Int. Ed. 2013, 125, 6330-
6333.). Copyright (2013). John Wiley and Sons. and from (Rebecca F. Wissner, Anne M. 
Wagner, John B. Warner, E. James Petersson. Synlett. 2013, 24, 2454-2458.). Copyright 
(2013). Georg Thieme Verlag KG Stuttgart. 
 
3.1 Introduction 
 The synthesis of chemically-modified proteins is a valuable tool for the study of 
their function432.  One of the most enabling protein synthesis technologies is native 
chemical ligation (NCL), in which a peptide thioester is reacted with a peptide bearing an 
N-terminal cysteine (Cys) to form a native amide bond437.  In many cases, one of these 
two fragments can be expressed in E. coli and then ligated to a smaller synthetic peptide 
so that a large semi-synthetic protein can be made with a minimum of peptide synthesis.  
This sort of expressed protein ligation (EPL) can be implemented in two ways438.  For a 
synthetic C-terminus, the N-terminal region can be expressed as a fusion to an intein and 
then converted to a thioester for ligation.  Likewise, a protein can be expressed with an 
N-terminal Cys and ligated to a synthetic thioester.  EPL is an extremely efficient way of 
making large quantities of synthetic proteins.  However, there are limitations to the 
method, most notably, the need for Cys at the site of ligation. 
 Since many proteins do not have Cys residues at convenient locations or lack Cys 
entirely, several research groups have developed methods for “erasing” the ligation site.  
The most common strategies are alkylation of Cys to make lysine (Lys) or glutamate 
(Glu) analogs and desulfurization to convert Cys to alanine (Ala)227,439,440.  Danishefsky 
and others have developed strategies using synthetic Cys analogs that are converted to 
other amino acids such as leucine (Leu), phenylalanine (Phe), valine (Val), threonine 
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(Thr), and Lys by desulfurization441-447.  Dawson and Muir have used nitrobenzyl Cys 
surrogates that can be removed by photolysis after ligation448,449.  Raines and Bertozzi 
have demonstrated “traceless” ligations based on Staudinger reductions and Bode has 
developed a novel ligation using ketoacid/alkoxyamine partners56,450,451.  Homocysteine 
(Hcs) has been used for ligation and then converted to methionine (Met) by selective 
methylation452-455.  While chemically elegant, most of these strategies are still limited in 
that they require the ligation handles to be incorporated synthetically.  Therefore, these 
handles can be placed in a synthetic peptide to be ligated to an intein-derived thioester, 
but cannot be applied to an expressed C-terminal fragment for ligation to a synthetic 
thioester. 
 One way of functionalizing protein N-termini makes use of the aminoacyl 
transferase (AaT) enzyme from E. coli, which transfers Phe, Leu, or Met from an 
aminoacyl tRNA (Zaa-tRNA) to the N-terminus of a protein417,420.  Our laboratory has 
recently shown that AaT does not require full length tRNAs, and can use aminoacyl 
adenosine (Zaa-A) substrates to transfer a variety of amino acids261.  Previous work from 
Tirrell and Sisido demonstrated that AaT could transfer unnatural amino acids from Zaa-
tRNAs produced either through semi-synthesis or by the activity of a modified aminoacyl 
tRNA synthetase (RS)255,256.  These two strategies are complementary.  Our Zaa-A donor 
substrates are easily synthesized and allow us to explore the inherent substrate specificity 
of AaT without the necessity of identifying a novel RS.  Once a useful substrate is 
identified, higher yields can be achieved with the catalytic regeneration of Zaa-tRNA by 
an appropriate RS. We wished to determine whether AaT could be used to functionalize 
proteins with erasable Cys analogs for ligation.  Varshavsky and others have shown that 
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AaT recognizes N-terminal arginine (Arg) or Lys residues regardless of the adjacent 
sequence420,425.  Therefore, we expected that any transferable analogs we identified would 
be applicable to a wide variety of protein targets.  Here, we show that AaT can deliver 
disulfide-protected Hcs to the N-terminus of a protein under mild conditions.  After 
reduction, Hcs can be used in a ligation reaction and then converted to Met by alkylation 
(Figure 3.1).  We demonstrate the utility of this approach by synthesizing α-Synuclein 
(αS), a protein whose aggregation contributes to Parkinson’s disease pathology456. 
  
 
Figure 3.1-Expressed Protein Ligation at Methionine.   
An expressed protein bearing an N-terminal Arg or Lys (green) is functionalized with a protected Hcs analog from an 
aminoacyl adenosine donor, under catalysis by AaT transferase.  A synthetic peptide thioester (red) is ligated to the 
modified protein under reducing conditions that allow deprotection of Hcs.  After ligation, Hcs is converted to Met. 
Reprinted from Tanaka 2013262. 
  
 We then sought to explore the ability to combine NCL at Met with other protein 
labeling techniques for generating dual labeled protein. Unnatural amino acids (Uaas) are 
readily introduced into proteins using Amber codon suppression368,457. Recently, our lab 
has combined unnatural amino acid mutagenesis with NCL to install the FRET pair, p-
cyanophenylalanine (Cnf) and a thioamide, into full-length S for misfolding studies283. 
However, using standard ligation techniques introduced an exogenous Cys residue. Cys 
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mutants of S display enhanced aggregation kinetics and altered fibril morphology as a 
result of intermolecular disulfide bond formation283,458,459,460.  Although we performed the 
previous FRET studies with our Cys-containing double-labeled constructs in the presence 
of a reducing agent, it is nonetheless possible that some amount of disulfide formation 
occurred during our experiments. While many laboratories carry out protein synthesis 
with subsequent radical desulfurization of Cys to form Ala, this strategy is not viable for 
us as desulfurization of the thioamide would also occur461. By combining Amber codon 
suppression with EPL at Hcs (which is converted to Met), we can incorporate our 
minimal FRET pair into S in a traceless manner that minimizes unnecessary synthesis 
of peptide fragments composed of natural amino acids (Figure 3.2). 
 
Figure 3.2-Retrosynthetic analysis of Ac-SFAsp'2Cnf39. 
Adapted from Wissner 2013284. 
 
3.2 Results and Discussion 
3.2.1 Expressed Protein Ligation at Methionine: N-terminal Attachment of 
Homocysteine, Ligation, and Masking.   
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 AaT efficiently transfers Leu and Phe and some Met analogs to the N-terminus of 
Arg or Lys containing peptides or proteins. Previous studies had shown that Cys-tRNA is 
not a substrate for AaT and our own preliminary experiments showed that Hcs was not 
transferred (data not shown)425,462.  Hcs analogs were prepared masked as aliphatic or 
aromatic disulfides in order to mimic the endogenous AaT substrates.  Disulfide 
protecting groups (MeS, i-PrS, t-BuS, and PhS) were used so that they could be removed 
in situ under the reducing conditions of the subsequent NCL reaction (Figure 3.3)262. 
 
Figure 3.3-Amino Acid Transfer to Reporter Peptide.   
Reagents and conditions: a) 1 mM Zaa-A, 0.1 mg/mL AaT; or b) 1mM Zaa, 2 mg/mL E. coli total tRNA, 0.1 mg/mL 
Met*RS, 0.1 mg/mL AaT; with 100 µM LysAlaAcm in 50 mM HEPES, 150 mM KCl, 10 mM MgCl2, pH 8.0, 37 °C, 4 
h.  Yields determined by HPLC analysis. Reprinted (adapted) from Tanaka 2013262. 
 
 Screening of possible disulphide protected amino acids was accomplished using 
adenosine donor molecules. However, for protein labelling a chemoenzymatic approach 
was used. Wild type E. coli MetRS and an L13G mutant (Met*RS) previously used by the 
Tirrell group were tested with Hcm, ATP, and E. coli total tRNA84.  Met*RS was more 
active than MetRS, giving full transfer at ≤ 0.1 mg/mL loading.  This is consistent with 
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 Incorporation of Mcm into αS was additionally confirmed using fluorescence 
spectroscopy (Figure 3.5B). Ac-Mcm-αS6-140 was excited at 325 nm and the fluorescence 
spectra was recorded and compared to that of a WT αS.  
 A similar ligation was carried out with Ac-MetAspValPhe-SR (7), yielding N-Ac-
αS after methylation (13b).  The ligation product 13b was subjected to trypsin digest and 
MALDI MS analysis to confirm that methylation occurred with high yield and few side 
reactions.  Observation of the Ac-MetAspValPheMetLys fragment (Ac-αS1-6) with only 
trace Ac-MetAspValPheHcsLys contamination confirmed that methylation proceeded in 
> 95% yield within the limitations of quantitation by MS.  Furthermore, MALDI MS 
analysis of the rest of the tryptic fragments demonstrated that there were no substantial 
alkylation side reactions, even on His50 in the αS46-58 fragment. Such selectivity is 
rewarding, but probably not completely general; for any novel protein, similar analysis by 
digestion and MS should be performed.  It should also be noted that protein targets 
containing unprotected Cys residues would also be methylated on the free thiols.  
However, more conventional NCL strategies using ligation at Cys are probably viable in 
those cases. 
 
3.2.2 Efficient, Traceless Semi-Synthesis of α-Synuclein Labeled with a 
Fluorophore/Thioamide FRET Pair. 
 With a suitable method for NCL at Met in hand we next sought to expand its 
utility. Dual labeling of a protein using NCL at Met and Uaa incorporation through 
Amber codon suppression was achieved as depicted in Figure 3.6.  To minimize 
perturbation of native S dynamics resulting from Cnf incorporation, we chose to replace 
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the similarly sized tyrosine (Tyr) or Phe at position 39.  A plasmid containing the C-
terminal protein fragment (SF6-140) with a TAG codon installed at position 39 was 
prepared.  Where αSF is a construct in which all Tyr residues have been mutated to Phe. 
An N-terminal His11 tag and a Factor Xa proteolysis site precede the S gene.  The 
expressed protein, HisTag-SF6-140Cnf39 (13), was purified by Ni-affinity chromatography 
and subsequently cleaved by Factor Xa to yield SF6-140Cnf39 (14).  Following 
purification by ion-exchange chromatography, the truncated protein was incubated with 
AaT, Met*RS, E. coli total tRNA, Hcm, and ATP for 2 h resulting in complete formation 
of SF5-140Hcm5Cnf39 (15).  SF5-140Hcm5Cnf39 was subjected to an additional round of 
ion-exchange chromatography prior to use in the NCL reaction.  Typically, about 1 mol 
of pure 15 is obtained from a 1 L protein expression. 
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SFAsp2Cnf39 was isolated from the NCL reaction by HPLC and characterized by 
MALDI MS, as well as UV-Vis and fluorescence spectroscopy (Figure 3.6).  The yield 
over the two-step ligation and methylation sequence was 41%.  MALDI MS analysis of 
trypsin-digested 17 confirmed selective alkylation of Hcs to form Met in the purified 
product (Figure 3.6). 
 With a fluorophore FRET pair synthesized we then sought to probe the 
conformational dynamics of αS monomer. Trimethylamine oxide (TMAO) was used as a 
small molecule crowder to mimic the crowded environment of a cell. To correct for any 
changes in Cnf fluorescence that are not due to the presence of the thioamide, an 
oxoamide control protein (SFCnf39) was also prepared for fluorescence experiments.  In 
buffer without TMAO, thioamide quenching of Cnf in Ac-SFAsp2Cnf39 (i.e., FRET) 
was minimal.  In accordance with our previous observations283, thioamide quenching of 
Cnf increased as a function of TMAO concentration (Figure 3.7, left axis).   To assign 
distance constraints based on these measurements, the measured quenching efficiency 
(EQ) values were converted to distances using Förster theory.  In 2 M and 4 M TMAO, 
RFRET was calculated as 16.4 Å and 13.7 Å, respectively (Figure 3.7, right axis).  Taken 
together with our previous results, these data indicate that the N-terminal region of S 
undergoes significant compaction in high TMAO concentrations.  Furthermore, our new 
results conclusively demonstrate that the observed quenching is not due to Cys-mediated 
dimerization of S. 
  89 
 
 
 
Figure 3.7-αS Refolding Assay.   
Left: Monomeric double-labeled S (Ac-SFAsp2Cnf39) is mixed with TMAO to induce compaction and an increase 
in quenching efficiency (EQ).  Right: EQ (blue dashed line) of Ac-SFAsp2Cnf39 determined at varying concentrations 
of TMAO.  Interchromophore distance (RFRET, green solid line) computed using Förster theory. Reprinted from 
Wissner 2013284. 
 
 
3.3 Conclusions  
 By combining unnatural amino acid mutagenesis with EPL at Met, we can install 
our minimal Cnf/thioamide FRET probe pair into S without introducing a mutation at 
the ligation site.  We have demonstrated that selective alkylation of Hcs can be performed 
in the presence of a thioamide, rendering our new ligation strategy compatible with the 
minimal probe pairs that we have developed.  The αS refolding studies presented here 
demonstrate how this methodology can be used to study protein folding dynamics, 
though these techniques are by no means limited to S.  
 Application of our system to targets other than αS may require mild denaturation 
of the protein in order to access the N-terminal amino acids.  Therefore, we have tested 
AaT activity in the presence of low concentrations of denaturants and detergents.  We 
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find that AaT activity has a Gdn•HCl IC50 of 0.4 M and that full activity could be 
maintained in 5% v/v Triton X-100.  While the N-termini of some proteins may be buried 
in important structural interactions, these concentrations should allow one to partially 
unfold many proteins to access the terminus for Hcm transfer and ligation. 
 While our experiments begin to remove the sequence limitations for EPL, they 
certainly do not eliminate them entirely.  Essentially, one can now use XxxMetArg or 
XxxMetLys as a disconnection point in a retrosynthetic analysis of a potential protein 
target.  The utility of our approach depends on how frequently this motif occurs.  An 
extensive search of the PDB revealed that out of the 60,325 proteins surveyed, 5,405 
possible N-terminal ligation sites (< 40 amino acids from the N-terminus) were identified 
in 5,156 unique proteins.  Though a common motif, we are exploring expanding the 
recognition specificity of AaT for other N-terminal residues other than Arg or Lys. We 
are also exploring mutations to the binding pocket of AaT to further expand the substrate 
scope to include transfer of Uaas with increased functionality.  
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3.5 Materials and Methods  
3.5.1 General Information. 
 Benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate 
(PyBOP), Fmoc-Met-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-
β-(7-methoxy-coumarin-4-yl)-Ala-OH, and 2-chlorotrityl chloride resin were purchased 
from Bachem (Torrance, CA) or EMD Chemicals (Philadelphia, PA).  Piperidine and 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from American Bioanalytical (Natick, MA).  Sigmacote, N,N-
diisopropylethylamine (DIPEA), thiophenol, methyl mercaptopropionate, sodium 
thiomethoxide, 2-propanthiol, 2-methyl-2-propane thiol, mercaptophenylacetic acid 
(MPAA), trifluoroacetic acid (TFA), tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP), and 5,5'-dithiobis-(2-nitrobenzoic acid (DTNB) were purchased from Sigma-
Aldrich (St. Louis, MO).  Ni-NTA resin was from Qiagen (Valencia, CA).  E. coli 
BL21(DE3) cells were purchased from Stratagene (La Jolla, CA). Sequencing-grade 
trypsin was purchased from Promega (Madison, WI).  Restriction-grade Factor Xa 
protease was purchased from Novagen (San Diego, CA).  QuikChange® site-directed 
mutagenesis kits were purchased from Stratagene.  DNA oligomers were purchased from 
Integrated DNA Technologies, Inc (Coralville, IA).  Protease inhibitor cocktail was 
purchased from Sigma-Aldrich.  All other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA).  MilliQ filtered (18 MΩ) water was used for all solutions (Millipore, 
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Billerica, MA).  Matrix-assisted laser desorption/ionization (MALDI) mass spectra were 
collected with a Bruker Ultraflex III MALDI-TOFTOF mass spectrometer (Billerica, 
MA).  Electrospray ionization (ESI) mass spectra were collected with a Waters LCT 
Premier XE liquid chromatograph/mass spectrometer (Milford, MA).  UV/vis absorbance 
spectra were obtained with a Hewlett-Packard 8452A diode array spectrophotometer 
(Agilent Technologies, Santa Clara, CA).  
3.5.2 General Donor Synthesis and Evaluation. 
 Hcm and disulfide protected analogs were prepared by Tomohiro Tanaka and 
Anne M. Wagner and can be found in Tanaka et al. 2013262. 
3.5.3 Peptide Synthesis. 
 All peptides were synthesized using a manual, Fmoc-solid phase procedure on 2-
chlorotrityl (ClTrt) resin as described previously.2  Protected αS1-4 peptides Ac-MetAsp(t-
Bu)ValPhe-OH (S9) and Ac-McmMetAsp(t-Bu)ValPhe-OH (S10), where Mcm is β-(7-
methoxy-coumarin-4-yl)-alanine, were cleaved by treatment with acetic acid 
/trifluoroethanol/dichloromethane (1/1/3, v/v) for 1h.  After the resin was filtered, solvent 
was removed in vacuo.  Ac-MetAspValPheHcsLys (S11) and Ac-MetAspValPheMetLys 
(S12) were cleaved with TFA/triisopropylsilane/water (95/2.5/2.5, v/v) for 1 h, and 
purified by C18 reverse phase HPLC using Gradient 4a (S11) and Gradient 4b (S12). 
Thioesterification of Ac-MetAspValPhe-SR (7) and Ac-McmMetAspValPhe-SR (S13).  
100 µmol of protected S9 or S13 was dissolved in 10 mL of DMF in an ice bath.  10 
equiv each of PyBOP and triethylamine were added to the peptide solution.  Then, 20 
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equiv methyl mercaptopropionate were added and the solution was allowed to stir 
overnight.  Solvent was removed in vacuo. Pouring water onto the residue caused 
immediate precipitation of a white solid.  The precipitate was collected by centrifugation, 
and washed again with water.  The crude protected peptide thioester was dissolved in 
TFA/triisopropylsilane/water (95/2.5/2.5, v/v) and allowed to stir for 1 h.  After removal 
of the solvent in vacuo, pouring Et2O onto the residue gave a precipitate that was 
collected by centrifuge, and washed with Et2O (3 times).  Deprotected thioesters 7 or S13 
were then purified by C18 reverse phase semi-prep HPLC using Gradient 1. Section 3.5.3 
was performed in collaboration with Anne M. Wagner. 
 
Table 3.1-Solvent Gradients Used for Peptide Purification and Analysis. 
Gradient Time 
 (min) 
Buffer A 
(%) 
1 0:00 71 
4 mL/min 5:00 71 
 35:00 65 
 40:00 0 
 45:00 0 
 50:00 71 
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Table 3.2-Calculated and Observed Peptide and Protein Masses.  
Peptide 
Calcd 
(M+H)+ 
Obsvd 
(M+H)+ 
Calcd 
(M+Na)+ 
Obsvd 
(M+Na)+ 
Ac-MetAspValPhe-SRa (7) 655.247 - 677.229 677.302 
Ac-MetAspValPheHcsLysa (S11) 798.352 798.600 820.334 820.591 
Ac-MetAspValPheMetLysa (S12) 812.368 812.449 834.350 834.437 
Ac-McmMetAspValPhe-SRa (S13) 900.31 - 922.31 922.25 
Ac-MetAspValPheHcsLysAlaAcma (8a) 1026.44 1026.59 1048.42 1048.56 
Ac-MetAspValPheMetLysAlaAcma (8b) 1040.46 1040.24 1062.44 - 
αS6-140b (10) 13, 837.3 13, 837.7 13, 859.3 - 
Hcm-αS6-140b (11) 14, 000.6 14, 001.0 14, 022.6 - 
AcMcm-αS-Hcs5b (12a) 14, 733.4 14, 735.1 14, 755.4 - 
AcMcm-αSb (13a) 14, 747.4 14, 748.4 14, 769.4 - 
Ac-αS-Hcs5b (12b) 14, 489.2 14, 490.0 14, 511.2 - 
Ac-αSb (13b) 14, 503.2 14, 502.7 14, 525.2 - 
(aExact mass, bmolecular weight) 
3.5.4 MetRS and Met*RS Expression and Purification.  
 E. coli MetRS and Met*RS were obtained from David Tirell. Plasmids were 
transformed into E. coli BL21 (DE3) and grown to OD600 0.6 in LB media. Protein 
expression was induced with 1.0 mM isopropyl β-D-thiogalactoside and grown for 18 h 
at 25 °C. The cells were harvested at 5000 x g for 15 min and the resulting pellet was 
resuspended in a lysis buffer (300 mM KCl, 50 mM Tris pH 8.0) and included protease 
inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) and sonicated. 
Soluble protein was obtained by centrifugation for 20 minutes at 30,000 x g, 4 °C. 
Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA resin.  Protein 
was purified by rinsing with lysis buffer followed by washing with wash buffer (300 mM 
KCl, 50 mM Tris pH 8.0, and 15 mM imidazole).  Protein was eluted with 4 x 1 mL 
Elution Buffer A (300 mM KCl, 50 mM Tris pH 8.0, and 50 mM imidazole) followed by 
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4 x 1 mL Elution Buffer B (300 mM KCl, 50 mM Tris pH 8.0, and 250 mM imidazole). 
SDS-PAGE analysis was performed to analyze the purity of elution fractions.  Collected 
protein fractions were dialyzed against storage buffer (50 mM Tris pH 7.5 in 50% 
glycerol) at 4 °C. Protein was stored in 0.5 mL aliquots at -80 °C. 
3.5.5 Construction of Recombinant αS6-140 Expression Plasmid.   
 We have previously described the cloning of the αS gene from a pT7-7 vector into 
the pET-16b prokaryotic expression vector, which contains an N-terminal His tag 
followed by a Factor Xa recognition site (IEGR) (Figure 3.8Ia). QuikChange® 
mutagenesis was used to delete residues H-1 and M1 (Figure 3.8Ib) followed by a D2K 
mutation (Figure 3.8Ic) to yield the αS2-140K2 plasmid.  Residues K2-M5 were deleted 
(Figure 3.8Id) from the αS2-140K2 plasmid using QuickChange® mutagenesis to give the 
αS6-140 plasmid.  All mutagenesis steps were confirmed by DNA sequencing using the T7 
promoter primer. 
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I. Construction of αS6-140 Plasmid DNA 
a. -ATC GAA GGT CGT CAT ATG GAT GTA TTC ATG AAA GGA CTT TCA AAG GCC- 
         I        E        G       R       H-1     M1      D2      V3      F4      M5       K6      G7       L8     S9      K10     A11 
 
b. -ATC GAA GGT CGT GAT GTA TTC ATG AAA GGA CTT TCA AAG GCC- 
         I        E        G       R       D2      V3      F4      M5       K6      G7       L8     S9      K10     A11 
 
c. -ATC GAA GGT CGT AAA GTA TTC ATG AAA GGA CTT TCA AAG GCC- 
         I        E        G       R       K2      V3      F4      M5       K6      G7       L8     S9      K10     A11 
 
d. -ATC GAA GGT CGT AAA GGA CTT TCA AAG GCC- 
         I        E        G       R       K6      G7       L8     S9      K10     A11 
 
II. DNA Oligomers Used for QuickChange® Mutagenesis 
a. Deletion of H-1 and M1 
Forward: 5’-GGC CAT ATC GAA GGT CGT GAT GTA TTC ATG AAA GGA-3’ 
Reverse: 5’-TCC TTT CAT GAA TAC ATC ACG ACC TTC GAT ATG GCC-3’ 
b. Mutation of D2K 
Forward: 5’-GCG GCC ATA TCG AAG GTC GTA AAG TAT TCA TGA AAG GAC TTT C-3’ 
Reverse: 5’-GAA AGT CCT TTC ATG AAT ACT TTA CGA CCT TCG ATA TGG CCG C-3’ 
c. Deletion of K2-M5 
Forward: 5’-GGC CAT ATC GAA GGT CGT AAA GGA CTT TCA AAG GCC AAG G-3’ 
Reverse: 5’-CCT TGG CCT TTG AAA GTC CTT TAC GAC CTT CGA TAT GGC C-5’ 
 
Figure 3.8-Construction of αS6-140 Plasmid. 
Reprinted from Tanaka 2013262. 
  
3.5.6 Expression and Purification of αS6-140.   
 The plasmid containing the αS gene was used to transform Escherichia coli 
BL21(DE3) cells.  Transformed cells were selected on the basis of ampicillin resistance. 
Single colonies were used to inoculate 5 mL of LB media supplemented with ampicillin 
(100 μg/mL).  The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm 
for 5 hours. 500 mL of LB media supplemented with ampicillin was inoculated with 1 
mL of the primary culture.  The 500 mL culture was incubated at 37 °C with shaking at 
250 rpm until an OD600 of 0.6 was reached.  Expression was induced with the addition of 
1.0 mM isopropyl β-D-thiogalactoside and cells were incubated at 25°C for 16 hours.  
The cells were harvested at 5000 x g for 15 min and the resulting pellet was resuspended 
in a Factor Xa cleavage buffer (100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2) and 
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included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) 
and sonicated.  Following sonication, the cell lysate was boiled for 20 minutes prior to 
centrifugation for 20 minutes at 30,000 x g, 4 °C.  Collected soluble protein was gently 
shaken for 1 h on ice with Ni-NTA resin.  Protein was purified by rinsing with Factor Xa 
cleavage buffer followed by washing with Factor Xa wash buffer (100 mM NaCl, 50 mM 
Tris pH 8.0, 5 mM CaCl2, and 50 mM imidazole).  Protein was eluted with Factor Xa 
elution buffer 100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2¸and 250 mM imidazole). 
SDS-PAGE analysis was performed to analyze the purity of αS elution fractions.  
Collected protein fractions were dialyzed against Factor Xa cleavage buffer at 4 °C.  The 
His10 purification tag was removed by incubation of purified αS (0.5 mg/mL) with Factor 
Xa, Restriction Grade, Bovine Plasma (Novagen) (20 Units) overnight at 37°C.  Factor 
Xa was removed by boiling for 20 minutes and centrifugation for 20 minutes at 30,000 x 
g, 4 °C.  Soluble protein was purified from N-terminal peptide and uncleaved protein by 
1 h incubation with Ni-NTA resin.  Protein concentration was determined by BCA assay 
(Pierce) and adjusted to 1.0 mg/mL, purity was confirmed by SDS-PAGE and MALDI 
MS.  Protein was stored at - 80°C until further use. 
3.5.7 Full Enzymatic Transfer to αS6-140.   
 For a typical reaction, 4.25 mg αS6-140 in AaT Ligation Buffer pH 8.0 was 
modified with Hcm (1 mM) containing 20 mg E. coli total tRNA, 2.5 mM ATP, 1.0 - 0.1 
mg E. coli Met*RS, and 0.1 mg E. coli AaT.  The reaction was carried out at 37 °C for 4 
h. Hcm-αS6-140 (11) was further purified on the with a HiTrap Q HP column (GE 
Healthcare).  Protein was buffer exchanged into MilliQ water and stored at -80 °C. 
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3.5.8 Ligation of Ac-MetAspValPhe-SR (S12) and Ac-McmMetAspValPhe-SR (S13) to 
Hcsm-αS6-140 (11).  
 Ligation buffer was prepared fresh as follows: 100 mM sodium phosphate dibasic, 
20 mM TCEP, 6 M guanidine hydrochloride and 2% v/v thiophenol at pH 7.2.  The 
buffer was sparged twice with argon: 20 minutes for a 100 mM sodium phosphate dibasic 
and 6 M guanidine hydrochloride solution and then for an additional 10 min post addition 
of TCEP, thiophenol, and pH adjustment to 7.2.  Sparged ligation buffer (100 uL) was 
added to 0.0404 µmol (1 equivalent) of dried Hcm-αS6-140 protein.  The mixture was 
briefly vortexed and allowed to reduce for 10 min.  Next, the protein solution was added 
to 0.1212 µmol (3 equivalents) of Ac-MetAspValPhe-SR (7) or Ac-McmMetAspValPhe-
SR (S13).  The reaction was mixed overnight at 250 RPM at 37°C.  The reaction was 
quenched the following day with a 3 mL addition of MilliQ water and buffer exchanged 
solvent with six water washes using a 3 kDa protein concentrator microfuge tube and 
analyzed by HPLC.  Protein retention times were monitored at 215 nm (and 325 nm for 
S13).  MALDI MS analyses are in Table 3.2.  Example HPLC traces are shown in Figure 
3.9. Section 3.5.8 was performed by in collaboration with Anne M. Wagner. 
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3.5.9 Ellman’s Reagent Analysis.  
 0.8 nmoles of αS-Mcm-Hcs5 (12a) were methylated with 1000 equivalents of 
methyl iodide in 0.1 M sodium biocarbonate pH 8.6 for 5 min at room temperature.  
Following methylation, the reaction was incubated with 150 μM 5,5'-dithiobis-(2-
nitrobenzoic acid (DTNB) for 5 min. at room temperature.  UV/Vis measurements were 
taken using a Tecan M1000 plate reader.  Excitation slit width was 5 nm, integration time 
0.02 s, data interval 2.0 nm, flash frequency 400 Hz, 25 flashes, gain set to 100, and z-
height 20 mm. 
3.5.10 αS-Mcm Fluorescence settings.  
 Fluorescence spectra were collected with a Varian Cary Eclipse fluorescence 
spectrophotometer fitted with a Peltier multicell holder.  Fluorescence spectra were 
collected using quartz cells with 1 cm path lengths.  Excitation and emission slit widths 
were 5 nm, scan rate 120 nm/min, averaging time 0.5 s, and data interval 1.0 nm. 
3.5.11 Trypsin Digest and MALDI MS Analysis.   
 Ac-αS 13b (5.4 μg) was buffer-exchanged into 100 μL of freshly prepared 25 mM 
NH4HCO3 (pH 7.6), and digested with 2 μL of sequencing-grade modified trypsin (0.1 
μg/μL).  The digestion was allowed to proceed at 37 °C for 3 h.  An aliquot (1.0 μL) of 
the digest was taken and analyzed by MALDI MS in CHCA matrix  (Figure 3.4,Figure 
3.11, Table 3.3).  MALDI MS data shown in Figure 3.11 confirm that no methylation of 
His50 took place. 
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3.5.12 Ligation Motif Prevalence Analysis.  
 An extensive search of the Protein Data Bank for the prevalence of a XaaMetArg 
and XaaMetLys motifs (Xaa = any amino acid) in protein sequences was performed by 
Yanxin J.Wang and can be found in Tanaka et al. 2013262. 
3.5.13 Experimental for Section 3.2.2. 
 This section was performed by Rebeeca F. Wissner and related details can be 
found in Wissner et al. 2013284. 
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CHAPTER 4 : EFFICIENT SYNTHESIS AND IN VIVO INCORPORATION OF 
ACRIDON-2-YLALANINE, A FLUORESCENT AMINO ACID FOR LIFETIME 
AND FÖRSTER RESONANCE ENERGY TRANSFER/LUMINESCENCE 
RESONANCE ENERGY TRANSFER STUDIES 
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Reprinted (adapted) with permission from (Lee C. Speight, Anand K. Muthusamy, Jacob 
M. Goldberg, John B. Warner, Rebecca F. Wissner, Taylor S. Willi, Bradley F. 
Woodman, Ryan A. Mehl, and E. James Petersson. J. Am. Chem. Soc. 2013, 135, 18806–
18814.). Copyright (2013) American Chemical Society. 
4.1 Introduction 
 Fluorescence spectroscopy is a powerful technique for monitoring protein folding 
and dynamics.  Fluorescence experiments can be carried out with ns time resolution, at 
the single molecule level, and in real time in living cells.  Structural information can be 
derived from fluorescence experiments by exploiting distance-dependent interactions 
such as Förster resonant energy transfer (FRET) or fluorescence quenching through 
photo-induced electron transfer (PET)466,467-469,470. Making such measurements in a time-
resolved manner allows for the tracking of protein conformation as two regions of the 
protein undergo relative translational and rotational motion.  The developments in 
spectroscopy over the last 25 years have afforded tremendous improvements in 
sensitivity as well as temporal and spatial resolution.  Today, the information that one can 
derive from these experiments is often limited not by instrumentation, but by one’s ability 
to label the protein in an efficient, site-specific, and non-perturbing manner. 
 Many strategies exist for fluorescently labeling proteins, each with advantages 
and drawbacks.  Use of the intrinsic fluorescence of tryptophan (Trp) and tyrosine (Tyr) 
is often limited to relatively small or simple proteins because most large proteins have 
multiple Trp or Tyr residues, complicating the interpretation of fluorescence data.  The 
most common extrinsic labeling strategies use genetic fusions of green fluorescent 
protein (GFP) or its derivatives, but the large size of GFP may perturb the folding event 
of interest471-473.  Smaller synthetic fluorophores can often be attached in an amino acid 
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specific manner, for example by exploiting the unusual reactivity of the cysteine (Cys) 
thiol433.  However, if one wishes to carry out experiments in vivo or in cell lysate, 
reaction with a specific Cys is extremely difficult to achieve. 
 Sisido and co-workers have previously shown that acridon-2-ylalanine (Acd) can 
be ribosomally-incorporated into proteins by in vitro translation using the PURE 
system474.  Since protein yields from this system can be quite low due to its small scale, 
we sought to develop an in vivo system for Acd incorporation using methods pioneered 
by Schultz and co-workers123,368.  These methods require the generation of an aminoacyl 
tRNA synthetase (RS) that is selective for an unnatural amino acid (Uaa).  The UaaRS 
charges a cognate tRNA that recognizes the UAG stop codon (tRNACUA).  The UAG stop 
codon is inserted into the gene for the protein target at the site of interest, while a 
different stop codon (e.g. UGA) is used for translation termination.  After aminoacylation 
by the UaaRS, the tRNACUA delivers the unnatural amino acid to the site of interest in the 
protein during ribosomal biosynthesis. (Figure 4.1)  Plasmids coding for the UaaRS, 
tRNACUA, and protein of interest are transformed into E. coli.  After growth in the 
presence of the Uaa, protein containing the Uaa is purified for use in biochemical 
experiments.  Because tRNACUA must compete with release factors, protein production 
levels are lower than those for normal expression, but one can generally obtain 1- 10 
mg/L quantities of protein from cultures121. With this, we expressed several proteins to 
demonstrate the usage of Acd fluorescence in monitoring conformational changes, 
aggregation, and protein binding through steady state or fluorescence lifetime 
measurements. 
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Figure 4.1-Ribosomal Incorporation of Unnatural Amino Acids.   
E. coli cells are transformed with two DNA plasmids: one encoding mRNA for the protein of interest with a UAG stop 
codon at the site of interest, and one encoding an aminoacyl tRNA synthetase that is selective for an unnatural amino 
acid (UaaRS) with a cognate tRNA that recognizes the UAG stop codon (tRNACUA).  The mRNA must also contain a 
different stop codon (e.g. UGA) for translation termination.  The UaaRS charges tRNACUA with the unnatural amino 
acid and the aminoacyl tRNACUA delivers the Uaa to the site of interest in the protein during ribosomal biosynthesis.  
Inset: UaaRSs were screened for successful incorporation of acridon-2-ylalanine (1, Acd, δ) from a pool previously 
selected for incorporation of 4-(2′-bromoisobutyrlamido)phenylalanine (2, Brb, ζ) and p-benzoylphenylalanine (3, Bzf, 
β). 
  
4.2 Results and Discussion 
 In order to understand how best to use Acd, we began by assessing its sensitivity 
to local environment.  This is clearly important if one wishes to use Acd as a probe of 
protein environment, but it is also an important background correction for those who wish 
to use Acd in PET or FRET studies.  Acd has previously been shown to have an inherent 
solvatochromic response475.  Its spectral shape blue shifts and its quantum yield changes 
from 0.95 to 0.29 on moving from water to THF.  However, quenching of fluorophores 
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by specific amino acids can also lead to environmental sensitivity476,477.  In fact, we have 
recently shown that Acd fluorescence can be quenched by a thioamide through a PET 
mechanism12.  To determine the effects of natural amino acids on Acd fluorescence, we 
performed Stern-Volmer titrations with the common redox-active amino acids: Trp, Tyr, 
methionine (Met), Cys, and histidine (His).  As seen in Figure 4.2, only Trp and Tyr 
quench Acd significantly. 
 Comparisons of data from steady state and fluorescence lifetime measurements 
indicate that Trp and Tyr quench Acd through a PET mechanism with both static (i.e. a 
non-emissive ground state complex is formed) and dynamic (i.e. excited state electron 
transfer) components.  This can be seen in the Figure 4.2 inset where the dotted lines 
show the dynamic component observed in lifetime measurements made by time-
correlated single photon counting (TCSPC)478.  Since Acd is quenched by Trp and Tyr, it 
should be sensitive to protein motions that change the proximity of these residues. 
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Figure 4.2-Acd Chromophore Interactions.   
Left: Quenching by natural amino acids assessed through steady state fluorescence Stern-Volmer titrations with five 
amino acids: Trp (filled red circles), Met (orange squares), Cys (green upright triangles), His (pale blue downward 
triangles), Tyr (filled dark blue diamonds).  Tyr methyl ester used for solubility, all other amino acids used as free acid.  
Left inset: Fluorescence lifetime Stern-Volmer titrations with Trp (open red circles) and Tyr (open dark blue 
diamonds).  Steady state data shown as solid lines for comparison.  Right: Absorbance (grey) and fluorescence 
emission (light blue) of Mcm and absorbance of Acd (blue), with spectral overlap shaded.  Absorbance spectra are 
normalized by extinction coefficient, the emission spectrum scaling is arbitrary. Reprinted from Speight 2013138. 
  
 Acd can also function as a FRET acceptor for Trp because the tail of the Trp 
emission spectrum overlaps significantly with Acd absorbance. The Förster radius for this 
FRET pair is 23 Å, making them useful in monitoring distance changes in the 13 to 37 Å 
range.  Since Trp can also act as a quencher of Acd, care must be taken in interpreting 
FRET measurements at short distances (< 15 Å) where both processes may be operative.   
 Typical protein expressions requires mM concentrations of the unnatural amino 
acid in the media.  Thus, a highly efficient synthesis of Acd was designed starting from 
Tyr138. To incorporate Acd ribosomally, we then screen a library of synthetase mutants 
for the ability to incorporate Acd in response to a TAG codon. A M. janaschii TyrRS 
previously selected for 4-(2′-bromoisobutyramido)phenylalanine (2, Brb, ζ) was 
identified as capable of utilizing Acd for protein incorporation. With a synthetase mutant 
identified, we tested incorporation in several other proteins by expressing them in E. coli, 
including α-synuclein (αS), triose phosphate isomerase (TIM, data not shown), and 
calmodulin (CaM, data not shown).  PAGE gel, fluorescence emission spectra, and 
MALDI MS analyses of αS wild type (WT) and mutants labeled at position 39 or 94 are 
shown in Figure 4.3.  In general, we obtained yields of purified protein that ranged from 
3 to 69% of the yields of an equivalent expression of the WT protein. 
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Figure 4.3-Incorporation of Acd into αS.   
Left: PAGE gel image of purified αS.  Lanes: 1) molecular weight markers (17, 25, 32 kDa), 2) WT, 3) αS-Y39δ) αS-
F94δ and fluorescence emission spectrum of αS-Y39δ  Right: Trypsin digest MALDI MS analyses of αS-Y39δ (top) and αS-F94δ (bottom) from incorporations using AcdRS show masses consistent with Acd incorporation with no Tyr 
misincorporation. 
  
 In addition to protein binding and monitoring conformational changes which have 
been demonstrated with CaM and TIM, respectively, another type of experiment for 
which Acd can be useful is monitoring the misfolding of amyloidogenic proteins.  A 
number of studies have shown that in vitro aggregation can be subtly dependent on 
mutations in the protein and the conditions of the experiment292,479,480,342. Yet, in many 
cases, fluorescent monitoring of such aggregation occurs through tagging with relatively 
bulky fluorophores such as fluorescein maleimide or non-specific labeling of lysine (Lys) 
residues346,481-483.  Acd, on the other hand, is relatively small and can easily be 
genetically-encoded site-specifically into the protein.  To show the value of Acd 
fluorescence quenching in monitoring the aggregation of the Parkinson’s Disease (PD) 
protein αS, we analyzed αS-Y39δ and αS-F94δ.  We allowed these to aggregate in 
phosphate buffer with shaking, using Acd fluorescence emission to monitor aggregation 
over time.  Additionally, αS fibrillization was monitored using a Congo Red binding 
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assay (Figure 4.4). These data show that in both cases Acd is quenched when buried in 
fibrils, possibly through proximity to the Tyr residues at positions 39 (for αS-F94δ), 129, 
133, or 136. 
 
Figure 4.4-Monitoring αS Aggregation By Changes in Acd Fluorescence.   
Top: Fluorescence spectra of 50 µM αS-Y39δ before (black) and after (red) 96 h of aggregation, soluble fraction at 96 h 
(green), and resuspended insoluble fraction (blue).  Emission from resuspended WT insoluble fraction shown in grey.  
Inset: Cartoon of aggregation process showing quenching of Acd in fibrils.  Bottom: Fluorescence emission (blue) and 
Congo Red absorbance (red) of 50 µM solutions of αS-Y39δ (circles) or αS-F94δ (squares) during aggregation. 
  
 In an effort to better understand the decrease in fluorescence observed over the 
course of the aggregation experiment fluorescence lifetime measurements were made 
using TCSPC of monomeric and fibrillized αS-Y39δ and αS-F94δ (Figure 4.5). Both αS-
Y39δ and αS-F94δ monomeric species exhibited single exponential fluorescence lifetimes 
similar to Acd free amino acid. In comparison, the Acd labeled fibrils exhibited 
fluorescence lifetimes best fit to a double exponential equation. Fluorescence lifetime 
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with common fluorophores such as Trp and coumarin.  We have also demonstrated the 
incorporation of Acd into several proteins and used changes in Acd fluorescence to 
monitor protein aggregation, protein folding, and peptide binding and ion binding. 
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4.5 Materials and Methods 
4.5.1 General Information. 
 E. coli BL21(DE3) cells and a QuickChange® site-directed mutagenesis kit were 
purchased from Stratagene (La Jolla, CA, USA). E. coli DH10B cells were purchased 
from Invitrogen (Grand Island, NY, USA). DNA oligomers were purchased from 
Integrated DNA Technologies, Inc (Coralville, IA, USA). All other reagents were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). MilliQ filtered (18 MΩ) water 
was used for all solutions (Millipore; Billerica, MA, USA). All peptide synthesis reaction 
vessels (RVs) were treated with Sigmacote® prior to use. 
 DNA sequencing was performed at the University of Pennsylvania DNA 
sequencing facility. Matrix-assisted laser desorption ionization (MALDI) mass spectra 
were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer 
(Billerica, MA). UV/vis absorbance spectra were obtained with a Hewlett-Packard 8452A 
diode array spectrophotometer (currently Agilent Technologies; Santa Clara, CA). UV 
absorbance spectra were obtained with a Hewlett-Packard 8452A diode array 
spectrophotometer (currently Agilent Technologies; Santa Clara, CA, USA). 
Fluorescence spectra were collected with a Tecan M1000 plate reader (Mannedorf, 
Switzerland) with a black bottomed 96 well plate. Protein purification was conducted on 
an ÄKTA fast protein liquid chromatography (FPLC) system (GE Healthcare Life 
Sciences; Piscataway Township, NJ, USA).  
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4.5.2 Synthesis of Acd. 
 Synthesis of Acd and derivative molecules were performed by Lee C. Speight and 
Anana K. Muthusamy and can be found in Speight et al. 2013138.  
4.5.3 Absorption and Fluorescence Spectroscopy of Fluorophore Pairs.   
 Photophysical characterization of Acd and fluorophore or quencher pairs was 
performed by Jacob M. Goldberg and Lee C. Speight and can be found in Speight et al. 
2013138. Plots of FRET efficiency for each chromophores are shown in Table 4.1. 
 
Table 4.1-Photophysical Characteristics of Acd FRET Pairs. 
FRET Pair 
(Donor, Acceptor) 
ΦD 
 
J 
(M-1•cm-1•nm4) 
R0 
(Å) 
εA (M-1•cm-1) 
@ λmax (nm) 
Trp, Acd     0.13484 5.47 x 1013 22.6 5, 700 @ 386 
Mcm, Acd    0.18485 7.96 x 1013 25.4 5, 700 @ 386 
Acd, Fam 0.95 9.64 x 1014 50.8 68, 000 @ 492 
Acd, BODIPY 0.95 8.18 x 1014 49.4 82, 000 @ 504 
Acd, R6G 0.95 7.86 x 1014 49.1 116, 000 @ 530 
Acd, NBD 0.95 5.47 x 1014 37.0 6, 835 @ 484 
 
4.5.4 Synthetase Selection Strategy  
 Candidate Synthetase Screening was performed by Taylor S. Willi and Bradley F. 
Woodman and can be found in Speight et al. 2013138.  
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4.5.5 Cloning of α-Synuclein Expression Constructs.   
 A plasmid containing the human wild-type αS gene cloned between NdeI and 
HindIII in the expression vector pRK172 was provided by Dr. Virginia Lee (Perelman 
School of Medicine, University of Pennsylvania).  Quikchange® site-directed 
mutagenesis was used to generate Y39δ and F94δ.  Sequencing was confirmed using a T7 
promoter. 
A. αS Gene 
5'atggatgtattcatgaaaggactttcaaaggccaaggagggagttgtggctgctgctgagaaaaccaaacagggtgtggcagaagcagcag
gaaagacaaaagagggtgttctctatgtaggctccaaaaccaaggagggagtggtgcatggtgtggcaacagtggctgagaagaccaaaga
gcaagtgacaaatgttggaggagcagtggtgacgggtgtgacagcagtagcccagaagacagtggagggagcagggagcattgcagcag
ccactggctttgtcaaaaaggaccagttgggcaagaatgaagaaggagccccacaggaaggaattctggaagatatgcctgtggatcctgaca
atgaggcttatgaaatgccttctgaggaagggtatcaagactacgaacctgaagcctaa-3' 
 
B. Human αS Amino Acid Sequence 
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQV
TNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMP
SEEGYQDYEPEA 
 
C. DNA Oligomers used for Quikchange® Mutagenesis 
Y39δ_For 5'-AAAAGAGGGTGTTCTCTAGGTAGGCTCCAAAACCAAG-3' 
Y39δ_Rev 5'-CTTGGTTTTGGAGCCTACCTAGAGAACACCCTCTTTT-3' 
F94δ_For 5'-GCATTGCAGCAGCCACTGGCTAGGTCAAAAAGGACCAGTTGGG-3' 
F94δ_Rev 5'-CCCAACTGGTCCTTTTTGACCTAGCCAGTGGCTGCTGCAATGC-3' 
 
Figure 4.6-Sequence and Primers for αS Mutagenesis.  
A) DNA sequence of human αS gene from start to stop codon.  B) Amino acid sequence of human αS. Y39 and F94 are 
highlighted in bold red.  C) Forward and reverse DNA oligomers used for site-directed mutagenesis. Reprinted from 
Speight 2013138. 
 
4.5.6 Wild-Type α-Synuclein Expression.  
 The plasmid containing the αS gene was transformed into E. coli BL21(DE3) 
cells.  Single colonies were used to inoculate 4 mL of LB media supplemented with 
ampicillin (100 μg/mL).  The primary culture was grown at 37 °C with shaking at 250 
rpm for 4 h. A 500 mL secondary culture was inoculated using 1 mL of the primary 
culture and grown at 37 °C with shaking at 250 rpm for 20 h.  The cells were harvested at 
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5000 x g for 15 min and the resulting pellet was resuspended in 20 mM Tris, pH 8.0 with 
1 mM PMSF and sonicated.  Following sonication, the cell lysate was boiled for 30 min 
prior to centrifugation for 20 min at 30,000 x g, 4 °C.  The cleared lysate was dialyzed 
overnight against 20 mM Tris pH 8.0 at 4 °C prior to loading on a Superdex 200 column 
(25 cm) connected to a BioCad Sprint (FPLC) system.  FPLC fractions were dialyzed 
against 20 mM Tris pH 8.0 at 4 °C and further purified using a HiTrap Q HP column (GE 
Healthcare) on the BioCad FPLC. Fractions were dialyzed against MilliQ water at stored 
at 4 °C.  Protein was concentrated using 3 kDa Amicon Ultra-0.5 mL centrifugal filters 
(EMD Millipore) and adjusted to 500 μM by BCA assay and stored at -80 °C until further 
use.  SDS-PAGE analysis was performed to analyze the purity of αS. 
4.5.7 Acd Mutant α-Synuclein Expression.  
 E. coli BL21-Gold (DE3) cells were transformed with the  αS-TAGx plasmid and 
a pDULE2 plasmid containing the AcdRS and tRNACUA pair.  Cells were selected for 
resistance to both ampicillin (100 μg/mL) and streptomycin (100 μg/mL).  Single 
colonies were used to inoculate 4 mL of LB media.  The primary culture was grown at 37 
°C with shaking at 250 rpm for 4 h.  A 500 mL secondary culture was inoculated using 1 
mL of the primary culture and grown at 37 °C with shaking at 250 rpm until OD600 0.8.  
Protein expression was induced with 1 mM Acd (282 mg in 4 mL sterile water 
solubilized with 4 drops 10 M NaOH) and 1 mM IPTG, then cells were grown at 37 °C 
for 18 h.  The cells were harvested at 5000 x g for 15 min and the resulting pellet was 
resuspended in 20 mM Tris, pH 8.0 with 1 mM PMSF and sonicated.  Following 
sonication, the cell lysate was boiled for 30 min prior to centrifugation for 20 min at 
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30,000 x g, 4 °C.  The cleared lysate was dialyzed overnight against 20 mM Tris, pH 8.0 
at 4 °C prior to loading on a Superdex 200 column (25 cm).  FPLC fractions were 
dialyzed against 20 mM Tris, pH 8.0 at 4 °C and further purified using a HiTrap Q HP 
column (GE Healthcare).  Fractions were dialyzed against MilliQ water and stored at 4 
°C.  Protein was concentrated using 3 kDa Amicon Ultra-0.5 mL centrifugal filters (EMD 
Millipore) and adjusted to 500 μM by BCA assay.  Protein was then stored at -80 °C until 
further use.  SDS-PAGE analysis was performed to analyze the purity of αS. 
 
Table 4.2-αS Acd Protein Expression. 
protein yield (mg/L) % yield relative to WT 
WT 30.0 100.0 
Y39δ 2.0 6.7 
F94δ 5.0 16.7 
 
 
Figure 4.7-PAGE Analysis of Acd Mutant Protein Expression.   
αS mutants.  Coomassie stained gels are shown at left, fluorescence images at right.  Molecular weight (MW) markers: 
7, 10, 17, 25, 40, 50, 75, 100, and 150 kDa.  The 25 and 75 kDa markers are fluorescently stained. 
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4.5.8 Trypsin Digest Analysis of Acd Mutants.  
 Protein (αS-Y39δ, or αS-F94δ) was precipitated using 1:4 8.75 M trichloroacetic 
acid/protein sample and incubated at 4 °C for 15 minutes. The precipitate was centrifuged 
for 15 min at 13,200 rpm to pellet protein. The protein pellet was then washed three times 
with cold acetone to remove trace trichloroacetic acid. Trace acetone was removed by 
incubating protein pellets in a 95 °C water bath for 5 min open to the atmosphere. Protein 
pellets were then re-suspended in 6 M guanidinium hydrochloride with 50 mM Tris pH 
8.0, and denatured by boiling at 95 °C for 10 minutes. Protein samples were then diluted 
to 0.75 M guanidinium hydrochloride with 50 mM Tris pH 7.6 and 1 mM calcium 
chloride. Sequencing grade modified trypsin (0.6 μg, Promega) was used to digest 
samples for 24 hours at 37 °C. Trypsin digest aliquots (1 μL) were combined with α-
cyano-4-hydroxycinnamic acid (1 μL of a saturated solution in 1:1 H2O/CH3CN with 1 % 
TFA) and analyzed by MALDI MS.  
 
Figure 4.8-MALDI MS of Trypsinized Acd αS.  
Asterisks indicate the absence of peaks corresponding to Tyr incorporation at the site of interest. αSY39δ35-43: Calcd 
m/z (M+H)+ 1052.5, found 1052.5; αS-Y94δ81-96: Calcd m/z (M+H)+ 1595.8, found 1595.8. No evidence of Npf 
incorporation is observed. 
 
4.5.9 αS Aggregation Studies.  
 αS WT, αS-Y39δ, and αS-F94δ were incubated at 50 μM in aggregation buffer (0.1 
M dibasic sodium phosphate, pH adjusted to 7.3 with monobasic sodium phosphate, plus 
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164 mM sodium chloride) at 37 °C with 1000 rpm orbital shaking.  2.5 μL aliquots were 
taken prior to aggregation for post-aggregation sedimentation analysis by PAGE gel.  
Fibrillization was monitored by removing 10 μL aliquots at t = 0, 24, 48, 72, and 96 h 
which were diluted to 50 μL with aggregation buffer.  Fluorescence spectra were 
obtained using a Tecan M1000 plate reader with settings as above.  Acd was excited at 
386 nm and emission monitored between 400 and 550 nm.  Following fluorescence 
recording, 100 μL of a 20 mM CongoRed solution was added to the wells and incubated 
for 30 min at room temperature.  UV/Vis spectra were obtained between 230 and 650 nm 
using a Tecan M1000 plate reader with the following settings: excitation slit width was 
2.5 nm, emission slit width was 5 nm, integration time 0.02 ms, data interval 2.0 nm, 50 
flashes at 400 Hz, and gain set to 100.  Following aggregation, fibrils were centrifuged at 
13.2 krpm for 30 min.  The supernatant was carefully removed and the fibrils were 
resuspended in an equal volume of aggregation buffer. Fluorescence spectra were 
obtained of the soluble and resuspended insoluble fractions. 
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Figure 4.9-Fluorescence Spectra of αS Mutants During Aggregation.   
Top: αS-Y39δ, Middle: αS-F94δ.  Spectra were recorded for 50 µM protein after 0 (black), 24 (purple), 36 (light blue), 
72 (light green), and 96 h (red) solutions.  Bottom: αS-F94δ.  Fluorescence spectra before (black) and after (red) 96 h of 
aggregation, soluble fraction at 96 h (dark green), and resuspended insoluble fraction (dark blue). 
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Figure 4.10-Absorbance Spectra of Congo Red Binding to αS Mutants During Aggregation.   
Top: αS-Y39δ, Middle: αS-F94δ, Bottom: WT.  Spectra were recorded for 50 µM protein after 0 (black), 24 (red), 36 
(dark green), 72 (dark blue), and 96 h (grey) solutions. 
 
4.5.10 αS Fibril Fluorescence Lifetimes.   
 Fluorescence lifetimes for αS or Acd solutions in aggregation buffer pH 7.3 were 
recorded and fit to biexponential equations as described in Goldberg et al. 201310.  
Amplitude-weighted exponential fit data are shown in Figure 4.11. 
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CHAPTER 5 : MULTIFUNCTIONALIZATION OF -SYNUCLEIN: 
COMBINING MULTIPLE LABELING STRATEGIES AND BIOORTHOGONAL 
CHEMISTRY 
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5.1 Introduction 
 Our understanding of the dynamics of protein folding, protein-protein 
interactions, cellular trafficking, and the effects of protein post-translational 
modifications is facilitated by protein functionalization. Functionalization entails the 
attachment of chemical entities that allow one to probe the location of a protein, 
determine its conformation, and identify interacting partners with spatial and temporal 
resolution.  These chemical entities are typically, fluorophores, crosslinking agents, and 
affinity purification handles, respectively. 
Ideally, reactions used to modify proteins should be bioorthogonal: 
chemoselective against endogenous protein functionalities. The concept of ‘click’ 
chemistry, introduced by Sharpless and coworkers, has been adopted to biomolecule 
labeling with great success32. Often borrowing from underutilized Organic Chemistry 
reactions, numerous protein labeling strategies have been identified that are high 
yielding, proceed rapidly, and are bioorthogonal. The simultaneous site-specific 
introduction of multiple functionalities into a protein inherently requires the use of one or 
more bioorthogonal labeling techniques. These bioorthogonal labeling techniques need to 
be mutually orthogonal or capable of being carried out sequentially. The introduction of 
multiple bioorthogonal reactive handles into proteins presents a significant challenge and 
limitation for researchers. Fulfilling the selectivity requirements for click chemistry 
demands the introduction of functional groups outside of the 20 natural amino acids 
(Naas). Thus, the development of methods for introducing multiple unnatural amino acids 
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(Uaas) with ‘clickable’ functional groups has been essential to implementing these 
reactions on proteins. 
 Several genetically controlled strategies currently exist for incorporating Uaas 
into proteins. Amber codon suppression is a method pioneered by Schultz and co-workers 
for site-specifically incorporating Uaas into proteins using evolved orthogonal 
tRNACUA/aminoacyl tRNA synthetase (RS) pairs in response to an inserted Amber 
(UAG) stop codon 368,457. This methodology has been expanded by Chin and co-workers 
using four base codons and evolved orthogonal ribosomes177,180,181185,186. Alternatively, 
Tirrell and co-workers have demonstrated the utility of so-called auxotrophic organisms 
to incorporate Uaas into proteins.  Auxotrophic organisms are engineered to be deficient 
in a specific natural amino acid.  Tirrell’s methods involve taking advantage of the 
promiscuity of endogenous RSs by depleting the growth medium of a specific amino 
acid, and then supplying an isosteric Uaa during protein expression486,487. Using these 
codon-specific methods, Uaas with handles for click chemistry that allow for the 
subsequent introduction of nearly any chemical entity204,433,488. Other Uaas can be 
incorporated that endow functionality without the need for subsequent modification, such 
as intrinsic fluorophores134,138,164,165 or photocrosslinkers122,124. Genetic incorporation of 
Uaas provides a powerful strategy for the installation of functional handles into proteins.  
 Additionally, several enzymatic modification strategies exist to transfer Uaas onto 
proteins containing unique recognition motifs 489-491. Sortase is a transpeptidase 
responsible for the attachment of proteins to the cell wall peptidoglycans of gram-positive 
bacteria. Using Sortase A from Staphylcoccus aureus, fluorophores, biotin, and Uaas for 
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click chemistry can be incorporated into a tri- or penta-glycine containing peptide that is 
then ligated to the C-terminus of a peptide or protein bearing the requisite LPXTG 
recognition motif 235,236. Biotin ligase (BirA from E. coli or yBL from yeast) catalyzes the 
ligation of a biotin substrate to the ε-amine of a Lys residue located within a 15 amino 
acid acceptor peptide (AP or yAP). Biotin derivatives have been utilized that contain 
ketone, azide, or alkyne functional groups for subsequent protein modification240,242. 
Evolution of a yAP derivative with a novel recognition motif has allowed for 
orthogonality between BirA and yBL for multifunctionalization of proteins241. Use of 
Sortase or Biotin ligase requires insertion of a substantial peptide recognition sequence 
that may perturb protein function. In contrast, E. coli aminoacyl transferase (AaT) 
requires only a single amino acid for recognition.  AaT is an enzyme in the N-end rule 
pathway that transfers leucine (Leu), phenylalanine (Phe), or methionine (Met) to 
proteins containing an N-terminal lysine (Lys) or araginine (Arg)251,252. Aminoacylated 
tRNA serves as an activated donor for N-terminal transfer. AaT is relatively 
promiscuous; discrimination for aminoacylation of tRNA is controlled by the amino acid 
RSs. Therefore, AaT can be used to transfer a wide range of Uaas to the N-termini of 
peptides and proteins253-255,256. In our own laboratory, a chemoenzymatic method for 
protein N-terminal labeling was developed utilizing synthetic aminoacylated adenosine 
donors261. Amber codon suppression, auxotrophic incorporation, and AaT mediated N-
terminal modification are mutually orthogonal techniques that can be combined for 
protein multifunctionalization using Uaas.  
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 α-Synuclein (αS) is an intrinsically disordered 140 amino acid protein, aggregates 
of which are among the hallmarks of Parkinson’s disease (PD)285,287,290. Residues 61-95 
of αS comprise the so-called non-amyloid-β component (NAC) domain and drive the 
formation of β-sheet rich amyloidogenic aggregates. In vitro aggregation studies suggest 
a nucleation-propagation mechanism for αS fibril assembly that is highly sensitive to 
experimental conditions292,492. Labeling of αS has been used previously to investigate the 
mechanisms that drive αS fibril formation and cellular toxicity. Macromolecular labeling 
of αS using a yellow fluorescent protein (YFP) fusion construct or immuno-tags were 
used as a direct method for monitoring protein fibrillization both in vitro and in vivo335, 
336 and imaging intracellular oligomeric αS337. Imaging of fibrillization in vivo was 
accomplished using the insertion of a small tetracysteine peptide to the C-terminus of αS 
and labeling using either biarsenical fluorescein (FlAsH) or biarsenical resorufin 
(ReAsH)339. Though effective and highly specific, attachment of large macromolecules 
such as YFP or labeled antibodies has the potential to perturb protein function. Cysteine 
(Cys)-maleimide labeling requires only the introduction of a single Cys mutant into αS 
(which lacks endogenous Cys)346,347. Cys-maleimide fluorophore labeling was combined 
with tryptophan (Trp) fluorescence to generate a fluorescence resonance energy transfer 
(FRET) fluorophore pair to probe αS conformational dynamics just prior to 
aggregation359. Alternatively, several groups have doubly labeled αS using stochastically 
controlled fluorophore-maleimide labeling of double Cys mutants 308,351-354,356-358. This 
leads to a mixture of forms of singly and doubly labeled proteins, which can be difficult 
to separate. Using Cys and pH-dependent N-terminal α-amine labeling, it was shown that 
a conformational change proceeds fibril formation and that fibril nucleation is 
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concentration dependent360. However, it is difficult to achieve complete specificity for the 
N-terminus in this way.  
 Recently, our laboratory has demonstrated the ability to incorporate a minimally 
perturbing thioamide/p-cyanophenylalanine (Cnf) FRET pair into αS via native chemical 
ligation (NCL) and Amber codon suppression365. Additionally, we have demonstrated a 
chemo-enzymatic approach to αS semi-synthesis using NCL at Met for tracelessly 
incorporating N-terminal modifications262. Amber codon suppression was used with 
either NCL or NCL at Met to incorporate a Cnf/thioamide FRET pair into αS semi-
synthetically283,284. These methods have been used with small molecule protein 
compaction reagents to probe conformational dynamics of αS monomers. Despite 
extensive study, the exact mechanisms underlying αS fibrillization and cellular toxicity 
have yet to be defined. Understanding of the mechanisms and interactions of αS in 
normal neuronal function and under disease state conditions can be greatly aided by the 
generation of modified and labeled proteins. Here, we demonstrate the 
multifunctionalization of αS using Amber codon suppression, auxotrophic incorporation, 
and AaT mediated N-terminal modification to install combinations of fluorophores, 
photocrosslinkers, and affinity purification reagents. 
5.2 Results and Discussion 
 We have previously shown that AaT is capable of modifying protein N-termini 
with p-azidophenylalanine (Azf) using semi-synthetic aminoacyl adenosine donors261.  
Additionally, we have used a mutant methionine amino acyl tRNA synthetase (Met*RS) 
to transfer Met analogs such as disulfide protect homocysteine (Hcm) to the N-terminus 
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of proteins for NCL262,284. Aminoacyl adenosine donors are useful for screening the 
substrate specificity of AaT. However, higher yields are achieved with the enzymatic 
turnover of Uaa-tRNA using RSs. Therefore, we sought to develop general protocols for 
labeling the αS N-terminus with azide and alkyne amino acids using mutant RSs in 
conjunction with AaT. An αS construct with an N-terminal Lys or Arg was generated by 
inserting a His10- tag with a Factor Xa proteolysis site at the protein N-terminus, deleting 
Met1, and making the mutation Asp2Lys (His10-αS2-140K2) (see Figure 5.1). Following 
Ni-NTA affinity purification of His10-αS2-140K2, the His10-tag was cleaved with Factor Xa 
and the N-terminal Lys was revealed. Factor Xa cleavage proceeded optimally with 
minimal aggregation using protein concentrations of less than or equal to 0.5 mg/mL in 
the presence of 100 mM urea. Azidohomoalanine (Aha) was then transferred to αS2-140K2 
using E. coli Met*RS, ATP, and E. coli total tRNA. Transfer was complete within 2 h as 
monitored by MALDI MS. αS2-140K2AhaN (1) was subsequently modified with 
dibenzylcyclooctyne-fluorescein (DBCO-FAM) or –tetramethylrhodamine (DBCO-
TMR) fluorophores using strain-promoted azide-alkyne cycloaddition (SPAAC). It 
should be noted that labeling of 1 can also utilize copper-catalyzed azide-alkyne 
cycloaddition (CuAAC), but this was generally avoided due to concerns about enhanced 
aggregation in the presence of copper. SPAAC labeling was facilitated by the presence of 
1 M urea to minimize protein aggregation. Purified proteins, αS2-140K2FAMN (2a) and 
αS2-140K2TMRN (2b), were characterized by whole protein MALDI MS as well as trypsin 
digest followed by MALDI MS (Figure 5.1).  
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Figure 5.3-Double Labeling of αS using Amber Codon Suppression and AaT Mediated Labeling.  
Left: Functionalization of αS2-140K2Azf by a) labeling of Azf with DBCO-TMR b) cleavage of His10-tag at Factor Xa 
site, c) attachment of Aha by AaT-catalyzed modification, d) DBCO-FAM labeling of Aha. Top Right: SDS-PAGE 
analysis of αS2-140K2TMR39FAMN (9a) and αS2-140K2TMR94FAMN (9b). Protein is visualized by Coomassie staining 
and fluorescence imaging merge of FAM and TMR channels. Middle Right: MALDI MS analysis of full length 9a.  
Calcd m/z (M+H)+ 15817.6, found 15816.3. Bottom Right: MALDI MS analysis of full length 9b.  Calcd m/z (M+H)+ 
15833.6, found 15833.7.   
  
 
 In our efforts towards 9a and 9b we observed incomplete labeling of Azf at Tyr39 
and Phe94. Aryl azides, such as Azf, are subject to chemical reduction and 
photodegradation493. Unfortunately, Azf-containing peptide fragments are ionized to p-
aminophenylalanine species during MALDI MS analysis.  Therefore, it is difficult to 
determine the extent of Azf reduction directly, and we infer it from the yields of click-
chemistry reactions with alkynes. To address the limitation of incomplete Azf labeling 
using the αS2-140K2TAG constructs, we sought to explore additional Uaas. Several RSs 
have been identified that are promiscuous, in that they can accept multiple Uaas, while 
retaining selectivity against the Naas150,151. Ppy is a tyrosine analog that substitutes a 
terminal alkyne functionality for the azide of Azf. Utilizing the same mutant Mj TyrRS 
for Azf incorporation, we have demonstrated Ppy incorporation into αS. The extent of 
protein labeling of Azf versus Ppy was compared using Cu-catalyzed fluorescein 
labeling. Cells expressing Azf containing protein were found to produce 39% less protein 
compared to matched Ppy expression. Adjusting for the difference in protein yields, Azf 
protein was labeled with fluorescein-alkyne 53% less efficiently than Ppy protein labeled 
with carboxyrhodamine110-azide (Figure 5.9). The observed increase in efficiency of 
Ppy labeling may be due in part to the increased stability of the alkyne.  
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 To multifunctionalize αS, we wished to combine AaT mediated N-terminal 
labeling, Amber codon suppression, and auxotrophic Uaa incorporation. As a first step 
toward multifunctionalized αS, we demonstrated the viability of auxotrophic 
incorporation. A Met auxotrophic E. coli host (E. coliΔMet) was used to incorporate Met 
analogs azidohomoalanine (Aha) or homopropargylglycine (HPG) into αS. Global 
replacement of αS’s four Met residues with either Aha (αSAhaGlb, 10) or HPG 
(αSHPGGlb, 11) was observed when protein induction was supplemented with either Aha 
or HPG, respectively (Figure 5.4). p-Benzoylphenylalanine (Bzp) was incorporated into 
αS2-140K2TAG using Amber codon suppression with a mutant Mj TyrRS/tRNACUA pair 
(pEVOLBzp) selected for Bzp. pEVOLBzp is unique in that it contains two copies of Mj 
BzpRS, one constitutively expressed and the second under arabinose induction, for higher 
Uaa incorporation efficiencies. Bzp incorporation was performed in E. coliΔMet, allowing 
for concurrent global replacement of Met with HPG. Observed protein yields are 
currently low due to the incorporation of two different Uaas. This construct will then be 
N-terminally modified using Factor Xa proteolysis and subsequent AaT modification 
with Aha. Fluorescent labeling of Aha at the protein N-terminus will be carried out as 
described above. For proof-of-principle experiments, we will decorate αS2-
140K2Bzp39FAMNHPG with biotin-azide using CuAAC. Aha and HPG provide orthogonal 
reaction handles that allow for separate labeling of the two functionalities. By controlling 
the order of labeling, Aha can be first labeled using either SPAAC or a Staudinger 
ligation56. HPG can then be labeled using CuAAC and either a single azide probe or a 
mixture of azide probes to functionalize the protein.  
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5.3 Conclusions 
 The ability to functionalize a protein for biological study is paramount to 
understanding its physiological role in either a normal or disease state. Here, we have 
employed several strategies to multifunctionalize αS with fluorophores, click-chemistry 
handles, and photocrosslinking probes by combining AaT mediated N-terminal 
modification, Amber codon suppression, and auxotrophic incorporation. Site-specific 
attachment of either a single fluorophore or a FRET pair should facilitate the study of 
intracellular protein trafficking and conformational dynamics during aggregation. The 
combination of photocrosslinkers with click-chemistry handles to attach affinity 
enrichment tags such as biotin can aid in the discovery of novel protein-protein 
interactions.  
 The requisite orthogonality can be easily achieved by the combination of 
techniques chosen here. AaT N-terminal modification is a useful post-translational 
modification technique that is compatible with in vivo modification techniques such as 
Amber codon suppression and auxotrophic Uaa incorporation. An ever growing number 
of Uaas with a diverse of scope of functionality, have been incorporated in E. coli, yeast, 
and mammalian cells457,495,496. Though extremely useful for time-pulsed experiments497, 
auxotrophic Uaa incorporation imposes the global replacement of a Naa in a protein, and 
thus may not be tolerated. While limited to isosteres of Naas, Uaa diversity and 
incorporation efficiencies have been improved by coupling overexpression of either a 
wild type RS or a mutant RS with an expanded substrate binding pocket during 
auxotrophic cell growth83,84,86-89 . Though demonstrated solely on αS, we envision that 
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our approach towards protein multifunctionalization can be applied to a wide variety or 
proteins. 
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5.5 Materials and Methods 
5.5.1 General Information.   
 Azf was purchased from Bachem (Torrance, CA).  5(6)’-
carboxytetramethylrhodamine was purchased from Novabiochem, EMD Millipore 
(Darmstadt, Germany).  Dibenzylcyclooctyne-amine and carboxyrhodamine110-azide 
were purchased from ClickChemistryTools (Scottsdale, AZ).  All deuterated solvents 
were purchased from Cambridge Isotopes Laboratories, Inc. (Andover, MA).  Ni-NTA 
resin was purchased from Qiagen (Valencia, CA).  E. coli BL21(DE3) cells were 
purchased from Stratagene (La Jolla, CA).  T4 DNA Ligase, XhoI and NdeI restriction 
enzymes were purchased from New England Biolabs (Ipswich, MA). Max Efficiency 
DH5alpha Competent Cells, Opti-MEM®, BioPORTER®,  and trypsin 0.25% EDTA 
were purchased from Life Technologies (Grand Island, NY).  DMEM (high glucose) and 
penicillin-streptomycin, solution (100X) was purchased from Corning (Mediatech, 
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cellgro; Manassas,VA). Sequencing-grade trypsin was purchased from Promega 
(Madison, WI).  Bovine Factor Xa protease was purchased from Haematologic 
Technologies (Esses Junction, VT).  QuikChange® site-directed mutagenesis kits were 
purchased from Stratagene.  DNA oligomers were purchased from Integrated DNA 
Technologies, Inc (Coralville, IA).  5(6)’-carboxyfluorescein, triethylamine (Et3N), 
trifluoroacetic acid (TFA), protease inhibitor cocktail, fetal bovine serum (FBS), and 
DOWEX 50XW4 cation exchange resin were purchased from Sigma-Aldrich (St. Louis, 
MO).  Potassium cyanide was purchased from J.T. Baker (Avantor) (Center Valley, PA). 
All other reagents were purchased from Fisher Scientific (Pittsburgh, PA).  MilliQ 
filtered (18 MΩ) water was used for all solutions (Millipore, Billerica, MA).  The pEG6 
plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander Varshavsky 
(California Institute of Technology).  The pDULE2Azf plasmid was a gift from Ryan 
Mehl (Oregon State University).  The pCDNA3.1-RSAzf plasmid was a gift from Thomas 
Sakmar (The Rockefeller University). pEVOLBzp was purchased from Addgene 
(Cambridge, MA). 
 Matrix-assisted laser desorption/ionization (MALDI) mass spectra were collected 
with a Bruker Ultraflex III MALDI-TOF/TOF mass spectrometer (Billerica, MA).  
Electrospray ionization (ESI) mass spectra were collected with a Waters LCT Premier 
XE liquid chromatograph/mass spectrometer (Milford, MA).  UV/vis absorbance spectra 
were obtained with a Hewlett-Packard 8452A diode array spectrophotometer (Agilent 
Technologies, Santa Clara, CA).  NMR spectra, 1H and 13C, were collected with a Bruker 
DRX 500 MHz instrument (Billerica, MA, USA). Gel images were obtained with a 
 142 
 
 
Typhoon FLA 7000 (GE Lifesciences, Princeton, NJ). Fluorescence spectra were 
collected with a Tecan M1000 plate reader (Mannedorf, Switzerland) with a UV 
transparent 96 well plate.  
 
5.5.2 Synthesis of L/D-homopropargylglycine (L/D-HPG).  
 Synthesis of 4-pentynal was performed as previously described498. Dry DMSO 
(209.2 mmol) dissolved in dry dichloromethane (40 mL) was added to a solution of 
oxalyl chloride (104.6 mmol) dissolved in dry dichloromethane (200 mL) at -78°C over a 
period of 20 min. The reaction was kept under argon until workup. The solution was 
stirred for an additional 30 min. 4-Pentynol (95.1 mmol) dissolved in dry 
dichloromethane (80 mL) was added to the stirred solution at -78°C over 10 min. The 
reaction was kept at -78°C for an additional hour. Et3N (475.5 mmol) was slowly added 
at -78°C and stirred for an additional hour. The reaction was then allowed to warm to 
room temperature. Water (200 mL) was added and the aqueous layer was separated. The 
aqueous layer was acidified with 1% aqueous hydrochloric acid saturated with sodium 
chloride. The acidified aqueous layer was extracted with dichloromethane (3 x 100 mL). 
The combined organic layers were washed with 1% hydrochloric acid saturated with 
sodium chloride (6 x 100 mL) and 5% aqueous sodium bicarbonate (2 x 50 mL). The 
aqueous extracts were back-extracted with dichloromethane (2 x 100 mL). The combined 
organic extracts were washed with brine (2 x 50 mL) and dried with magnesium sulfate. 
Solvent was removed by rotary evaporation. Care was taken to monitor temperature and 
pressure at which solvent was evaporated to prevent concurrent product loss. 4-pentynal 
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was obtained as a red/yellow oil and taken directly into the next reaction. Yield: 4.45 g 
(57%).   
 Synthesis of (2RS)-2-aminohex-5-ynenitrile was performed as previously 
described499. Potassium cyanide (54.08 mmol) and ammonium chloride (54.08 mmol) 
were dissolved in 25% ammonia (16.6 mL) and water (16.6 mL). After stirring for 1 h at 
room temperature, 4-pentynal (54.2 mmol) in methanol (12.5 mL) was added. The 
solution was heated with stirring for 4 h at 40 °C with a chilled water condenser to 
prevent evaporation of solvent. The reaction was then quenched with 5% sodium 
bicarbonate (21 mL) and the solution was extracted with dichloromethane (3 x 30 mL, 
and the combined organic extracts were washed by 5% sodium bicarbonate (2 x 21 mL), 
brine (2 x 21 mL) and dried over magnesium sulfate. Solvent was removed by rotary 
evaporation. Care was taken to monitor temperature and pressure at which solvent was 
evaporated to prevent concurrent product loss. Yield: 3.90 g (67%) of a yellow oil. The 
product was used directly in the next step.  
 Synthesis of L/D-homopropargylglycine (L/D-HPG) was performed as previously 
described499. (2RS)-2-aminohex-5-ynenitrile (3.9 g, 36.1 mmol) in 88 mL 10% aqueous 
sulphuric acid was refluxed with vigorous stirring at 120 °C for 24 h. The mixture was 
cooled to room temperature and loaded on a Dowex 50WX8 cation exchange resin (150 
mL). Prior to loading, the column was washed with 1 L 1.5 M ammonia hydroxide, 1 L 
MilliQ water (pH ~5.5), and 1 L 10% sulphuric acid in MilliQ water. The cooled reaction 
was loaded onto the equilibrated resin. The resin was washed with 3 L MilliQ water and 
then eluted with 1.5 M ammonia hydroxide (2 x 500 mL). The eluate was concentrated 
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by rotary evaporation, resuspended in MilliQ water and lyophilized. An analytical sample 
was crystallized from ethanol/water (2/1); 1H and 13C NMR were consistent with 
published data499. LRMS (ESI) calcd for C6H10NO2 (M+H)+ 128.07, found 128.01. 
Obtained 2.09 g (46%) L/D-HPG, overall yield: 18%.   
5.5.3 Synthesis of p-Propargyltyrosine (Ppy). 
 Synthesis of (tert-butoxycarbonyl)-L-tyrosine. Di-tert-butylprocarbonate (30.36 
mmol) was added to a stirred solution of L-tyrosine (27.6 mmol) in dioxanes (55.2 mL), 
MilliQ water (27.6 mL), and 1.0 M sodium hydroxide (27.6 mL) on ice. The solution was 
allowed to warm to room temperature and stirred for 6 h. The solution was concentrated 
by rotary evaporation and cooled in an ice-water bath and covered with ethyl acetate (40 
mL) and acidified with a dilute solution of potassium bisulfate to pH 2-3. The aqueous 
layer was extracted with ethyl acetate (2 x 80 mL). The combined organic layers were 
dried over magnesium sulfate and concentrated by rotary evaporation. 7.16 g of a white 
solid were obtained. Yield: 92%. 1H and 13C NMR were consistent with published data12.  
 Synthesis of prop-2-yn-1-yl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-
1-yloxy)phenyl)propanoate was performed as previously described500. Propargylbromide 
(76.08 mmol) was added dropwise to a stirred solution of (tert-butoxycarbonyl)-L-
tyrosine (25.5 mmol) and potassium carbonate (76.62 mmol) in dry DMF on ice. The 
reaction was allowed to warm to room temperature and stirred for 24 h. Water (230 mL) 
and ethyl ether (140 mL) were added to the reaction. The aqueous layer was separated 
and extracted with ethyl ether (3 x 115 mL). The combined organic layers were dried 
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over magnesium sulfate and concentrated by rotary evaporation. 11.02 g of a yellow oil 
was obtained and taken crude to the next reaction. 
 Synthesis of prop-2-yn-1-yl (S)-2-amino-3-(4-(prop-2-yn-1-
yloxy)phenyl)propanoate was performed as previously described500. Prop-2-yn-1-yl (S)-
2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoate (11.02 g) 
was dissolved in 4 M hydrochloric acid in dioxanes (115 mL) and stirred at room 
temperature for 24 h. Solvent was removed by rotary evaporation and a yellow solid was 
obtained. Product was taken crude to the next reaction. 
 Synthesis of p-propargyltyrosine (Ppy) was performed as previously described500. 
Crude prop-2-yn-1-yl (S)-2-amino-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoate was 
dissolved in MilliQ water:methanol (1:1, 77 mL) with 4.1 g sodium hydroxide and stirred 
at room temperature for 16 h. The reaction was then adjusted to pH 7 with 1.0 M 
hydrochloric acid. MilliQ water (47 mL) was added and precipitated overnight at 4°C. 
Precipitate was filtered and washed with cold MilliQ water. 3.8 g of an off-white solid 
was obtained. Yield 71% from (tert-butoxycarbonyl)-L-tyrosine. LRMS (ESI) calcd for 
C12H14NO3 (M+H)+ 220.097, found 220.114. 
5.5.3 Synthesis of Dibenzocyclooctyne-Tetramethylrhodamine (DBCO-TMR). 
 As described in section 6.5.2 below. 
5.5.4 Synthesis of Dibenzocyclooctyne-Fluorescein (DBCO-FAM).   
 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (72 μmol), H-
hydroxybenzotriazole (72 μmol), and Et3N (144 μmol) was added to a solution of 5(6)’-
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carboxyfluorescein (36.2 μmol) in 2 mL dimethylformamide.  The reaction was stirred on 
ice for 10 minutes and then dibenzocyclooctyne-amine (36.2 μmol) was added.  The 
reaction was stirred and allowed to warm to room temperature overnight.  Solvent was 
removed under vacuum with a liquid nitrogen trap.  The reaction was purified using 100 
mL silica gel in 1:9 methanol/dichloromethane with 1 % acetic acid.  Product fractions 
were concentrated by rotary evaporation and dried on high-vac overnight, affording 
DBCO-FAM as a dark orange/yellow solid in 66 % yield.  LRMS (ESI) calcd for 
C39H27N2O7 (M+H)+ 635.18, found 635.45. 
5.5.5 Click Chemistry Reagents 
 Fluorescein-alkyne and tris-(3-hydroxypropyltriazolylmethyl)amine (THPTA) 
were synthesized as described previously261. 
 
Scheme 5.2-Fluorophore Probes Used for Protein Labeling. 
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5.5.6 Met*RS Expression and Purification.  
 E. coli Met*RS was obtained from David Tirell. Plasmids were transformed into 
E. coli BL21 (DE3) and grown to OD600 0.6 in LB media with ampicillin (Amp, 100 
μg/mL). Protein expression was induced with 1.0 mM isopropyl β-D-thiogalactoside and 
grown for 18 h at 25 °C. The cells were harvested at 4,200 x g for 15 min and the 
resulting pellet was resuspended in a lysis buffer (300 mM KCl, 50 mM Tris pH 8.0) and 
included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) 
and sonicated. Soluble protein was obtained by centrifugation for 20 minutes at 26,900 x 
g, 4 °C. Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA resin.  
Protein was purified by rinsing with lysis buffer followed by washing with wash buffer 
(300 mM KCl, 50 mM Tris pH 8.0, and 15 mM imidazole).  Protein was eluted with 4 x 1 
mL Elution Buffer A (300 mM KCl, 50 mM Tris pH 8.0, and 50 mM imidazole) 
followed by 4 x 1 mL Elution Buffer B (300 mM KCl, 50 mM Tris pH 8.0, and 250 mM 
imidazole). SDS-PAGE analysis was performed to analyze the purity of elution fractions.  
Collected protein fractions were dialyzed against storage buffer (50 mM Tris pH 7.5 in 
50% glycerol) at 4 °C. Protein was stored in 0.5 mL aliquots at -80 °C. 
5.5.7 Overexpression and Purification of Wild Type αS.  
 A plasmid containing the human wild type (WT) αS gene cloned in the expression 
vector pRK172 was provided by Dr. Virginia Lee (Perelman School of Medicine, 
University of Pennsylvania). WT αS was transformed into competent E. coli BL21 (DE3) 
cells. Single colonies were used to inoculate 4 mL of LB media supplemented with Amp 
(100 ug/mL). The primary 4 mL culture was incubated at 37 ºC with shaking at 250 rpm 
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for 4 h. The primary culture was used to inoculate 1 L of a LB media. Protein expression 
was induced by addition of 1.0 mM IPTG at OD600 0.6 and the culture was incubated 
overnight at 37 ºC with shaking at 250 rpm. The cells were harvested at 4,200 x g for 15 
min and the resulting pellet was resuspended in 20 mM Tris, pH 8.0. Following 
sonication, the cell lysate was boiled for 20 min prior to centrifugation for 20 min at 
26,900 x g, 4 ºC. The cleared lysate was dialyzed against 20 mM Tris pH 8.0, loaded onto 
a Superdex 200 column (25 cm) and eluted with 20 mM Tris, pH 8.0. The fractions 
containing αS were then loaded onto a HighTrap Q HP column and eluted over a 120 min 
sodium chloride gradient (0 to 1 M NaCl in 20 mM Tris, pH 8.0). Protein fractions were 
analyzed by MALDI-MS, combined, concentrated, and buffer exchanged into PBS pH 
7.3 using Amicon Ultra 0.5 Centrifugal 3 kDa spin columns (EMD Millipore 
Corporation; Billerica, MA). Concentration determined by BCA assay and protein was 
stored at -80°C. 
5.5.8 Construction of αS2-140K2 Plasmid.  
 A plasmid containing a WT αS gene cloned between NdeI and HindIII in pT7-7 
vector was provided by Dr. Elizabeth Rhoades (Department of Molecular Biophysics and 
Biochemistry, Yale University).  An XhoI site (CTCGAG) was introduced 3' to the WT 
αS gene in the pT7-7 vector using QuikChange® mutagenesis.  The αS gene was digested 
by NdeI and XhoI and cloned into the pET-16b prokaryotic expression vector (EMD 
Biosciences; San Diego, CA), which contained an N-terminal His-tag followed by a 
Factor Xa recognition site (IEGR).365  QuickChange® mutagenesis was then used to 
delete residues H-1 and M1 followed by a D2K mutation to yield the H10-αS2-140K2 
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plasmid.  The plasmid identity was confirmed using DNA sequencing with a T7 promoter 
primer. 
Human αS2-140K2 Gene 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTAAAG
TATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGAGAAAACCAAAC
AGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTCCAAAACCA
AGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAAT
GTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGG
GAGCATTGCAGCAGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGC
CCCACAGGAAGGAATTCTGGAAGATATGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCT
TCTGAGGAAGGGTATCAAGACTATGAACCTGAAGCCTAA 
 
DNA Oligomers Used for QuickChange® Mutagenesis 
a. Deletion of H-1 and M1 
Forward: 5’-GGC CAT ATC GAA GGT CGT GAT GTA TTC ATG AAA GGA-3’ 
Reverse: 5’-TCC TTT CAT GAA TAC ATC ACG ACC TTC GAT ATG GCC-3’ 
b. Mutation of D2K 
Forward: 5’-GCG GCC ATA TCG AAG GTC GTA AAG TAT TCA TGA AAG GAC TTT C-3’ 
Reverse: 5’-GAA AGT CCT TTC ATG AAT ACT TTA CGA CCT TCG ATA TGG CCG C-3’ 
 
Human αS2-140K2 Amino Acid Sequence 
MGHHHHHHHHHHSSGHIEGRKVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKT
KEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAP
QEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 
Figure 5.7-Construction of αS2-140K2 Plasmid. 
 
5.5.9 N-terminal modification of αS using AaT.  
 The H10-αS2-140K2 plasmid described above was transformed into E. coli BL21 
(DE3) cells using Amp (100 μg/mL) resistance. Single colonies were inoculated into 4 
mL of LB media supplemented with Amp and grown for 4 hours at 37 °C with shaking at 
250 rpm. A 1 L secondary culture was inoculated using the 4 mL starter culture and 
grown at 37 °C with 250 rpm shaking until an OD600 of 0.8 was reached. Protein 
expression was induced by addition of 1 mM isopropyl β-D-thiogalactoside (IPTG) and 
cells were incubated at 25 °C with 250 rpm shaking for 16 hours. Cells were harvested by 
centrifugation at 4,200 x g for 15 min and the resulting pellet was resuspended in Factor 
Xa cleavage buffer (100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2) and included 
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protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II. Cells were 
lysed by sonication and the cell lysate was boiled for 20 minutes prior to centrifugation 
for 20 minutes at 26,900 x g, 4 °C. Cleared cell lysate was incubated with gentle shaking 
for 1 h on ice with Ni-NTA resin. Protein was purified by rinsing with Factor Xa 
cleavage buffer followed by washing with Factor Xa wash buffer (Factor Xa cleavage 
buffer and 50 mM imidazole). Protein was eluted with Factor Xa elution buffer (Factor 
Xa cleavage buffer and 250 mM imidazole). SDS-PAGE analysis using an 18% gel was 
performed to analyze the purity of αS elution fractions. Collected protein fractions were 
dialyzed against Factor Xa cleavage buffer and 100 mM urea at 4 °C. The His10 
purification tag was removed by incubation of purified αS (0.5 mg/mL) with Bovine 
Factor Xa (3.0 mg/mL, 1752 Units/mg, Haematologic Technologies, Inc.; Essex Junction, 
VT) (80 Units) overnight at 37°C. Cleavage of the His10  tag was monitored by MALDI-
MS with samples being diluted 1:9 in a saturated solution of sinipinic acid dissolved in 
1:1 water:acetonitrile with 0.1% trifluoroaceticacid (TFA). Cleaved protein was loaded 
directly onto a HiTrap Q HP column (GE Healthcare) equilibrated with 20 mM Tris pH 
8.0. Protein was eluted using 20 mM Tris pH 8.0 with a linear gradient of sodium 
chloride from 0 M to 1 M over 120 min. Protein fractions were analyzed by MALDI-MS 
as described above. Fractions were combined and concentration was determined by BCA 
assay (Pierce). Protein was N-terminally modified with azidohomoalanine (Aha) using 
the following conditions: αS2-140K2 (0.5 mg/mL), ATP (2.5 mM), Aha (2.0 mM), E. coli 
total tRNA (2 mg/mL), E. coli Met*RS (0.1 mg/mL), and AaT (0.1 mg/mL) in 50 mM 
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2. The reaction was incubated at 37 °C for 
1.5 hours. Upon completion the reaction was diluted 1:1 with 20 mM Tris pH 8.0 and 
 151 
 
 
purified using a HiTrap Q HP column. Protein fractions were analyzed by MALDI-MS, 
combined, and concentration determined by BCA assay. 
5.5.10 Fluorescent labeling of αS2-140K2AhaN.  
 αS2-140K2AhaN was adjusted to 0.5 mg/mL from above using 20 mM Tris pH 8.0 
and urea was added to a final concentration of 1.0 M. Protein was labeled with 3 
equivalents of either DBCO-FAM or DBCO-TMR at 37 °C for 3 hours. Excess dye was 
removed by dialysis against 20 mM Tris pH 8.0 (2 x 5 L) with the first dialysis at room 
temperature and the second at 4 °C. Protein was purified using a HiTrap Q HP column 
and fractions were analyzed by MALDI-MS. Combined fractions were concentrated and 
buffer exchanged into PBS pH 7.3 using Amicon Ultra 0.5 Centrifugal 3 kDa spin 
columns. Protein concentration was determined by BCA assay and stored at -80 °C until 
further use. 
5.5.11 Construction of αSTAG39 and αSTAG94 Plasmids.  
 Quickchange® mutagenesis was used to introduce TAG codons at positions Tyr39 
(αSTAG39) and Phe94 (αSTAG94) into the pT7-7 WT αS plasmid. Plasmid identities were 
confirmed using DNA sequencing with a T7 promoter primer. 
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Human αS Gene (T7) 
5’ATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGA
GAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGT
AGGCTCCAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAA
AGAGCAAGTGACAAATGTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAA
GACAGTGGAGGGAGCAGGGAGCATTGCAGCAGCCACTGGCTTTGTCAAAAAGGACCAGTT
GGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGAAGATATGCCTGTGGATCC
TGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGGGTATCAAGACTACGAACCTGAAGCC
TAA-3’ 
 
DNA Oligomers used for Quickchange ® Mutagenesis  
A. Mutation Tyr39TAG 
Forward: 5' – AAAAGAGGGTGTTCTCTAGGTAGGCTCCAAAACCAA – 3' 
Reverse: 5' – CTTGGTTTTGGAGCCTACCTAGAGAACACCCTCTTTT – 3' 
B. Mutation Phe94TAG 
Forward: 5' – GCATTGCAGCAGCCACTGGCTAGGTCAAAAAGGACCAGTTGGG – 3' 
Reverse: 5' – CCCAACTGGTCCTTTTTGACCTAGCCAGTGGCTGCTGCAATGC – 3' 
 
Human αSTAG39 or αSTAG94 Amino Acid Sequence 
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTK
EQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDN
EAYEMPSEEGYQDYEPEA 
Figure 5.8-Construction of αSTAG39 and αSTAG94 Plasmids. 
  
5.5.12 Overexpression of αSAzf39 and αSAzf94.  
 Either αSTAG39 or αSTAG94 were co-transformed with a pDULE2Azf plasmid 
containing a M. jannaschii mutant tRNA synthetase and tRNACUA pair into E. coli BL21 
(DE3) cells. Single colonies were selected and grown in 4 mL of LB using Amp (100 
μg/mL) and streptomycin (Strep, 100 μg/mL) for 4 hours at 37 °C with shaking at 250 
rpm. The 4 mL primary culture was inoculated into 1 L of M9 minimal media containing 
6 g of Na2HPO4, 3 g of KH2PO4, 0.5 g of NaCl, and 1 g of NH4Cl: 1 mL of 2 M MgSO4, 
1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15mg/mL ZnCl2 (in acidified water), 2 
mL of 10% Bacto yeast extract, 25 mL of 40% glycerol (v/v) supplemented with Amp 
and Strep and grown at 37 °C with shaking at 250 rpm until OD600 1.0. Protein 
expression was induced with 0.75 mM p-azidophenylalanine (Azf) and 1.0 mM IPTG and 
cells were incubated at 25 °C with 250 rpm shaking for 16 hours. Cultures and purified 
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protein containing Azf are kept shielded from light. The cells were harvested at 4,200 x g 
for 15 min and the resulting pellet was resuspended in 20 mM Tris, pH 8.0. Following 
sonication, the cell lysate was boiled for 20 min prior to centrifugation for 20 min at 
26,900 x g, 4 ºC. The cleared lysate was dialyzed against 20 mM Tris pH 8.0 and purified 
using a HighTrap Q HP column and eluted over a 120 min sodium chloride gradient (0 to 
1 M NaCl in 20 mM Tris, pH 8.0). Protein fractions were analyzed by MALDI-MS, 
combined, and concentration determined by BCA assay. 
5.5.13 Fluorescent Labeling of αSAzf39 and αSAzf94.  
 αSAzf39 or αSAzf94 were adjusted to 0.5 mg/mL from above using 20 mM Tris 
pH 8.0 and urea was added to a final concentration of 1.0 M. Protein was labeled with 3 
equivalents of either DBCO-FAM at 37 °C for 3 hours. Excess dye was removed by 
dialysis against 20 mM Tris pH 8.0 (2 x 5L) with the first dialysis at room temperature 
and the second at 4 °C. Protein was purified using a HiTrap Q HP column and fractions 
were analyzed by MALDI-MS. Combined fractions were concentrated and buffer 
exchanged into PBS pH 7.3 using Amicon Ultra 0.5 Centrifugal 3 kDa spin columns. 
Concentration was determined by BCA assay and concentrated protein was stored at -80 
°C until further use. 
5.5.14 Construction of αS2-140K2TAG39 and αS2-140K2TAG94 Plasmids.  
 QuickChange® mutagenesis was used to introduce a TAG Amber codon into the 
αS2-140K2 plasmid described previously at either position Tyr39 or Phe94 using the 
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previously described primers. Plasmid identities were confirmed using DNA sequencing 
with a T7 promoter primer.  
5.5.15 Dual Labeled αS.  
 Either H10-αS2-140K2TAG39 or H10-αS2-140K2TAG94 were co-transformed with the 
pDULE2Azf plasmid into E. coli BL21 (DE3) cells. Single colonies were selected and 
grown in 4 mL of LB using Amp (100 μg/mL) and Strep (100 μg/mL) for 4 hours at 37 
°C with shaking at 250 rpm. The 4 mL primary culture was inoculated into 1 L of M9 
minimal media, as described above, and grown at 37 °C with shaking at 250 rpm until 
OD600 1.0. Protein expression was induced with 0.75 mM Azf and 1.0 mM IPTG and 
cells were incubated at 25 °C with 250 rpm shaking for 16 hours. Cultures and purified 
protein containing Azf are kept shielded from light. Cell lysis and Ni-NTA purification 
were performed as described for αS2-140K2. Protein concentration was determined by 
BCA assay and adjusted to 0.5 mg/mL with Factor Xa cleavage buffer. The His10 
purification tag was removed by incubation of purified αS (0.5 mg/mL) with Factor Xa in 
the presence of 100 mM urea overnight at 37°C. Upon completion of Factor Xa cleavage 
the reaction was quenched by adjusting the urea concentration to 1.0 M. αS2-140K2Azf39 
and αS2-140K2Azf94 were labeled in situ with 3 equivalents of DBCO-TRM at 37 °C for 3 
hours. Excess dye was removed by dialysis against 20 mM Tris pH 8.0 (3 x 5 L ) with the 
first dialysis at room temperature and the subsequent dialysis at 4 °C. Protein was 
purified using a HiTrap Q HP column and fractions were analyzed by MALDI-MS. 
Protein concentration was determined by BCA assay. αS2-140K2TMR39 and αS2-
140K2TMR94 were then N-terminally modified as described above for αS2-140K2 with Aha. 
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Reactions were diluted 1:1 with 20 mM Tris pH 8.0 and purified using a HiTrap Q HP 
column. Protein fractions were analyzed by MALDI-MS, concentration determined by 
BCA assay, and adjusted to 0.5 mg/mL with 20 mM Tris pH 8.0. Protein was N-
terminally labeled with 3 equivalents of DBCO-FAM in the presence of 1.0 M urea at 37 
°C for 3 hours. Excess dye was removed by dialysis against MilliQ water (3 x 5 L ) with 
the first dialysis at room temperature and the subsequent dialysis at 4 °C. Doubly labeled 
protein was concentrated using Amicon Ultra 0.5 Centrifugal 3 kDa spin columns and 
purified by rpHPLC using a C4 semi-prep column. Fractions were analyzed by MALDI-
MS and combined. Protein was buffer exchanged into PBS pH 7.3 using Amicon Ultra 
0.5 Centrifugal 3 kDa spin columns. Concentrated protein was stored at -80 °C until 
further use.  
5.5.16 Incoporation and modification of Ppy into αS. 
 H10-αS2-140K2TAG39 was co-transformed with the pDULE2Azf plasmid into E. coli 
BL21 (DE3) cells. Single colonies were selected and grown in 4 mL of LB using Amp 
(100 μg/mL) and Strep (100 μg/mL) for 4 hours at 37 °C with shaking at 250 rpm. The 
primary culture was used to inoculated 100 mL of M9 minimal media, as described 
above, and grown at 37 °C with shaking at 250 rpm until OD600 1.0. Protein expression 
was induced with either the absence of Uaa, 0.75 mM Azf, or 0.75 mM Ppy and 1.0 mM 
IPTG and cells were incubated at 25 °C with 250 rpm shaking for 16 hours. Cultures and 
purified protein containing Azf are kept shielded from light. Cell lysis was performed as 
described for αS2-140K2. Cleared lysates were then incubated with either fluorescein-
alkyne (FAM-Alk, 333 μM) or carboxyrhodamine110-azide (Rh110-N3, 333 μM) and 
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5.5.17 Lysogenization of E. coli strain JB2580-1.  
 E. coli strain JW2580-1 (methionine auxotroph, E. coli Genetic Resources at Yale 
CGSC, The Coli Genetic Stock Center) was lysogenized with λDE3 phage using λDE3 
Lysogenization Kit plus pLysS & pLysE (EMD Millipore Corporation; Billerica, MA) 
according to manufacturer’s protocols to generate E. coliΔMet(λDE3). 
5.5.18 Labeling of αS with Aha or HPG.  
 The pT7-7 WT αS plasmid was transformed into E. coliΔMet(λDE3). Single 
colonies were grown in 4 mL of LB supplemented with Amp and methionine (Met, 30 
μM) at 37 °C with shaking at 250 rpm for 4 hours. The primary culture (1 mL) was 
inoculated into 1 L of new minimal media (NMM) consists of the following per 1 L of 
media: 6 g of Na2HPO4, 3 g of KH2PO4, 0.5 g of NaCl, and 1 g of NH4Cl: 1 mL of 2 M 
MgSO4, 1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15mg/mL ZnCl2 (in acidified 
water), and 25 mL of 40% glycerol (v/v) and supplemented with 17 amino acids (50 
mg/L; minus Met, Cys, and Trp), Met (30 μM), biotin (10 mg/L), thiamine (10 mg/L), 
and Amp. Cultures were grown at 37 °C with shaking at 250 rpm until OD600 1.0. Cells 
were pelleted at 2,700 x g for 15 min and resuspended in 1 L NMM without addition of 
methionine and grown at 37 °C for 1 h. Protein expression was induced by addition of 1.0 
mM IPTG and either 0.5 mM Aha or 1.0 mM L/D-HPG and grown at 30 °C with shaking 
at 250 rpm for 16 hours. Cells were pelleted at 4,200 x g for 15 min and the resulting 
pellet was resuspended in 20 mM Tris pH 8.0 and included protease inhibitor cocktail, 1 
mM PMSF, and 10 units/mL DNAse1–Grade II. Cells were lysed using sonication and 
the lysate was boiled for 20 min prior to centrifugation for 20 minutes at 26,900 x g. 
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Cleared lysate was then dialyzed against 5 L 20 mM Tris pH 8.0 at 4 °C. Protein was 
purified using a HiTrap Q HP column and fractions were analyzed using MALDI-MS. 
Combined fractions were concentrated and buffer exchanged against PBS pH 7.3 using 
Amicon Ultra 0.5 Centrifugal 3 kDa spin columns. Concentration was determined by 
BCA assay and protein was stored at -80 °C until further use.  
5.5.19 Triple labeling of αS.  
 Plasmids for either αS2-140K2TAG39 or αS2-140K2TAG94 were co-transformed with 
pEVOLBzp plasmid (Addgene, Cambridge MA) containing an M. jannaschii mutant 
tRNA synthetase and tRNACUA pair into E. coliΔMet(λDE3) cells. Single colonies were 
selected and grown in 4 mL of LB using Amp (100 μg/mL), chloramphenicol (Chlor, 34 
μg/mL), and Met (30 μM) for 4 hours at 37 °C with shaking at 250 rpm. The primary 
culture (1 mL) was inoculated into 1 L of NMM supplemented with 17 amino acids (50 
mg/L; minus Met, Cys, and Trp), Met (30 μM), biotin (10 mg/L), thiamine (10 mg/L), 
Amp, and Chlor. Cultures were grown at 37 °C with shaking at 250 rpm until OD600 0.25 
at which 0.02% arabinose was added and cell growth was continued to an OD600 1.0. 
Cells were pelleted at 2,700 x g for 15 min and resuspended in 1 L NMM containing 
0.02% (w/v) arabinose without addition of methionine and grown at 37 °C for 1 h. 
Protein expression was induced by addition of 1.0 mM IPTG, 0.5 mM p-
benzoylphenylalanine (Bzp), and 1.0 mM L/D-HPG and grown at 30 °C with shaking at 
250 rpm for 16 hours. Cultures and purified proteins containing Bzp are kept shielded 
from light. Cell lysis and Ni-NTA purification were performed as described above for 
αS2-140K2. Following Ni-NTA purification protein concentration was determined by BCA 
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assay. Protein yields are currently insufficient for subsequent Factor Xa cleavage and N-
terminal addition of Aha using AaT. Protein expression conditions are being optimized to 
obtain increased protein yields with two different Uaas. Factor Xa cleavage, AaT N-
terminal modification, and subsequent N-terminal labeling will be performed as 
described is section 5.5.15. 
5.5.20 Whole Protein and Trypsin Digest MALDI MS Analysis.   
 For whole protein MALDI MS analysis samples were diluted 1:10 in sinapinic 
acid matrix (a saturated solution of sinapinic acid in 1:1 MilliQ water/acetonitrile with 
1% TFA) and analyzed directly. For trypsin digests concentrated (≥200 μM) protein 
samples (5 μL) were diluted with freshly prepared 25 mM ammonium bicarbonate (10 
μL, pH 7.6), and digested with 2 μL of sequencing-grade modified trypsin (0.1 μg/μL).  
Trypsin digests were allowed to proceed at 37 °C for 24 h.  Digests were analyzed by 
diluting 1:10 in CHCA matrix (a saturated solution of α-cyano-4-hydroxycinnamic acid 
in 1:1 MilliQ water/acetonitrile with 1% TFA).   
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Table 5.1-Trypsin Digest and MALDI MS Analysis of Labeled αS Constructs. 
αS2-140K2AhaN (1) 
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 AhaKVFK 778.458 778.833 
13-21 EGVVAAAEK 873.468 873.468 
24-32 QGVAEAAGK 830.437 830.429 
35-43 EGVLYVGSK 951.515 951.53 
46-58 EGVVHGVATVAEK 1295.7 1295.69 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.02 
81-96 TVEGAGSIAAATGFVK 1478.78 1478.78 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4285.03* 
 
αS2-140K2FAMN (2a)
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 (FAM)AhaKVFMK 1412.66 1412.61 
13-21 EGVVAAAEK 873.468 873.469 
24-32 QGVAEAAGK 830.437 830.433 
35-43 EGVLYVGSK 951.515 951.303 
46-58 EGVVHGVATVAEK 1295.7 1295.7 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.04 
81-96 TVEGAGSIAAATGFVK 1478.78 1478.79 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4285.3* 
    
 αSFAM39 (3)   
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 770.34 
13-21 EGVVAAAEK 873.468 873.461 
24-32 QGVAEAAGK 830.437 830.414 
35-43 EGVLYVGSK 951.515 NF 
35-43 EGVL(Azf-FAM)VGSK 1610.72 1610.68 
46-58 EGVVHGVATVAEK 1295.7 1295.69 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.03 
81-96 TVEGAGSIAAATGFVK 1478.78 2153.89 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4285.23* 
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αSFAM94 (4) 
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 770.342 
13-21 EGVVAAAEK 873.468 873.455 
24-32 QGVAEAAGK 830.437 830.451 
35-43 EGVLYVGSK 951.515 951.502 
46-58 EGVVHGVATVAEK 1295.7 1295.68 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.01 
81-96 TVEGAGSIAAATGFVK 1478.78 NF 
81-96 TVEGAGSIAAATG(Azf-FAM)VK 2153.28 2154.89 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4286.01* 
 
αS2-140K2TMR39FAMN (9a) 
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 (FAM)AhaKVFMK 1412.66 1424.05 
13-21 EGVVAAAEK 873.468 873.109 
24-32 QGVAEAAGK 830.437 NF 
35-43 EGVLYVGSK 951.515 NF 
35-43 EGVL(Azf-TMR)VGSK 1665.78 1665.08 
46-58 EGVVHGVATVAEK 1295.7 1295.16 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.26 
81-96 TVEGAGSIAAATGFVK 1478.78 1479.06 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4285.18* 
 
αS2-140K2TMR94FAMN (9b) 
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 (FAM)AhaKVFMK 1412.66 1422.06 
13-21 EGVVAAAEK 873.468 873.102 
24-32 QGVAEAAGK 830.437 NF 
35-43 EGVLYVGSK 951.515 951.90 
46-58 EGVVHGVATVAEK 1295.7 1295.15 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.26 
81-96 TVEGAGSIAAATGFVK 1478.78 NF 
81-96 TVEGAGSIAAATG(Azf-TMR)VK 2209.10 2208.15 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* 4285.41* 
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 αSAhaGlb (10)   
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 (Aha)DVF(Aha)K 760.378 760.369 
13-21 EGVVAAAEK 873.468 873.457 
24-32 QGVAEAAGK 830.437 830.418 
35-43 EGVLYVGSK 951.515 951.506 
46-58 EGVVHGVATVAEK 1295.7 1295.68 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928.00 
81-96 TVEGAGSIAAATGFVK 1478.78 1478.76 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* NF 
103-140 NEEGAPQEGILED(Aha)PVDPDNEAYE(Aha)PSEEGYQDYEPEA 4275.75* 4275.37* 
 
αSHPGGlb (11) 
Res Sequence 
calcd 
(M+H)+ 
found 
(M+H)+ 
1-6 MDVFMK 770.358 NF 
1-6 (HPG)DVF(HPG)K 726.378 726.365 
13-21 EGVVAAAEK 873.468 873.457 
24-32 QGVAEAAGK 830.437 830.417 
35-43 EGVLYVGSK 951.515 951.51 
46-58 EGVVHGVATVAEK 1295.7 1295.68 
61-80 EQVTNVGGAVVTGVTAVAQK 1928.04 1928 
81-96 TVEGAGSIAAATGFVK 1478.78 1478.76 
103-140 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 4285.73* NF 
103-140 NEEGAPQEGILED(HPG)PVDPDNEAYE(HPG)PSEEGYQDYEPEA 4241.75* 4242.07* 
NF= not found. * Indicate the data was obtained in negative mode and masses of (M - H)-. 
Table 5.2-Whole Protein MALDI MS of Labeled αS Constructs. 
 cald  
(M + H)+ 
found 
(M + H)+ 
WT αS WT 14461.1 14461.8 
αS-AhaN 1 14469.3 14469.5 
αS2-140K2FAMN 2a 15103.4 15103.4 
αS2-140K2TMRN 2b 15158.5 15173.4* 
αS-FAM39 3 15120.3 15120.5 
αS-FAM94 4 15136.3 15136.8 
αS2-140K2TMR39FAMN 9a 15817.6 15816.3 
αS2-140K2TMR94FAMN 9b 15833.6 15833.7 
αSAhaGlb 10 14441.2 14441.6 
αSHPGGlb 11 14373.2 14375.4 
* Indicates observation of oxidation product. 
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5.5.21 αS Aggregation Studies.  
 αS protein were incubated at 50 μM in aggregation buffer (0.1 M dibasic sodium 
phosphate, pH adjusted to 7.3 with monobasic sodium phosphate with 164 mM sodium 
chloride and 0.05% sodium azide) at 37 °C with 1100 rpm orbital shaking.  Labeled 
protein samples were present at 5% total αS protein content in a background of WT αS. 
2.5 μL aliquots were taken prior to aggregation for post-aggregation sedimentation 
analysis by SDS-PAGE.  Fibrillization was monitored by removing 10 μL aliquots at t = 
0, 24, 48, 72, and 96 h which were diluted to 50 μL with aggregation buffer.  
Fluorescence spectra were obtained using a Tecan M1000 plate reader with the following 
settings: excitation slit width was 2.5 nm, emission slit width was 5 nm, integration time 
0.02 ms, data interval 2.0 nm, 50 flashes at 400 Hz, and gain set to 125.  FAM was 
excited at 486 nm and emission monitored between 500 and 700 nm.  Following 
fluorescence recording, 100 μL of a 20 mM CongoRed solution was added to the wells 
and incubated for 30 min at room temperature.  UV/Vis spectra were obtained between 
230 and 700 nm using a Tecan M1000 plate reader with the following settings: 
integration time 0.02 s, data interval 2.0 nm, flash frequency 400 Hz, 25 flashes, gain set 
to 100, and z-height 20 mm (See Figure 5.5 and Figure 5.10). Aggregations were 
performed in triplicate. Following aggregation, fibrils were centrifuged at 13,200 rpm for 
30 min.  The supernatant (2.5 μL) was carefully removed for sedimentation assay post-
aggregation (Figure 5.11).  
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CHAPTER 6 : CLICKABLE MAGIC BULLETS: HIGHLY SPECIFIC 
MODULATION OF PROTEIN ACTIVITY THROUGH A BIOORTHOGONAL 
REACTION 
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6.1 Introduction 
 Most pharmaceuticals are designed to function as molecular entities acting on 
specific biological targets, what Erlich referred to as “magic bullets” (MBs)501.  A key 
early event in the development of any pharmaceutical is target-validation: confirmation 
that modulation of a particular gene or protein will improve a disease phenotype502,503.  In 
modern drug discovery efforts, validating a target often begins with genetic deletion of 
the protein product.  This can be accomplished either with RNA interference (RNAi) or 
the breeding of knock out animal models504-507.  The next stage involves finding a small 
molecule that binds to the specific protein targeted by the genetic experiment.  However, 
identifying such a compound can often be difficult, particularly if the target protein is 
highly similar to other proteins.  The field of Chemical Genetics encompasses an array of 
strategies to link genotypes and phenotypes using small molecules in model 
systems508,509.  Here, we present a method designed to attain small molecule specificity 
rapidly and simply using a combination of genetic manipulation and molecular design. 
 Our strategy is simple: use unnatural amino acid mutagenesis to insert 
bioorthogonal functional groups (Z in Figure 6.1) into a “magic bullet” target (MBT) 
protein at positions such that reaction with a small molecule partner bearing a 
complementary reactive group (X in Figure 6.1) will alter protein function.  In this work, 
we will use azidophenylalanine (Azf) as the Z group and dibenzocyclooctynes (DBCOs) 
as X groups, taking advantage of the strain-promoted cycloaddition of Azf and DBCO to 
rapidly and specifically attach X to the MBT protein124,510,199. We note that our general 
strategy is equally applicable to other bioorthogonal “click” chemistry reactive pairs such 
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as cycloalkene/tetrazine50,136,433,511.  Protein modulation will be specific, provided that the 
reactions are truly chemoselective and only the MBT protein contains the targeting group 
Z.  The position of the Z targeting moiety can be easily scanned throughout the protein 
sequence to identify positions for which the MBT protein has wild type (WT) activity 
prior to reaction with an X molecule.  These MBT mutants will be taken forward to 
studies in which they are reacted with X molecules and the phenotype of the modified 
protein is evaluated. 
 
Figure 6.1-Clickable Magic Bullet Strategy.   
Top: Replacing WT protein B with MBT protein B enables selective inhibition by reaction of Z with X.  Inset: 
Allosteric inhibition through ZX reaction.  Bottom: Cycloaddition of azidophenylalanine (Azf, Z) with 
dibenzocyclooctyne derivative (DBCO-R, X). 
 
 The two previous Chemical Genetics experiments most relevant to our work are 
the “bump-and-hole” strategy employed by Schreiber, Shokat, and others; and the 
tethering approach of Erlanson and Wells512-514.  In the “bump-and-hole” method, a bump 
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must be added to the small molecule in a way that precisely matches a hole generated in 
the binding pocket of the target enzyme515,516.  To be implemented well, this strategy 
generally requires prior structural knowledge and a deep binding pocket like an active 
site.  Tethering uses reaction with an exogenous Cys thiol to covalently attach small 
molecules to the surface of proteins512,517.  These molecules can act as allosteric 
modulators, so they do not need to reside in active sites518.  Moreover, the Cys thiol can 
be scanned across the surface of a protein in a screening protocol, so that careful, 
structure-based design is not necessary.  However, since many proteins contain Cys, 
specificity derived from tethering is not easily retained in lysates or in vivo.  Our method 
shares many features with these two strategies, but the ability to scan Z through a protein 
sequence should make it much more broadly applicable than the bump-and-hole strategy 
and the chemoselectivity of “click” reactions should allow it to be applied in vivo, unlike 
the tethering strategy.  We note examples of similar strategies using tetracysteine motifs 
and bisarsenical compounds, but these methods have not been broadly applied519,520. 
 To incorporate Azf into the MBT proteins site-specifically, we can employ 
unnatural amino acid mutagenesis techniques developed by Schultz and coworkers.368  
These methods allow one to insert an unnatural amino acid by using a “21st” aminoacyl 
tRNA synthetase which charges a tRNACUA that recognizes the UAG stop codon. Two 
plasmids are transformed into E. coli: pDULE2Azf, encoding Azf synthetase and 
tRNACUA, and a plasmid encoding the MBT protein with the UAG mutation521.  After 
growth in the presence of Azf, the MBT protein is either purified for in vitro studies, or 
reacted with DBCO reagents in vivo. 
 173 
 
 
6.2 Results and Discussion 
 To show proof-of-concept, we have used the MB strategy to inhibit the E. coli 
aminoacyl transferase (AaT) protein522.  This protein functions in the N-end rule pathway 
by tagging proteins bearing N-terminal Lys or Arg with Leu, Phe, or Met using 
aminoacyl tRNA as a substrate252,426.  Addition of the hydrophobic amino acid constitutes 
a recognition motif for ClpS, which targets the tagged protein for degradation by ClpAP.  
We and others have previously shown that AaT can accept a variety of hydrophobic 
unnatural amino acids, which can be used to report on AaT activity254,256,261. 
 Using existing AaT crystal structures, we chose seven locations for incorporation 
of Azf258,418.  These ranged from positions right in the active site to positions near the 
termini that were not expected to alter activity.  We expressed and purified His-tagged 
versions of each AaT mutant and assessed the ability to react them with X molecules 
using DBCO rhodamine derivatives (DBCO545 or DBCOTMR).  MALDI MS and PAGE 
gel data showed that all of the positions chosen could be labeled, and for those taken 
forward to additional study labeling was near quantitative. Next, we tested the activity of 
these Azf mutants prior to reaction with DBCO545.  Five mutants – Z47, Z59, Z68, Z81, and 
Z135 – were found to have activities within 4-fold of WT.  The positions of these amino 
acids are shown in Figure 6.2.  All five mutants were taken forward to inhibition assays. 
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Figure 6.2-Analysis of AaT Inhibition by DBCO545 Reaction.   
Top: Transferase activity assay uses tRNA aminoacylated in situ with Phe analogs.  AaT activity is evaluated before 
and after reaction of Azf mutants with DBCO545.  Middle: Structures of seven AaT Azf mutants showing the position of 
adenosine donor (gray), peptide product (black), and Azf substitution sites.  Structures with aminoacyl adenosine (PDB 
ID: 2Z3K, orange) or peptide product (PDB ID: 2Z3N, cream) are overlayed418.  Bottom: Activity before (dark colors) 
and after (light colors) reaction with DBCO545 evaluated based on conversion of LysAlaAcm.  Z1 activity levels were 
inconsistent. Data in this figure is from AaT untreated with β-mercaptoethanol (β-ME) or iodoacetamide (IAM) prior to 
DBCO545 treatment. *Protein was not pre-treated with iodoacetamide prior to DBCO inhibition. 
 
 All five mutants were inhibited by DBCO545 treatment.  The levels of inhibition 
that we observed varied from 52% for Z135 (relative to unmodified protein) to 98% for 
Z47.  It is perhaps not surprising that Z47 was most inhibited, since the mutation occurred 
in the active site.  Inhibition presumably occurs by simply occluding access to the active 
site.  Inhibition of Z68, Z81, or Z135, on the other hand, probably occurs through an 
allosteric mechanism.  Using crystal structures of either the acyl nucleotide-bound or 
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peptide product-bound states of AaT, we made simple computational models of the 
DBCO adducts418. The DBCO545 and DBCOTMR adducts should not be able to reach the 
active site in either state of the enzyme.  In WT AaT, W135 occurs at a crystallographic 
dimer interface, and some weak dimerization has been observed in gel analysis of 
purified AaT.  However, our analysis of WT AaT indicates that activity varies linearly 
with concentration. Therefore, we believe that AaT is monomeric in the concentration 
range used, and that Z68, Z81, and Z135 inhibition occurs through allostery. 
 During the course of our investigations we observed that Cys thiolates of AaT 
react readily, if un-treated, with DBCO containing probes through a Michael-like 
addition, giving us off-target activity. One solution to this problem would be to treat the 
protein with excess β-mercaptoethanol (β-ME) and form Cys-β-ME adducts to prevent 
DBCO addition, and then cleave these disulfides in a second reduction step. However, 
Azf is an aryl-azide that is succeptible to reduction by thiol-reducing agents, including β-
ME493. As an alternative, we chose to block the Cys sites by alkylating with 
iodoacetamide (IAM). Treatment of AaT with IAM significantly reduced non-specific 
Cys-DBCO additions (Figure 6.3) while having no affect of AaT activity (data not 
shown). Data for Figure 6.2 was collected without IAM pre-treatment to block Cys 
reactivity. Experiments are currently being rerun with IAM pre-treated protein. 
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collected without IAM pre-treatment to block Cys reactivity. Experiments are currently 
being rerun with IAM pre-treated protein. 
 Initially, we used DBCO545 as an inhibitor because we could assess the levels of 
protein modification using the chromophore.  However, modelling studies implied that 
for Z47, the rhodamine moiety was unnecessary since the DBCO moiety occupied the 
binding pocket and rhodamine extended into solution.  Therefore, we also tested 
inhibition of the DBCO amine (DBCOA) alone and saw 99 % inhibition, similar to that 
obtained with DBCO545.  If necessary, the DBCO moiety can also be functionalized with 
other groups (R in Figure 6.1), so that a variety of inhibitors can be made. 
 Next, we wished to demonstrate that our method could be used to inhibit AaT 
selectively in complex mixtures.  Therefore, we carried out labelling reactions using a 
reporter protein derived from α-synuclein (αS) in lysates of TS351G E. coli cells, which 
lack endogenous AaT activity252.  Here, we determined the activity of AaT based on its 
ability to transfer Azf to the reporter protein from Azf-acylated tRNA generated in situ by 
a mutant Tyr tRNA synthetase.  Transfer of Azf was then imaged using a copper-
catalyzed “click” reaction to append a fluorescein derivative.  We note that no cross-
reactivity of the click reagents is expected because of the order of addition.  To make 
appropriate calculations of inhibition levels, we carried out control experiments in which 
we either withheld ATP (necessary for acylation of the tRNA with Azf) from the transfer 
reaction or added DMSO vehicle only.  Since no Azf should be transferred in the “- 
ATP” controls, this control allowed us to determine that the level of non-specific 
fluorescein binding was very low.  Therefore, we calculated inhibition by comparing the 
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levels of fluorescence in DBCO545 treated lanes to those treated with DMSO.  In all 
cases, we observed inhibition levels comparable to those observed with the small reporter 
peptide in purified reactions: > 99% for Z47, 66% for Z68, and 73% for Z135. This shows 
that we can effectively inhibit AaT in the presence of the other proteins in the TS351G 
lysates using 200 µM DBCO545. 
 Finally, in order to demonstrate that we can inhibit AaT mutants in living cells, 
we reacted DBCOTMR (which we expected to be more cell permeable than DBCO545 or 
DBCOA) with AaT in intact E. coli cells, and then analyzed activity in crude lysates as 
described above.  We transformed BL21 cells with pDULE2Azf and plasmids encoding 
the AaT mutants.  After growth in the presence of Azf and IPTG, the cells were pelleted, 
washed repeatedly to remove unincorporated Azf, and then treated with a DBCOTMR 
solution or DMSO vehicle.  The cells were washed, resuspended, and lysed.  The levels 
of Azf transfer were analyzed by reaction with fluorescein alkyne as described above.  
Once again, trials in which ATP was withheld from the transfer reaction served as 
controls for non-specific fluorescein binding. 
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Figure 6.4-AaT Inhibition in Cells.   
AaT WT and mutants were subjected to one of three conditions, + DBCO: AaT-expressing cells were treated with 
DBCOTMR in DMSO, then used to transfer Azf to the αS reporter protein in TS351G lysate; + Veh.: AaT-expressing 
cells were treated with DMSO only, then used to transfer Azf to the αS reporter protein in TS351G lysate; - ATP: AaT-
expressing cells were treated with DMSO only, then used in a mock transfer assay in which ATP was withheld to 
prevent Azf transfer.  In all cases, Azf transfer was detected with a fluorescein alkyne.  Transfer yields calculated from 
the fluorescence intensity of αS bands were used to determine percent inhibition.  All three images depict the same gel, 
stained with Coomassie dye (top), imaged using 532 nm excitation (middle), or using 473 nm excitation (bottom).  
MW: Molecular weight markers (kDa).   
 
 As one can see by comparing the “+ DBCO” and  “+ Veh.” lanes in Figure 6.4, 
significant inhibition of AaT activity was observed in all cases: 84 % for Z47, 83 % for 
Z68, and 77 % for Z135.  This shows that we can effectively inhibit AaT by dosing 
DBCOTMR in intact E. coli cells.  Moreover, we can track the selectivity of the DBCO 
reagent by analyzing the red fluorescence channel.  We see relatively low levels of non-
specific binding for WT AaT, indicating that the bands seen for the Azf mutants may be 
due to off-target incorporation of Azf or association of AaT with other proteins.  One 
feature of note is the green bands observed in the bottom gel, corresponding to 
fluorescein labeling of unreacted Azf in AaT mutants that had not been treated with 
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DBCOTMR.  This shows that Azf was present in the active site of these AaT samples.  
(Note: “+ DBCO” lanes appear to have higher background due to emission from TMR 
excited with 473 nm light.)  Thus, we see specific, DBCO-dependent inhibition of Azf 
mutants of AaT at levels that are comparable to or greater than those seen for the purified 
enzyme. 
6.3 Conclusions 
 We have shown, for the first time, that unnatural amino acids and bioorthogonal 
chemical reactions can be used as part of a general strategy to connect genotype to 
phenotype.  We believe that our method is a valuable alternative to RNAi for target 
validation.  While it is more complex to implement than RNAi, it offers validation in the 
context of a dosable small molecule.  Since many microRNAs (miRNAs) act 
catalytically, controlling dosage can be hard524.  A few additional advantages of our 
method are worth noting.  Firstly, RNAi prevents translation of the protein of interest, 
which may lead to phenotypes resulting from the absence of all of its protein interactions 
rather than inhibition of one specific activity.  These changes would be hard to replicate 
with a small molecule or protein therapeutic, which typically bind to one face of the 
target protein.  Second, although we have only found examples of inhibition in this initial 
study of AaT, the method can conceivably also be used to find activators.  RNAi can only 
reduce the activity of its protein target, not enhance it. 
 While we are excited about the many possible applications of this method, several 
considerations are worth noting: 
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1. Washout of unincorporated Azf is essential.  Azf can act as a buffer, consuming 
DBCO-R and preventing modification of Azf in the MBT protein. 
2. The ability to remove the endogenous copy of the protein, at least from cell lysates, is 
essential.  This can be done with a chromosomal deletion as in this work, or using 
miRNA in appropriate cell lines.  Judicious codon usage can prevent the miRNA from 
targeting the MBT as well as the WT protein525. 
3. The UAG stop codon, though rare (~ 5 %), is present in many natural proteins (~ 
300)526.  The presence of AzfRS could lead many of these codons to be read through, 
yielding proteins with aberrant activity and/or susceptibility to inhibition by reaction with 
DBCO reagents.  These proteins may be misfolded and degraded, but they may also 
contribute to the observed phenotype. 
4. If the tRNACUA does not efficiently deliver the unnatural amino acid at the UAG stop 
codon, high levels of truncated protein may be synthesized, resulting in a dominant 
negative phenotype that would mask the effect of any DBCO-based modulation of the 
MBT protein. 
 In spite of these potential complications, the ability to rapidly generate a protein 
that is selectively-targetable by simple small molecules could have tremendous value in 
the drug discovery process.  The fact that we can do this through a single amino acid 
substitution is a significant advantage relative to other similar technologies that require a 
greater perturbation to confer selectivity527,528.  The demonstration of our method in this 
manuscript is limited to a single-celled model organism, E. coli.  However, unnatural 
amino acid mutagenesis has been demonstrated in mammalian cells as well as 
multicellular organisms such as C. elegans and Drosophila melanogaster156,529-532.  
Moreover, alternate coding strategies have been employed leading to efficient 
incorporation at four base codons, which may address issues 3 and 4 above177,533-535.  
Church has also generated a strain of E. coli with the TAG stop codons replaced by TAA 
codons536.  We note that a great variety of R groups and X/Z reactive partners are 
possible, so there are many options, including meta-stable linkages (e.g. oxime) to make 
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reversible inhibitors433.  We will explore these applications and continue to improve our 
method.  We have begun to apply our method to other systems including membrane 
transporters and transcription factors.  The generality of our approach should make it 
equally applicable to the discovery of competitive inhibitors, allosteric modulators, or 
modulators of protein interactions with DNA or other proteins. 
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6.5 Materials and Methods 
6.5.1 General Information.   
 p-Azidophenylalanine (Azf) was purchased from Bachem (Torrance, CA).  5(6)’-
carboxytetramethylrhodamine was purchased from Novabiochem, EMD Millipore 
(Darmstadt, Germany).  Dibenzylcyclooctyne-amine (DBCOA) and dibenzylcyclooctyne-
545 (DBCO545) were purchased from ClickChemistryTools (Scottsdale, AZ).  Methyl-
sulfoxide-d6 was purchased from Cambridge Isotopes Laboratories, Inc. (Andover, MA).  
Ni-NTA resin was purchased from Qiagen (Valencia, CA).  E. coli BL21(DE3) cells 
were purchased from Stratagene (La Jolla, CA).  T4 DNA Ligase, XhoI and NdeI 
restriction enzymes were purchased from New England Biolabs (Ipswich, MA). Max 
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Efficiency  DH5alpha Competent Cells were purchased from Life Technologies (Grand 
Island, NY).  Sequencing-grade trypsin was purchased from Promega (Madison, WI).  
Restriction-grade Factor Xa protease was purchased from Novagen (San Diego, CA).  
QuikChange® site-directed mutagenesis kits were purchased from Stratagene.  DNA 
oligomers were purchased from Integrated DNA Technologies, Inc (Coralville, IA).  
Protease inhibitor cocktail was purchased from Sigma-Aldrich (St. Louis, MO).  All other 
reagents were purchased from Fisher Scientific (Pittsburgh, PA).  MilliQ filtered (18 
MΩ) water was used for all solutions (Millipore, Billerica, MA).  The pEG6 plasmid, 
containing His10-tagged E. coli AaT, was a gift from Alexander Varshavsky (California 
Institute of Technology).  E. coli TS351G cells were a gift from Emmanualle Graciet 
(Trinity College, Dublin).  The pDULE2Azf plasmid was a gift from Ryan Mehl (Oregon 
State University).  The pCDNA3.1-RSAzf plasmid was a gift from Thomas Sakmar (The 
Rockefeller University). 
 Matrix-assisted laser desorption/ionization (MALDI) mass spectra were collected 
with a Bruker Ultraflex III MALDI-TOF/TOF mass spectrometer (Billerica, MA).  
Electrospray ionization (ESI) mass spectra were collected with a Waters LCT Premier 
XE liquid chromatograph/mass spectrometer (Milford, MA).  UV/vis absorbance spectra 
were obtained with a Hewlett-Packard 8452A diode array spectrophotometer (Agilent 
Technologies, Santa Clara, CA).  NMR spectra, 1H and 13C, were collected with a Bruker 
DRX 500 MHz instrument.  DMSO-d6 was calibrated at δ 2.51 for 1H and δ 39.5 for 13C.  
Gel images were obtained with a Typhoon FLA 7000 (GE Lifesciences, Princeton, NJ).  
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HPLC assays were performed on an Agilent 1100 HPLC using a Waters Symmetry 
Shield C18 column. 
6.5.2 Synthesis of Dibenzocyclooctyne-Tetramethylrhodamine (DBCOTMR, S2).   
 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (72 μmol), H-
hydroxybenzotriazole (72 μmol), and triethylamine (144 μmol) was added to a solution of 
5(6)’-carboxytetramethylrhodamine (36.2 μmol) in 2 mL dimethylformamide. The 
reaction was stirred on ice for 10 minutes and then dibenzocyclooctyne-amine S1 (36.2 
μmol) was added.  The reaction was stirred and allowed to warm to room temperature 
overnight.  Solvent was removed under vacuum with a liquid nitrogen trap.  The reaction 
was purified using 100 mL silica gel in 1:9 methanol/dichloromethane with 1 % acetic 
acid.  Product fractions were concentrated by rotary evaporation and dried on high-vac 
overnight, affording DBCOTMR (S2) as a dark red solid in 72.5 % yield.  1H and 13C NMR 
spectra for 6’ isomer (isolated by HPLC purification) shown in Figure 6.6.  Protons 
identified in the 1H NMR are annotated below (tetramethylrhodamine assignments based 
on Kvach et al.).537  HRMS (ESI) m/z calcd for C43H37N4O5 [M + H]+ 689.2764, found: 
689.2761. 
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Figure 6.5-Structure of DBCO Used for Magic Bullet Chemistry. 
(Top) Dibenzylcyclooctyne-amine (S1), dibenzylcyclooctyne-tetramethylrhodamine (S2), and dibenzylcyclooctyne-545 
(S3). (Bottom) Structural assignment of DBCO-TMR for 1H-NMR assignment (see Figure 6.6). 
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Figure 6.6-DBCOTMR 1H and 13C NMR in DMSO-d6. 
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6.5.3 Aminoacyl Transferase Expression and Purification.   
 His10-tagged E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-
Gold (DE3) cells using a procedure modified from Graciet et al252.  Briefly, E. coli were 
grown in a primary culture of 4 mL LB at 37 °C to OD600 of 0.5 which was diluted into a 
secondary culture of 500 mL LB and grown to OD600 of 0.6 - 0.8.  AaT expression was 
induced using 0.1 mM isopropyl β-D-thiogalactoside (IPTG) and cells were grown at 25 
°C for 16 hours.  Cells were pelleted at 6, 000 rpm using a GS3 rotor and Sorvall RC-5 
centrifuge.  Cell pellets were resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 
mM imidazole, and 300 mM KCl, pH 8.0) that included protease inhibitor cocktail, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 10 units/mL DNAse1–Grade II.  Following 
resuspension, the cells were lysed using sonication.  Soluble proteins were collected via 
centrifugation at 13, 200 rpm for 15 minutes.  Collected soluble protein was gently 
shaken for 1 hour at on ice with Ni-NTA Superflow (Qiagen).  Protein was purified by 
rinsing with Ni-NTA binding buffer and then washing with Ni-NTA wash buffer (50 mM 
Tris, 50 mM imidazole, and 300 mM KCl, pH 8.0).  The proteins were eluted with 
elution buffer (50 mM Tris, 250 mM imidazole, and 300 mM KCl, pH 8.0).  Fractions 
containing E. coli AaT were dialyzed overnight in transferase buffer (50 mM HEPES, 30 
% glycerol, 120 mM (NH4)2SO4, 5 μM β-mercaptoethanol, pH 8.0).  The dialyzed 
enzymes were stored at – 80 °C. 
6.5.4 Unnatural Amino Acid Incorporation into Aminoacyl Transferase.   
 Site-directed mutagenesis was used to insert TAG stop codons into the pEG6 AaT 
plasmid in order to introduce an unnatural amino acid at position XX (pEG6-TAGXX).  
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The sequences and mutagenic primers are shown in Figure 6.7.  BL21-Gold (DE3) cells 
were transformed with the pEG6-TAGXX plasmid and a pDULE2Azf plasmid containing 
an M. jannaschii mutant tRNA synthetase and tRNACUA pair.  Cells were selected using 
ampicillin (100 mg/L) and streptomycin (100 mg/L).  Azf was incorporated into AaT as 
described above with the addition of 1.0 mM Azf (solubilized by dropwise addition of 1 
M NaOH) to the growth media.  When working with Azf, cultures and purified proteins 
were kept shielded from light.  
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E. coli AaT Gene 
5'ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCAT
ATGCGCCTGGTTCAGCTTTCTCGCCATTCAATAGCCTTCCCTTCCCCGGAAGGCGCATTACGTGA
GCCTAACGGCCTGCTGGCACTTGGGGGCGATCTTAGCCCTGCGCGCCTGTTAATGGCTTACCAG
CGTGGTATTTTTCCGTGGTTTTCTCCAGGCGACCCCATCCTCTGGTGGTCGCCCGATCCCCGCGC
GGTGCTATGGCCAGAATCACTGCATATCAGCCGTAGTATGAAGCGATTTCATAAACGCTCGCCC
TATCGTGTCACGATGAATTACGCTTTTGGTCAGGTCATTGAAGGCTGTGCCAGCGATCGCGAAG
AAGGAACCTGGATCACGCGTGGCGTGGTCGAAGCCTACCATCGCCTTCACGAACTCGGCCATGC
CCACTCCATTGAAGTCTGGCGTGAAGATGAGCTTGTCGGCGGTATGTACGGCGTGGCCCAGGGA
ACGCTATTTTGTGGCGAGTCCATGTTCAGCCGGATGGAAAATGCGTCTAAAACGGCGCTTCTGG
TATTCTGTGAGGAATTTATCGGTCATGGCGGTAAGCTTATCGACTGCCAGGTCCTTAACGATCAC
ACAGCATCGCTTGGTGCCTGCGAAATTCCCCGCCGGGATTACCTTAATTATCTCAATCAAATGCG
CCTCGGACGATTGCCGAATAATTTCTGGGTACCACGATGCTTGTTTTCACCACAAGAATGA–3' 
 
E. coli AaT Amino Acid Sequence 
MGHHHHHHHHHHSSGHIEGRHMRLVQLSRHSIAFPSPEGALREPNGLLALGGDLSPARLLMAYQRG
IFPWFSPGDPILWWSPDPRAVLWPESLHISRSMKRFHKRSPYRVTMNYAFGQVIEGCASDREEGTWI
TRGVVEAYHRLHELGHAHSIEVWREDELVGGMYGVAQGTLFCGESMFSRMENASKTALLVFCEEFI
GHGGKLIDCQVLNDHTASLGACEIPRRDYLNYLNQMRLGRLPNNFWVPRCLFSPQE 
 
DNA Oligomers used for Quikchange® Mutagenesis 
A. AaT-M1-TAG 
Forward: 5'GGCCATATCGAAGGTCGTCATTAGCGCCTGGTTC-3' 
Reverse: 5'GAACCAGGCGCTAATGACGACCTTCGATATGGCC-3' 
B. AaT-Y42-TAG 
Forward: 5’CGCCTGTTAATGGCTTAGCAGCGTGGTATTTTTCC-3’ 
Reverse: 5’GGAAAAATACCACGCTGCTAAGCCATTAACAGGCG-3’ 
C. AaT-F47-TAG 
Forward: 5’CTTACCAGCGTGGTATTTAGCCGTGGTTTTCTCCAGGC-3’ 
Reverse: 5’GCCTGGAGAAAACCACGGCTAAATACCACGCTGGTAAG-3’ 
D. AaT-W59-TAG 
Forward: 5’CCCATCCTCTGGTAGTCGCCCGATCCC-3’ 
Reverse: 5’GGGATCGGGCGACTACCAGAGGATGGG-3’ 
E. AaT-W68-TAG 
Forward: 5’CCGCGCGGTGCTATAGCCAGAATCACTGC-3’ 
Reverse: 5’GCAGTGATTCTGGCTATAGCACCGCGCGG-3’ 
F. AaT-F81-TAG 
Forward: 5’GCCGTAGTATGAAGCGATAGCATAAACGCTCGCCCTATC-3’ 
Reverse: 5’GATAGGGCGAGCGTTTATGCTATCGCTTCATACTACGGC-3’ 
G. AaT-W135-TAG 
Forward: 5’CCACTCCATTGAAGTCTAGCGTGAAGATGAGCTTG-3’ 
Reverse: 5’CAAGCTCATCTTCACGCTAGACTTCAATGGAGTGG-3’ 
Figure 6.7-Construction of AaT Azf Mutants. 
 
6.5.5 Trypsin Digest and MALDI MS Analysis of Unnatural Amino Acid Incorporation 
into Aminoacyl Transferase.   
 Proteins were expressed from 100 mL LB cultures as described above.  Elution 
fractions were checked by SDS-PAGE and combined. Protein was precipitated using 1:4 
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trichloroacetic acid/protein sample and incubated at - 20 °C for 15 minutes.  Precipitate 
was centrifuged for 15 minutes at 13,200 rpm to pellet protein.  The protein pellet was 
then washed three times with cold acetone to remove co-precipitated imidazole.  Trace 
acetone was removed by incubating protein pellets in a 95 °C water bath for 5 minutes.  
Protein pellets were then resuspended in 6 M guanidinium hydrochloride with 50 mM 
Tris pH 8.0.  Protein was further denatured by boiling at 95 °C for 10 minutes.  
Digestions were performed by diluting protein samples to 0.75 M guanidinium 
hydrochloride with 50 mM Tris pH 7.6 and 1 mM calcium chloride.  Sequencing grade 
modified trypsin (0.6 μg, Promega) was used to digest samples for 24 hours at 37 °C.  
Trypsin digest aliquots (1 μL) were combined with α-cyano-4-hydroxycinnamic acid (1 
μL of a saturated solution in 1:1 H2O/CH3CN with 1 % TFA) and analyzed by MALDI 
MS.  Representative MALDI MS data for AaT-Z47 are shown in Figure 6.8, data for AaT-
WT, AaT-Z47, AaT-Z68, and AaT-Z135 are collected in Table 6.1.  We were not able to 
observe the DBCOTMR adduct for Z135, but no residual Azf-containing peak was 
observed. 
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Figure 6.8-MALDI MS Analysis of AaT-Z47 DBCOTMR Labeling.   
Mass region corresponding to the trypsinized 45-64 region of WT or AaT-Z47 with or without DBCOTMR modification.  
The expected mass peak is denoted by an asterisk in each spectrum. 
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Table 6.1-Trypsin Digest AaT Mutant Sequence Coverage.   
Underline indicates observed fragment. AaT Sequence: 
 
MGHHHHHHHHHHSSGHIEGR/HMRLVQLSR/HSIAFPSPEGALREPNGLLALGGDLSPAR/LLMAYQR/GIFPW
FSPGDPILWWSPDPR/AVLWPESLHISR/SMKRFHKRSPYRVTMNYAFGQVIEGCASDREEGTWITRGVVEAYH
R/LHELGHAHSIEVWR/EDELVGGMYGVAQGTLFCGESMFSRMENASKTALLVFCEEFIGHGGK/LIDCQVLN
DHTASLGACEIPR/RDYLNYLNQMR/LGRLPNNFWVPR/CLFSPQE 
 
AaT-WT 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
45-64 GIFPWFSPGDPILWWSPDPR 2370.17 2371.00 
45-64 GIZ-N2PWFSPGDPILWWSPDPR 2385.17 -- 
65-76 AVLWPESLHISR 1407.77 1407.68 
65-76 AVLZ-N2PESLHISR 1383.77 -- 
123-136 LHELGHAHSIEVWR 1683.87 1683.76 
123-136 LHELGHAHSIEVZ-N2R 1659.87 -- 
AaT-F47Z 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
45-64 GIFPWFSPGDPILWWSPDPR 2370.17 -- 
45-64 GIZ-N2PWFSPGDPILWWSPDPR 2385.17 2386.09 
65-76 AVLWPESLHISR 1407.77 1407.64 
65-76 AVLZ-N2PESLHISR 1383.77 -- 
123-136 LHELGHAHSIEVWR 1683.87 1683.71 
123-136 LHELGHAHSIEVZ-N2R 1659.87 -- 
AaT-W68Z 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
45-64 GIFPWFSPGDPILWWSPDPR 2370.17 2370.97 
45-64 GIZ-N2PWFSPGDPILWWSPDPR 2385.17 -- 
65-76 AVLWPESLHISR 1407.77 -- 
65-76 AVLZ-N2PESLHISR 1383.77 1383.66 
123-136 LHELGHAHSIEVWR 1683.87 1683.74 
123-136 LHELGHAHSIEVZ-N2R 1659.87 -- 
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Table 6.1-Continued. 
AaT-W135Z 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
45-64 GIFPWFSPGDPILWWSPDPR 2370.17 2370.97 
45-64 GIZ-N2PWFSPGDPILWWSPDPR 2385.17 -- 
65-76 AVLWPESLHISR 1407.77 1407.65 
65-76 AVLZ-N2PESLHISR 1383.77 -- 
123-136 LHELGHAHSIEVWR 1683.87 -- 
123-136 LHELGHAHSIEVZ-N2R 1659.87 1659.71 
 
AaT-F47Z + DBCOTMR 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
45-64 GIFPWFSPGDPILWWSPDPR 2370.17 -- 
45-64 GIZ-N2PWFSPGDPILWWSPDPR 2385.17 -- 
45-64 GIZ(DBCOTMR)PWFSPGDPILWWSPDPR 3100.45 3101.59 
AaT-W68Z + DBCOTMR 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
65-76 AVLWPESLHISR 1407.77 -- 
65-76 AVLZ-N2PESLHISR 1383.77 -- 
65-76 AVLZ(DBCOTMR)PESLHISR 2073.05 2073.98 
AaT-W135Z + DBCOTMR 
Position Peptide Calcd (M+H)+ Obsvd (M+H)+
123-136 LHELGHAHSIEVWR 1683.87 -- 
123-136 LHELGHAHSIEVZ-N2R 1659.87 -- 
123-136 LHELGHAHSIEVZ(DBCOTMR)R 2349.15 -- 
 
 
6.5.6 AaT DBCOA, DBCO545, or DBCOTMR Labeling.   
 Ni-NTA-purified AaT and AaT-ZXX mutants (0.20 mg/mL) were incubated with 
200 μM (final concentration) DBCOA, DBCO545, or DBCOTMR from a DMSO stock for 2 
hours at 37 °C.  As a vehicle control, AaT and AaT-ZXX mutants were also treated with 
an equal volume dimethyl sulfoxide.  Excess DBCO reagent was removed by dialysis 
 194 
 
 
twice in transferase buffer (50 mM Tris, 30 % glycerol, 120 mM (NH4)2SO4, 1 μM β-
mercaptoethanol, pH 8.0).  Labeled proteins were then analyzed by PAGE gel or trypsin 
digest and MALDI MS as described above and stored at - 80 °C. 
 
Figure 6.9-PAGE Analysis of AaT DBCO545 Labeling. 
AaT WT and mutants were treated with DBCO545 in DMSO.  Both images depict the same gel, stained with Coomassie 
dye (top) or imaged using 532 nm excitation (bottom).  MW: Molecular weight markers (kDa). *Protein was not pre-
treated with iodoacetamide prior to DBCO inhibition. 
 
6.5.7 Activity of AaT using LysAlaAcm Ligation Assay.   
 The activity of DMSO- and DBCOTMR-treated purified AaT and AaT-ZXX 
mutants were assayed by transfer of Phe to the N-terminus of a LysAlaAcm peptide 
(Bachem; Torrance, CA) as previously described.261  Each ligation reaction, 125 μL total 
volume, contained the following reagents:  Phe (1 mM), yeast Phe tRNA (12.5 μg), 
Adenosine-5'-triphosphate (1.25 mM, ATP), yeast Phe tRNA aminoacyl synthetase 
(yPheRS, 2.5 µg), AaT (1 μM), and LysAlaAcm (100 μM) in the AaT Ligation Buffer 
(50 mm HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2, 50 mM Tris, pH 8.0; 30 % 
glycerol; 120 mM ammonium sulfate).  The reaction mixtures were incubated at 37 °C 
for 4 hours and quenched with 1 % acetic acid.  Proteins were removed from the peptide 
using four volumes of acetone and cooled at - 20 °C for 1 hour.  The reactions were 
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centrifuged at 13, 200 rpm at 4 °C for 20 minutes to separate the peptide from 
precipitated protein.  The supernatant was transferred to a 1.5 mL centrifuge tube and the 
acetone was allowed to evaporate overnight at room temperature.  Residual acetone was 
removed by drying in a Speedvac (Savant, Thermo Scientific, Fisher Inc.) for 30 minutes.  
The resulting reaction volume was  dissolved in a total volume of 1 mL of 1:9 0.1 % TFA 
in acetonitrile:water and analyzed by HPLC (gradient below) to determine ligation 
efficiency by integration of separated PheLysAlaAcm and LysAlaAcm peak intensities 
monitored at 325 nm. Data was obtained prior to elucidation of DBCO-Cys interactions 
and is being rerun with IAM pre-treated protein. 
6.5.8 HPLC Analysis of PheLysAlaAcm Ligations.   
 All HPLC analyses of PheLysAlaAcm ligations were monitored on an Agilent 
1100 HPLC using a Waters C18 column (Milford, MA).  The solvents used for peptide 
purification were the following: 0.1 % trifluoroacetic acid in water (Solvent A) and 0.1 % 
trifluoroacetic acid in acetonitrile (Solvent B).  The HPLC method had the following 
solvent gradient (Gradient 1): 0 min 1 % B, 5 min 1 % B, 10 min 30 % B, 15 min 40 % 
B, 20 min 100 % B, 25 min 100 % B, 27 min 1 % B, 30 min 1% B.  Peptides were 
monitored at two absorption wavelengths during HPLC analysis, 215 nm for peptide 
absorption, and 325 nm for Acm absorption. 
6.5.9 DBCOA Inhibition.   
 Ni-NTA purified AaT-WT and AaT-Z47 (0.20 mg/mL) were incubated with 100 
μM DBCOA for 2 hours at 37 °C.  As a vehicle control, AaT and AaT-Z47 mutants were 
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also treated with DMSO.  Clicked proteins were then stored at - 80 °C. LysAlaAcm 
ligation assays were performed as descried above.  All HPLC analyses of PheLysAlaAcm 
ligations were monitored on an Agilent 1100 HPLC using a Waters C18 column. Data 
was obtained prior to elucidation of DBCO-Cys interactions and is being rerun with IAM 
pre-treated protein. 
6.5.10 Concentration Dependence of AaT in LysAlaAcm Ligations.   
 Ligations were carried out in triplicate as described above for 30 minutes at 37 
°C.  AaT concentrations were used at 2.26, 1.13, 0.565, and 0.283 μM.  All HPLC 
analyses of PheLysAlaAcm ligation assays were monitored on an Agilent 1100 HPLC 
using a Waters C18 column. 
 
 
Figure 6.10-Representative HPLC Analysis of LysAlaAcm Transfer Reactions.   
Top: Conversion of LysAlaAcm starting material to PheLysAlaAcm product in the presence of AaT-Z47 treated with 
DMSO vehicle; Bottom: Conversion of LysAlaAcm starting material to PheLysAlaAcm product in the presence of 
AaT-Z47 treated with DBCO545. *Protein was not pre-treated with iodoacetamide prior to DBCO inhibition. 
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Table 6.2-HPLC Analysis of LysAlaAcm Reactions.   
Performed in the presence and absence (DMSO vehicle only) of DBCO545 labeling except for entries denoted with an 
asterisk, where DBCOA was used. *Protein was not pre-treated with iodoacetamide prior to DBCO inhibition. 
 
AaT Mutant 
+ Vehicle 
Conversion % 
+ DBCO 
Conversion % 
WT 100.0 ± 1.7 108.9 ± 0.5 
 WT* – 104.6 ± 0.5 
1/2X WT 71.2 ± 0.5  
1/4X WT 49.1 ± 0.6  
1/8X WT 30.6 ± 0.3  
Z1 X X 
Z42 4.8 ± 1.0 3.1 ± 0.2 
Z47 67.4 ± 5.4 0.9 ± 0.2 
 Z47* – 0.4 ± 0.2 
Z59 31.3 ± 2.6 11.8 ± 0.4 
Z68 26.7 ± 2.4 4.7 ± 0.6 
Z81 40.8 ± 3.1 25.0 ± 2.3 
Z135 52.8 ± 2.1 25.6 ± 2.3 
 
6.5.11 Dose Dependent Inhibition of AaT-Z47.   
 Ni-NTA purified AaT-Z47 (0.20 mg/mL) was incubated with DBCO545 at the 
following concentrations: DMSO, 0.5, 1.0, 5.0, 10.0, 17.5, 25.0, 50.0, 100.0, and 200.0 
μM.  SPAAC reactions were incubated for 1 hour at 37 °C and then immediately used in 
LysAlaAcm ligations. Ligations were carried out in triplicate as described above for 2 
hours at 37 °C.  All HPLC analyses of PheLysAlaAcm ligations were monitored on an 
Agilent HPLC using a Waters C18 column. Data was obtained prior to elucidation of 
DBCO-Cys interactions and is being rerun with IAM pre-treated protein. 
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Figure 6.11-Dose Dependent Inhibition of AaT-Z47.   
Activity of AaT-Z47 after modification with various concentrations of DBCO545 for 1 hour. *Protein was not pre-treated 
with iodoacetamide prior to DBCO inhibition. 
 
6.5.12 Investigation of AaT Cys-Thiolate DBCO Adducts. 
 Wild type AaT and Z47 were purified as described above but during affinity 
purification and dialysis either 5 μM β-ME or 5 mM β-ME was used for each protein. 
Purified proteins were then incubated with 100 μM DBCOTMR to assess the degree of 
Cys-DBCO non-specific labeling. SDS-PAGE analysis and fluorescence imaging was 
used to determine the degree of labeling (Figure 6.12). Wild type AaT and Z47 from 
batches purified using 5 μM β-ME were treated with or without 2 mM IAM for 30 min at 
room temperature. Following IAM pre-treatment, samples were incubated with 100 μM 
DBCOTMR for 1 h at 37°C. SDS-PAGE analysis and fluorescence imaging was used to 
determine the degree of labeling (see Figure 6.3). 
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moiety to approach the substrate pocket as closely as possible.  All of our DBCOTMR 
models are shown in Figure 6.13 (Z47-DBCOA is not shown). 
 
Figure 6.13-Models of DBCOTMR-Labeled AaT Mutants.   
Geometry-optimized models of Azf-DBCOTMR adducts at positions 47, 68, and 135 of AaT are shown overlain on the 
protein (PDB 2Z3K and 2Z3N). 
 
6.5.13 Construction of Recombinant αS2-140K2 Reporter Plasmid.   
 A plasmid containing a wild type αS gene cloned between NdeI and HindIII in 
pT7-7 vector was provided by Dr. Elizabeth Rhoades (Department of Molecular 
Biophysics and Biochemistry, Yale University).  An XhoI site (CTCGAG) was 
introduced 3' to the WT αS gene in the pT7-7 vector using QuikChange® mutagenesis.  
The αS gene was digested by NdeI and XhoI and cloned into the pET-16b prokaryotic 
expression vector (EMD Biosciences; San Diego, CA), which contained an N-terminal 
His-tag followed by a Factor Xa recognition site (IEGR).365  QuickChange® mutagenesis 
was then used to delete residues H-1 and M1 followed by a D2K mutation to yield the H10-
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αS2-140K2 plasmid.  The plasmid identity was confirmed using DNA sequencing with a T7 
promoter primer. 
Human αS2-140K2 Gene 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTAAAG
TATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGAGAAAACCAAAC
AGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTCCAAAACCA
AGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAAT
GTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGG
GAGCATTGCAGCAGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGC
CCCACAGGAAGGAATTCTGGAAGATATGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCT
TCTGAGGAAGGGTATCAAGACTATGAACCTGAAGCCTAA 
 
DNA Oligomers Used for QuickChange® Mutagenesis 
a. Deletion of H-1 and M1 
Forward: 5’-GGC CAT ATC GAA GGT CGT GAT GTA TTC ATG AAA GGA-3’ 
Reverse: 5’-TCC TTT CAT GAA TAC ATC ACG ACC TTC GAT ATG GCC-3’ 
b. Mutation of D2K 
Forward: 5’-GCG GCC ATA TCG AAG GTC GTA AAG TAT TCA TGA AAG GAC TTT C-3’ 
Reverse: 5’-GAA AGT CCT TTC ATG AAT ACT TTA CGA CCT TCG ATA TGG CCG C-3’ 
 
Human αS2-140K2 Amino Acid Sequence 
MGHHHHHHHHHHSSGHIEGRKVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKT
KEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAP
QEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 
Figure 6.14-Construction of αS Reporter Plasmid. 
 
6.5.14 Expression and Purification of αS2-140K2.   
 The plasmid containing the αS gene was used to transform E. coli BL21(DE3) 
cells.  Transformed cells were selected on the basis of ampicillin resistance.  Single 
colonies were used to inoculate 5 mL of LB media supplemented with ampicillin (100 
μg/mL).  The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm for 5 
hours.  500 mL of LB media supplemented with ampicillin was inoculated with 1 mL of 
the primary culture.  The 500 mL culture was incubated at 37 °C with shaking at 250 rpm 
until an OD600 of 0.6 was reached.  Expression was induced with the addition of 1.0 mM 
IPTG and cells were incubated at 25 °C for 16 hours.  The cells were harvested by 
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centrifugation at 5000 x g for 15 minutes and the resulting pellet was resuspended in a 
Factor Xa cleavage buffer (100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2) that 
included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) 
and sonicated.  Following sonication, the cell lysate was boiled for 30 minutes prior to 
centrifugation for 20 minutes at 30,000 x g, 4 °C.  Collected soluble protein was gently 
shaken for 1 hour at ambient temperature with Ni-NTA resin.  Protein was purified by 
rinsing with Factor Xa cleavage buffer followed by washing with Factor Xa wash buffer 
(100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2, and 50 mM imidazole).  Protein was 
eluted with Factor Xa elution buffer 100 mM NaCl, 50 mM Tris pH 8.0, 5 mM 
CaCl2¸and 250 mM imidazole).  SDS-PAGE analysis was performed to analyze the 
purity of αS elution fractions.  Collected protein fractions were dialyzed against Factor 
Xa cleavage buffer at 4 °C.  The His-10 purification tag was removed by incubation of 
purified H10-αS2-140K2 (0.5 mg/mL) with FactorXa, Restriction Grade, Bovine Plasma (20 
μL, Novagen; EMD Millipore Corporation, Billerica, MA) overnight at 37°C.  Uncleaved 
H10-αS2-140K2 was removed by treatment with Ni-NTA resin. Factor Xa was removed by 
boiling for 30 minutes and centrifugation for 20 minutes at 30,000 x g, 4 °C.  αS2-140K2 
was dialyzed into modified AaT buffer (50 mm HEPES pH 8.0, 150 mM KCl, 10 mM 
MgCl2) at 4 °C.  Protein concentration was determined by BCA assay (Thermo Scientific 
Pierce) and purity was confirmed by SDS-PAGE and MALDI mass spectrometry.  
Protein was stored at - 80 °C until further use. 
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6.5.15 Cloning of E. coli AzfRS from into pET21a.  
 An NdeI cut site was introduced into pCDNA3.1-RSAzf 5’ of the E. coli AzfRS 
gene and an XhoI cut site was introduced 3’ to the E. coli AzfRS gene using site-directed 
mutagenesis.  The sequences and mutagenic primers are shown in Figure 6.15.  The E. 
coli AzfRS gene was excised from pCDNA3.1-RSAzf using NdeI and XhoI restriction 
enzymes.  The pET21a plasmid, containing a C-terminal 6-His tag, was digested with 
NdeI and XhoI.  The pET21a vector and E. coli AzfRS insert were purified on a 0.8 % 
agarose gel and isolated using a Qiagen Gel Extraction Kit.  T4 DNA ligase reactions 
were performed using a 1:3 vector:insert ratio at 16 °C for 1 hour.  Library efficiency 
DH5α cells were then transformed with 5 μL of the ligation.  Colonies were “mini-
prepped” and preliminarily screened using NdeI and XhoI restriction enzyme digests.  
The DNA sequence identity of the product, pET21-RSAzf, was confirmed using T7 
primers. 
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A. NdeI Site Insertion 
Forward: 5’CTTAAGCTTGGTACCCCCATATGGCAAGCAGTAAC-3’ 
Reverse: 5’GTTACTGCTTGCCATATGGGGGTACCAAGCTTAAG-3’ 
B. XhoI Site Insertion 
Forward: 5’GCTGGAAAGACTACAAACTCGAGGACGACAAGTAA-3’ 
Reverse: 5’TTACTTGTCGTCCTCGAGTTTGTAGTCTTTCCAGC-3’ 
E. coli AzfRS Gene 
5’ATGGCAAGCAGTAACTTGATTAAACAATTGCAAGAGCGGGGGCTGGTAGCCCAGGTGACGGA
CGAGGAAGCGTTAGCAGAGCGACTGGCGCAAGGCCCGATCGCGCTCCTGTGCGGCTTCGATCCT
ACCGCTGACAGCTTGCATTTGGGGCATCTTGTTCCATTGTTATGCCTGAAACGCTTCCAGCAGGC
GGGCCACAAGCCGGTTGCGCTGGTAGGCGGCGCGACGGGTCTGATTGGCGACCCGAGCTTCAA
AGCTGCCGAGCGTAAGCTGAACACCGAAgAAACTGTTCAGGAGTGGGTGGACAAAATCCGTAA
GCAGGTTGCCCCGTTCCTCGATTTCGACTGTGGAGAAAACTCTGCTATCGCGGCGAACAACTAT
GACTGGTTCGGCAATATGAATGTGCTGACCTTCCTGCGCGATATTGGCAAACACTTCTCCGTTAA
CCAGATGATCAACAAAGAAGCGGTTAAGCAGCGTCTCAACCGTGAAGATCAGGGGATTTCGTTC
ACTGAGTTTTCCTACAACCTGTTGCAGGGTTATAGCATGGCCTGTGCGAACAAACAGTACGGTG
TGGTGCTGCAAATTGGTGGTTCTGACCAGTGGGGTAACATCACTTCTGGTATCGACCTGACCCGT
CGTCTGCATCAGAATCAGGTGTTTGGCCTGACCGTTCCGCTGATCACTAAAGCAGATGGCACCA
AATTTGGTAAAACTGAAGGCGGCGCAGTCTGGTTGGATCCGAAGAAAACCAGCCCGTACAAAT
TCTACCAGTTCTGGATCAACACTGCGGATGCCGACGTTTACCGCTTCCTGAAGTTCTTCACCTTT
ATGAGCATTGAAGAGATCAACGCCCTGGAAGAAGAAGATAAAAACAGCGGTAAAGCACCGCGC
GCCCAGTATGTACTGGCGGAGCAGGTGACTCGTCTGGTTCACGGTGAAGAAGGTTTACAGGCGG
CAAAACGTATTACCGAATGCCTGTTCAGCGGTTCTTTGAGTGCGCTGAGTGAAGCGGACTTCGA
ACAGCTGGCGCAGGACGGCGTACCGATGGTTGAGATGGAAAAGGGCGCAGACCTGATGCAGGC
ACTGGTCGATTCTGAACTGCAACCTTCCCGTGGTCAGGCACGTAAAACTATCGCCTCCAATGCC
ATCACCATTAACGGTGAAAAACAGTCCGATCCTGAATACTTCTTTAAAGAAGAAGATCGTCTGT
TTGGTCGTTTTACCTTACTGCGTCGCGGTAAAAAGAATTACTGTCTGATTTGCTGGAAAGACTAC
AAACTCGAGCACCACCACCACCACCACTGA-3’ 
 
E. coli AzfRS Amino Acid Sequence 
MASSNLIKQLQERGLVAQVTDEEALAERLAQGPIALLCGFDPTADSLHLGHLVPLLCLKRFQQAGH
KPVALVGGATGLIGDPSFKAAERKLNTEETVQEWVDKIRKQVAPFLDFDCGENSAIAANNYDWFGN
MNVLTFLRDIGKHFSVNQMINKEAVKQRLNREDQGISFTEFSYNLLQGYSMACANKQYGVVLQIGG
SDQWGNITSGIDLTRRLHQNQVFGLTVPLITKADGTKFGKTEGGAVWLDPKKTSPYKFYQFWINTA
DADVYRFLKFFTFMSIEEINALEEEDKNSGKAPRAQYVLAEQVTRLVHGEEGLQAAKRITECLFSGS
LSALSEADFEQLAQDGVPMVEMEKGADLMQALVDSELQPSRGQARKTIASNAITINGEKQSDPEYFF
KEEDRLFGRFTLLRRGKKNYCLICWKDYKLEHHHHHH 
Figure 6.15-Construction of AzfRS Expression Plasmid. 
 
6.5.16 Purification of E. coli AzfRS.  
 His6-tagged E. coli AzfRS was expressed from the pET21-RSAzf plasmid 
described above in E. coli BL21-Gold (DE3) cells.  Cells were grown in 4 mL LB 
containing ampicillin (100 μg/mL) at 37 °C to an OD600 of 0.5.  A secondary 500 mL LB 
culture was inoculated with 1 mL of the primary culture and grown to an OD600 of 0.6.  
Protein expression was induced with 1.0 mM IPTG and grown at 25 °C for 16 hours.  
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Cells were pelleted at 6,000 rpm using a GS3 rotor and Sorvall RC-5 centrifuge.  Cell 
pellets were resuspended in Ni-NTA binding buffer (50 mM Tris, 10 mM imidazole, and 
300 mM KCl, pH 8.0) that included protease inhibitor cocktail, 1 mM PMSF, and 10 
units/mL DNAse-Grade II.  Following resuspension, the cells were lysed using 
sonication.  Soluble proteins were collected via centrifugation at 13,200 rpm for 15 
minutes.  Collected soluble protein was gently shaken for 1 hour on ice with Ni-NTA 
Superflow.  Protein was purified by rinsing with Ni-NTA binding buffer and then 
washing with Ni-NTA was buffer (50 mM Tris, 50 mM imidazole, and 300 mM KCl, pH 
8.0).  Protein was eluted with elution buffer (50 mM Tris, 250 mM imidazole, and 300 
mM KCl, pH 8.0).  Fractions containing E. coli AzfRS were dialyzed overnight in 
synthetase buffer (50 mM Tris, 50% glycerol, and 1 μM β-mercaptoethanol, pH 7.5).  
The dialyzed enzymes were stored at – 80 °C. 
6.5.17 Cleared E. coli TS351G Lysate Preparation.  
 E. coli TS351G cells were transformed with pUC19 plasmid DNA.  Cells were 
grown in 4 mL LB containing ampicillin (100 μg/mL) at 37 °C to an OD600 of 0.5.  A 
secondary 500 mL LB culture was inoculated with 1 mL of the primary culture and 
grown overnight at 25°C.  Cells were pelleted at 6,000 rpm using a GS3 rotor and Sorvall 
RC-5 centrifuge.  Cell pellets were resuspended in 50 mM Tris and 300 mM KCl, pH 8.0 
that included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse-Grade II.  
Following resuspension, the cells were lysed using sonication.  Soluble proteins were 
collected via centrifugation at 13,200 rpm for 15 minutes.  Cleared lysates were then 
stored at – 80 °C. 
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6.5.18 In vitro AaT Labeling Activity Assay.   
 αS2-140K2 was N-terminally modified with Azf (Azf-αS2-140K2) using either DMSO 
or DBCOTMR treated AaT-WT, AaT-Z47, AaT-Z68, or AaT-Z135.  AaT protein was pre-
treated with 2 mM IAM for 30 min at room temperature prior to incubation with DMSO 
or 100 μM DBCOTMR. AaT activity was assayed by fluorescently modifying Azf-αS2-
140K2 with fluorescein-alkyne (synthesized as previously described).261  αS2-140K2 (24.5 
μg) was modified with Azf (1.0 mM) in cleared E. coli lysate using E. coli total tRNA 
(125 μg), ATP (2.5 mM), and E. coli AzfRS (2.5 µg) in a reaction volume of 62.5 μL in 
modified AaT buffer (50 mm HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2) and AaT 
(DMSO or DBCOTMR treated, 1.56 μg).  ATP was omitted and replaced with an 
equivalent amount of MilliQ water for negative controls.  The reaction mixture was 
incubated at 37 °C for 4 hours, Azf was removed by five buffer exchanges into phosphate 
buffered saline (PBS, 12 mM NaH2PO4, 50 mM NaCl, 4.7 mM KCl, pH 8.0) using 
Amicon Ultra 0.5 Centrifugal 10 kDa spin columns (EMD Millipore Corporation; 
Billerica, MA).  Azf-αS2-140K2 was then labeled with fluorescein-alkyne (33 μM) using 
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 3.5 mM), CuSO4 (681 μM), and 
sodium ascorbate (5.4 mM) at 37 °C for 1 hour.  Aliquots (15 μL) of fluorescein labeled 
Azf-αS2-140K2 were boiled with gel loading dye LDS (Pierce; Rockford, IL) for ten 
minutes at 95 °C and analyzed by SDS-PAGE.  Fluorescence images were obtained with 
a Typhoon FLA 7000 (GE Lifesciences).  Fluorescein was imaged using 473 nm 
excitation and an Y520 filter.  TMR was imaged using 532 nm excitation and an O580 
filter.  Images were collected using a 100 μm pixel size.  Total protein content was 
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6.5.19 In vivo AaT Labeling Activity Assay.   
 E. coli BL21(DE3) cells were grown with pDULE2Azf and either pEG6 or pEG6-
TAGXX plasmids using ampicillin and streptomycin.  A 4 mL primary culture was used to 
inoculate a 100 mL secondary culture.  Secondary cultures were grown to an OD600 of 0.6 
and induced with 1.0 mM Azf and 0.1 mM IPTG. Protein expression was induced for 16 
hours at 25 °C.  Cell pellets were harvested at 6,000 rpm for 10 min using a GS3 rotor 
and Sorvall RC-5 centrifuge.  Cell pellets were washed three times with wash buffer (50 
mM Tris and 300 mM KCl, pH 8.0) to remove excess Azf.  Washed cell pellets were 
resuspended in 2 mL wash buffer and incubated with either DMSO or 500 μM DBCOTMR 
at 37 °C for 2 h with 250 rpm shaking.  Cells were then washed three times with wash 
buffer containing 1% DMSO and then washed once with wash buffer.  Cell pellets were 
then resuspended in 1 mL wash buffer and sonicated (one minute on then one minute off) 
three times.  Lysed cells were stored on ice until further use.  αS2-140K2 (31.3 μg) was 
modified with Azf (0.85 mM) in the E. coli lysate using E. coli total tRNA (125 μg), ATP 
(2.1 mM), and AzfRS (2.5 µg) in a reaction volume of 73.2 μL in modified AaT buffer 
(50 mm HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2) and AaT (1.25 μg).  ATP was 
omitted and replaced with an equivalent amount of MilliQ water for negative controls.  
The reaction mixture was incubated at 37 °C for 2 hours.  The crude reaction (12.5 μL) 
was then labeled with fluorescein-alkyne (33 μM) using THPTA (3.546 mM), CuSO4 
(681 μM), and sodium ascorbate (5.4 mM) at 37 °C for 1 hour.  The reaction was boiled 
with gel loading dye LDS (5 μL, Pierce; Rockford, IL) for ten minutes at 95 °C and 
analyzed by SDS-PAGE.  Fluorescence images were obtained with a Typhoon FLA 
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7000.  Fluorescein was imaged using 473 nm excitation and an Y520 filter.  TMR was 
imaged using 532 nm excitation and an O580 filter.  Images were collected using a 100 
μM pixel size.  Total protein content was visualized using Coomassie Brilliant Blue. 
 
Figure 6.17-In Vivo Assay Protocol. 
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